|
Seventh International Congress on Drug Therapy in HIV InfectionGlasgow, UK - 14-17 November 2004 |
Cite as: Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. xx
| PLENARY KEYNOTE LECTURES |
|
| KL1 | [KL1] ANTIRETROVIRAL THERAPY 2004 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. KL1 Patrick Yeni Since it became clear that HIV infected patients might need a lifelong toxic therapy, efforts were developed in two directions: A limitation in drug exposure, and an improvement in drug characteristics. |
| KL2 | PREVENTION AND CONTROL OF GLOBAL HIV/AIDS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. KL2 Helene Gayle Although effective treatment for HIV is widely available in rich countries, they are not in widespread use in poor countries where the problem is greatest. Major impediments to access to antiretroviral drugs are the cost and the lack of stable health care infrastructures to administer and monitor what are rather complex treatment regiments. However, many efforts are underway to accelerate access to antiretroviral therapies in resource poor setting. Absent antiretroviral drugs, treatment of associated infections can have a substantial impact of improving the health of people with HIV infection. For example, tuberculosis, a treatable infectious disease, is the leading cause of death for people with HIV in developing countries. |
| KL3 | [KL3] HIV HOST GENETICS: DIFFERENT PEOPLE, DIFFERENT DISEASE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. KL3 Amalio Telenti Pharmacogenetics and pharmacogenomics, toxicogenetics and immunogenetics are the disciplines that are expected to deliver the future personalized medicine. This endeavor requires means to identify genes that are variant, and demands that genetic variants undergo biological and clinical validation. Implementation depends on obtaining a complete picture of the complex trait (multigene) nature of many clinical phenotypes. Detection needs the appropriate laboratory techniques, in the context of ethical limits to genetic testing. |
| SESSION 1: TREATMENT STRATEGIES |
|
| PL1.1 | [PL1.1] ANTIRETROVIRAL TREATMENT: WHAT TO START? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL1.1 Roy M. Gulick Some initial therapy regimens have demonstrated HIV RNA suppression rates exceeding 70-80% for up to 1-4 years. In addition, documentation of both increasing rates of drug resistance in untreated HIV-infected individuals and an increased risk for virologic failure on initial treatment regimens in this group supports routine baseline resistance testing in some groups of patients. Current options and management strategies for the initial treatment of HIV infection continue to evolve and it is critical to interpret and incorporate newer data into the current standard of care. |
| PL1.2 | [PL1.2] CAN ANTIRETROVIRAL TREATMENT BE SIMPLIFIED OR WILL TRIPLE REGIMENS REMAIN THE GOLD STANDARD? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL1.2 Pietro L. Vernazza Two major concerns remain with the use of PI-mono therapies: Given the high frequency of HIV-RNA blips, the long-term effect of this treatment strategy needs to be evaluated in larger studies. The second concern relates to the poor penetration of some PIs into sanctuary like brain and genital tract. Long-term studies which also investigate the effect of treatment in CSF are warranted. |
| PL1.3 | [PL1.3] SALVAGE THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL1-3 Brian G. Gazzard The belief of most clinicians and a post hoc analysis of the major studies performed with T20 (TORO 1 and 2) would suggest that these drugs would be better used in combination with other active agents and, therefore, the best method of treatment in salvage is to prevent it from occurring by using agents more judiciously at an earlier stage of disease. A number of other agents including new nucleosides, new NNRTIs, Capaverine and TMC125, and novel agents attacking either integrase or the process of interaction either between the CD4 receptor and GP120 or between CCR5 and GP 41 should also be licensed in the foreseeable future which gives further hope to people in this situation. |
| PL1.4 | [PL1.4] STRUCTURED TREATMENT INTERRUPTIONS (STI) IN THE MANAGEMENT OF HIV INFECTED INDIVIDUALS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL1-4 Julio Montaner In an attempt to limit drug exposure (for reasons such as adherence, toxicity, cost) several groups are currently evaluating CD4+ guided therapy interruptions. This form of intermittent or pulse therapy is not expected to provide a direct immunologic or virologic benefit. To date, this approach appears to be comparable to the continuous therapy arm in several ongoing studies. However, concerns have emerged regarding premature development of resistance in highly adherent patients following such treatment interruptions. Consequently, full evaluation of long-term results of such strategy studies will be needed before the possible role of this approach is fully understood. Until then, the only acceptable use of treatment interruptions in clinical practice today pertains to allow recovery from side effects or co-morbidities. |
| SESSION 2: TREATMENT STRATEGIES AND ORAL PAPERS |
|
| PL2.1 | [PL2.1] USE OF BOOSTED PROTEASE INHIBITORS: PROS AND CONS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL2-1 Schlomo Staszewski Patients with prior, extensive PI-resistant virus did not fare as well. This suggests that a double-boosted PI regimen is an effective salvage therapy in specific situations. The association between higher number of PI mutations and reduced likelihood of response suggests that the optimal indication for the use of such a regimen would be in patients with virologic failure of prior PI-sparing regimens, who may have reduced RTI options but retain PI-susceptible virus or in patients with low to moderate PI resistance. In contrast, patients with late-stage failure and extensive PI resistance should probably receive double-boosted PIs plus enfuvirtide and other active agents if available. |
| PL2.2 | [PL2.2] TREATMENT PREPAREDNESS: READYING COMMUNITIES FOR ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL2.2 Gregg Gonsalves Treatment access is also often hindered by the failure of governments to make and/or follow through on commitments to implement HIV treatment programs and/or implement them in an equitable manner; appropriate funds for HIV treatment and care; and enact and enforce laws and regulations to protect against HIV-related discrimination. The private sector frequently has imposed obstructions to treatment access as well through inadequate workplace policies and impractical pricing of pharmaceutical, diagnostic tests and other medical products. |
| PL2.3 | [PL2.3] EVOLUTION OF TRANSMITTED WILD-TYPE AND DRUG RESISTANT INFECTIONS IN PRIMARY HIV INFECTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL2.3 Mark A. Wainberg, Dan Turner, Bluma Brenner, Daniella Moisi, Maureen Oliveira, Jean Pierre Routy We performed a longitudinal analysis to characterize the differential evolution of transmitted wild-type (WT) and drug resistant infections over time in primary HIV infection (PHI). We evaluated genotypic changes over time (2-6 years) in 31 PHI subjects. |
| PL2.4 | [PL2.4] RANDOMISED COMPARISON OF MAINTENANCE THERAPY WITH TRIZIVIR [TZV] + EFAVIRENZ [EFV] VS TZV IN NAÏVE HIV-1 INFECTED SUBJECTS: TIME STUDY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL2.4 S. De Wit1, M. Johnson2, B. Gazzard3, J.F. Bergmann4, J. Reynes5, V. Estrada6, A. Castagna7, J. Rockstroh8 Simplification to TZV maintenance after TZV/EFV induction therapy reduces drug-related events, reduces fasting cholesterol and maintains an immunological and virologic response compared to continuous TZV/EFV therapy. |
| PL2.5 | [PL2.5] EARLY VIROLOGICAL FAILURE IN PERSONS WITH VIRAL LOADS > 100 000 COPIES/mL AND CD4 COUNTS < 200/mm³ RECEIVING DIDANOSINE(DDI)/TENFOVIR(TDF)/EFAVIRENZ(EFV): 12 WEEK RESULTS FROM A RANDOMISED COMPARATIVE TRIAL Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL2.5 D. Maitland, G. Moyle, J. Hand, M. Nelson, B. Gazzard TDF/ddI/EFV as initial therapy appears to have diminished efficacy in subjects with baseline viral loads >100 000 copies/ml and CD4 counts < 200/mm³. Failure was not attributable to poor adherence. |
| SESSION 3: |
|
| PL3.1 | [PL3.1] SALVAGE THERAPY FORUM FEEDBACK Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL3-1 Veronica Miller Abstract not available |
| PL3.2 | [PL3.2] PHASE 3 COMPARISON OF LOPINAVIR/RITONAVIR VS. INVESTIGATOR-SELECTED PROTEASE INHIBITORS IN SINGLE PI-EXPERIENCED, NNRTI-NAÏVE PATIENTS: 48-WEEK RESULTS OF STUDY M98-888 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL3-2 R.B. Pollard1, M.A. Thompson2, C.B. Hicks3, B. Grinsztejn4, A. Horban5, M.S. King6, M. Norton6, P.A. Cernohous6, S.C. Brun6, J.H. Omachi6 A LPV/r-based regimen demonstrated superior virologic efficacy and better tolerability in single PI-experienced pts, vs. a regimen based on investigator-selected PIs. |
| SESSION 4: RESOURCE-POOR SETTINGS [IAS SESSION] |
|
| PL4.1 | [PL4.1] The challenges for controlling maternal-child transmission in resource poor settings Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL4.1 Glenda E. Gray Mother-to-child-transmission of HIV (MTCT) can occur before, during and after delivery. Most of transmission occurs during late pregnancy and delivery, and in resource poor settings, breastfeeding contributes substantially to the overall risk. Other risk factors for MTCT include advanced maternal disease, prematurity; |
| PL4.2 | [PL4.2] Virtues of "opt-out" testing as the point of entry to expanded access to ART in developing countries Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL4.2 Ferdinand M. Mugusi The use of effective antiviral agents has significantly improved the prognostic possibilities for many people with AIDS in the developed world. There are initiatives by WHO and other international organizations to expand access to Antiretroviral therapy (ART) to as many people as possible, especially in high prevalent |
| PL4.3 | [PL4.3] Treatment access and other challenges for clinicians in Eastern Europe Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL4.3 Lars Kallings Russian Federation and other countries in Eastern Europe continues to have one of the fastest growing HIV epidemics in the world, the actual number of individuals living with HIV/AIDS in Russia alone is estimated to be from 600.000 to 1 million and in the whole region more than 1.5 million. There are a rapidly increasi |
| PL4.4 | [PL4.4] Treatment outcomes for antiretroviral therapy in a routine clinical setting in Kampala, Uganda Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL4.4 M.R. Kamya1, L.A. Spacek2, H.M. Shihab3, D. Mwesigire3, A. Ronald3, H. Mayanja1, R.D. Moore2, T.C. Quinn2 To evaluate response to antiretroviral therapy (ART) in Kampala, Uganda . We conducted a cross-sectional study of 137 HIV-infected patients on ART at Mulago Hospital Infectious Diseases Clinic. We measured prevalence of viral suppression, evaluated predictors of response to ART and documented phenotypic resistance patt |
| PL4.5 | [PL4.5] Access to treatment in Botswana 2 years on Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL4.5 Segolame Lekoko Ramotlhwa The National Anti-retroviral Therapy (ART) Program in Botswana is called Masa. Masa is a Setswana (local language) word for new dawn and the program was given this name in 2001 as a reflection of new hope for people living with HIV/AIDS (PLWA S). The Masa ART Program was launched in August 2001 following a Consultancy |
| SESSION 5: ADHERENCE, RESISTANCE, CLINICAL PHARMACOLOGY AND DISEASE MONITORING |
|
| PL5.1 | [PL5.1] ADHERENCE, RESISTANCE AND DISEASE MONITORING Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL5.1 Rainer Weber Intervention strategies to improve adherence include cognitive-behavioural methods, behavioural strategies, directly observed therapy, and affective strategies. In resource-limited settings adherence can be achieved by strengthening community-based efforts. In summary, monitoring adherence and promoting tailored socio-behavioural support is an integral part of antiretroviral therapy and patient care. |
| PL5.2 | [PL5.2] SIMILAR ADHERENCE RATES FAVOUR DIFFERENT VIROLOGIC OUTCOMES ACCORDING TO TYPE OF HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL5.2 Franco Maggiolo1, Laura Ravasio2, Diego Ripamonti1, Giampietro Gregis1, Giampaolo Quinzan1, Monica Airoldi2, Fredy Suter2 Adherence is a major determinant of HAART success and, in our study, highly correlates to virologic success of HAART within the following 6 months. NN-based therapies seem to have a higher degree of forgiveness in those patients with intermediate adherence (>75% but < 100%). Simpler regimens favor a significantly higher level of adherence. VAS is a simply reliable instrument for assessing adherence. |
| PL5.3 | [PL5.3] EPIDEMIOLOGY OF ANTIRETROVIRAL RESISTANCE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL5.3 Deenan Pillay/ Unfortunately, existing datasets vary significantly in the types of population surveyed, and definitions of resistance, making it difficult to draw clear conclusions on these issues. It is essential to identify the precise purpose for estimating for epidemiological analysis before implementing optimal methological approaches. |
| PL5.4 | [PL5.4] EFFECTS OF MUTATIONS ASSOCIATED WITH SUPPRESSION OF ZIDOVUDINE RESISTANCE IN HIV-1 REVERSE TRANSCRIPTASE ON REMOVAL OF TENOFOVIR FROM BLOCKED PRIMER/TEMPLATE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL5.4 Narges Hassani Espili, Alona Pavlova, Tobias Bergroth, Anders Sönnerborg, Johan Lennerstrand The M184V, Y181C and L100I mutation reduces the ATP mediated excision of incorporated tenofovir. Thus, our biochemical data is consistent with cell culture data. This indicates that there would be a benefit with tenofovir therapy combined with therapy rendering suppression mutations. |
| SESSION 6: RESISTANCE AND PHARMACOKINETICS |
|
| PL6.1 | [PL6.1] LONG TERM RISK OF DEVELOPMENT OF DRUG RESISTANCE AFTER STARTING ANTIRETROVIRAL THERAPY IN ROUTINE CLINICAL PRACTICE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL6.1 A. Phillips, D. Dunn, C. Sabin, A. Pozniak, R. Matthias, A. Geretti, J. Clarke, D. Churchill, I. Williams, T. Hill, H. Green, K. Porter, G. Scullard, M. Johnson, P. Easterbrook, R. Gilson, M. Fisher, C. Loveday, B. Gazzard, D. Pillay In routine practice, rates of viral load failure and of resistance detection in patients who started ART with three or four drugs are appreciable. |
| PL6.2 | [PL6.2] DRUG-DRUG INTERACTIONS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL6.2 David Back HIV medicine is rife with proven and potential drug-drug interactions. Although many interactions can be predicted on the basis of preclinical pharmacology, and regulatory agencies require PK studies when a significant interaction is anticipated, there are still many drug combinations that have been inadequately studied. Given also that unexpected interactions appear and unexpected failures of certain drug combinations occur, there is the need to have some understanding of the concentrations of antiretroviral drugs achieved in an individual patient. Here is a role for therapeutic drug monitoring. |
| PL6.3a | [PL6.3a] EFFECT OF ATAZANAVIR ON INTRACELLULAR AND PLASMA PHARMACOKINETICS OF SAQUINAVIR AND RITONAVIR ADMINISTERED ONCE-DAILY IN HIV INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL6.3a Jennifer Ford1, Marta Boffito2, Adrian Wildfire2, Andrew Hill3, David Back1, Saye Khoo1, Mark Nelson2, Graeme Moyle2, Brian Gazzard2, Anton Pozniak2 ATV increased both plasma and IC exposure (AUC0-24h) and Cmin of SQV but not RTV. Addition of ATV to a QD SQV/RTV regimen maybe useful for patients with SQV concentrations below the minimum effective concentrations, however, further efficacy studies are warranted. |
| PL6.3b | [PL6.3b] INTRACELLULAR AND PLASMA PHARMACOKINETICS OF SAQUINAVIR, ATAZANAVIR AND RITONAVIR (SQV/ATV/R) 1600/200/100mg ADMINISTERED ONCE DAILY IN HIV INFECTED PATIENTS/TI> Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL6.3b Jennifer Ford1, Marta Boffito2, Adrian Wildfire2, Andrew Hill3, David Back1, Saye Khoo1, Mark Nelson2, Graeme Moyle2, Brian Gazzard2, Anton Pozniak2 IC concentrations were higher than plasma concentrations for all PIs measured. Mechanisms of IC PI accumulation are unclear but may reflect affinities for influx transporters, since no relationships with efflux transporters were observed. |
| PL6.4 | [PL6.4] CHALLENGES IN INTEGRATING RESISTANCE, FITNESS AND DRUG LEVELS INTO OUR CLINICAL PRACTICE, NOW AND IN THE FUTURE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL6.4 Jonathan M. Schapiro The optimal use of antiretroviral agents requires integration of all these tests. Choices on which protease inhibitor to use and at what dose in heavily drug-experienced patients is an example of how both resistance and pharmacology data need to be integrated. But in addition to our refinements and improvements in assay development and interpretation, there is an urgent need to draw from our experience with these tests to improve treatment where they cannot be afforded. By analyzing large databases with sophisticated statistical techniques, we may be able to improve treatment algorithms for patients in resource poor settings. This insight may allow us to improve therapeutic choices based on patient characteristics and drug history, even when expensive testing is not feasible. |
| PL6.5 | [PL6.5] GENOTYPIC AND PHENOTYPIC INHIBITORY QUOTIENTS AS PREDICTORS OF THE VIROLOGICAL RESPONSE TO A RITONAVIR/AMPRENAVIR CONTAINING REGIMEN IN HIV-1 PROTEASE INHIBITOR EXPERIENCED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL6.5 A.G. Marcelin1, C. Delaugerre1, N. Ktorza1, H. Ait-Mohand1, M. Wirden1, A. Simon1, C. Lamotte 2, P. Bossi1, F. Bricaire1, D. Costagliola1, C. Katlama1, G. Peytavin2, V. Calvez1 APV harbored high PIQs on resistant strains that is in accordance with an efficacy when boosted by RTV in PI experienced patients. The predictive value of APV IC50 or fold change used alone are enhanced taking account of APV Cmin using a PIQ approach. |
| PL6.6 | [PL6.6] THE NORMALISED INHIBITORY QUOTIENT OF BOOSTED PROTEASE INHIBITORS IS PREDICTIVE OF VIRAL LOAD RESPONSE OVER 48 WEEKS IN A COHORT OF HIGHLY TREATMENT EXPERIENCED HIV-1 INFECTED INDIVIDUALS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL6.6 A. Winston1, G. Hales1, J. Amin1, E. van Schiack2, L. Bacheler3, B. Winters2, D. Cooper1, S. Emery1 In this cohort of highly treatment-experienced individuals treated with boosted PI regimens, baseline VL and NIQ were significantly predictive of virological response over 48 weeks. These prospective results support the use of a NIQ at week four, as a tool in predicting response to therapy in this setting. |
| SESSION 7: ADVERSE EVENTS I |
|
| PL7.1 | [PL7.1] PATHOGENESIS AND TREATMENT OF METABOLIC COMPLICATIONS OF HIV THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL7-1 Peter Reiss Although interventions aimed at established fat maldistribution thus far have not been very effective, the earlier mentioned demonstrated differences between particular drugs do offer promise for establishing combination therapy strategies (e.g. involving novel NRTI backbones such as abacavir+lamivudine or tenofovir+emtricitabine) which may be associated with a reduced or at least delayed incidence of lipodystrophy. |
| PL7.2 | [PL7.2] Living with adverse events: how does it affect adherence and decisions on starting or changing therapy? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL7-2 Kevin Moody Everyone taking antiretroviral treatment (ART) experiences adverse events, the type and extent of which vary greatly from person to person and cannot be predicted. Induction side effects decrease over time and can be managed, while long-term metabolic side effects are even less predictable and less is known about how t |
| PL7.3 | [PL7.3] MITOCHONDRIAL STUDIES IN ADIPOSE TISSUE OF HIV-INFECTED PATIENTS WITHOUT FAT REDISTRIBUTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL7-3 S. López1, G. Garrabou1, E. Martínez2, P. Domingo3, J. Fontdevila4, J.M. Gatell2, A.B. Infante1, X. Gallart5, A. Milinkovic2, F. Cardellach1, J. Casademont1, Miró1 Decreased mtDNA content in AT of HIV-infected patients is closely associated with decreased COX activity, irrespective of the presence of HAART, before LD appears. The exact role that HIV itself and HAART play in adipocyte changes remains to be determined. |
| PL7.4 | [PL7.4] Control and treatment of coronary heart disease risk factors in HIV-infected patients: the Swiss HIV cohort study Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL7-4 H.C. Bucher, T.R. Glass, C. Ungsedhapand, Swiss HIV Cohort Study To examine the extent of control and treatment of CHD risk factors in both treated and untreated individuals in the Swiss HIV Cohort Study (SHCS). Since April 1, 2000, HIV-infected individuals enrolled in the SHCS are biannually assessed for CHD risk factors and cardiovascular events. All scheduled visits with lab valu |
| PL7.5 | [PL7.5] NANDROLONE DECANOATE COMPARED WITH PLACEBO AND TESTOSTERONE FOR HIV ASSOCIATED WASTING: A MULTI-CENTRE INTERNATIONAL CLINICAL TRIAL Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL7-5 Julian Gold1, Marijka Batterham1, Peggy M.E. Helmyr3, Marloes Harms 3, Hans Rekers3 This is the first multi-centre clinical trial of its type which provides important evidence to assist clinicians to manage patients with HIV wasting. Treatment with ND increases body weight when compared with placebo and T. ND treatment results in greater increases in FFM than placebo and demonstrates a trend to a significant increase when compared with T. |
| PL7.6 | [PL7.6] THE EFFECTS OF NANDROLONE DECANOATE ON WEIGHT LOSS AND QUALITY OF LIFE IN MALE PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL7-6 Chris J. Duncombe, Theshinee Chuenyam, Paul T. Geurts, Marloes K. Harms, Praphan Phanuphak This was a multi-center, randomized, double blind, placebo controlled study of the effects of 24 weeks of treatment with ND in three different doses in the prevention or delay of weight loss and on quality of life in HIV-infected male patients. Subjects with 5-15% weight loss, stable on antiretroviral therapy for a minimum of eight weeks or on no antiretroviral therapy, were randomized to receive ND 50 mg, 100 mg or 150 mg by intramuscular injection once every two weeks or placebo. Efficacy was assessed by mean changes in body weight, LBM and anthropometry. Quality of life was measured using the MOS-SF30 questionnaire. |
| SESSION 8: IMMUNOLOGY, IMMUNE-BASED THERAPIES AND VACCINES |
|
| PL8.1 | [PL8.1] What is the status of IL-2? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL8.1 Jens D. Lundgren PURPOSE OF PRESENTATION: Provide an update on the current research efforts directed towards defining the potential clinical utility of interleukin 2 ( IL-2 ) in slowing the progression of HIV-1 infection. SUMMARY OF RESULTS: An extensive phase II database has established that intermittent 5 day cycles of IL-2 are capab |
| PL8.2 | [PL8.2] Where are we with vaccines? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL8-2 Jonathan Weber Abstract not available |
| PL8.3 | [PL8.3] Vaccine preparedness: building up an enabling environment for AIDS vaccines clinical research Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL8.3 Maite Suarez The goal of the International AIDS vaccines Initiative (IAVI) is to accelerate the development and subsequent use of a safe, efficacious and affordable AIDS vaccine for the world, and particularly for those regions most affected by the epidemic; hence, IAVI s commitment to developing a vaccine in and for these regions |
| SESSION 9: HIV-RELATED INFECTIONS, CO-INFECTIONS AND MALIGNANCIES |
|
| PL9.1 | [PL9.1] The management of tuberculosis in HIV infected patients Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL9-1 James Hakim In 2000 it was estimated that 9% of the 8.3 million new cases of tuberculosis in adults aged 15 to 49 years were HIV co-infected. Dual infection reaches its greatest extent in the developing world, but is important worldwide. The management of tuberculosis in HIV infected patients poses several challenges. These includ |
| PL9.2 | [PL9.2] Kaposi sarcoma herpesvirus: update Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL9.2 Chris Boshoff The incidence of HIV-related cancer before and during the ART era indicates that oncogenic viruses continue to contribute to the majority of these cancers and they are therefore considered opportunistic malignancies. ART has lead to a definitive decline in the incidence of certain AIDS-defining cancers including Kaposi |
| PL9.3 | [PL9.3] Similar profile of adverse events during treatment for tuberculosis in patients with and without HIV co-infection Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL9.3 Ronan Breen1, Robert Miller2, Jayne Ballinger1, Leonie Swaden1, Margaret Johnson1, Marc Lipman1 To describe the adverse events profile when both HAART and anti- tuberculosis medication are used together. Case-note review of 115 patients with active HIV/TB coinfection, compared to 114 unselected HIV negative TB patients treated over the same time period at our institution. HIV+ TB+ patients had a median age of |
| PL9.4 | [PL9.4] Co-infection with syphilis: natural history and management Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL9.4 Fiona Mulcahy WHO estimates approximately 12 million new cases of syphilis each year, the majority occurring in the developing world. In the last four years, however discrete outbreaks of syphilis have been reported in North America, United Kingdom, Ireland and Western Europe, where previous rates had been rela |
| PL9.5 | [PL9.5] HIV and syphilis: when to perform a lumbar puncture? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL9.5 A. Libois1, S. De Wit1, B. Poll1, M. Hildebrand1, E. Florence2, M. Vandenbruaene2, F. Garcia3, A. Del Rio4, P. Sanchez5, E. Negredo6, J.M. Gatell3, N. Clumeck1 HIV+ patients (P) with syphilis (S) are considered to be at increased risk for neuroS (NS). Whether this should prompt to systematic lumbar puncture (LP) remains controversial. This study aims to establish whether it is possible to optimize the use of LP by defining specific situations in which it should be performed. |
| SESSION 10: HEPATITIS CO-INFECTIONS AND ADVERSE EVENTS II |
|
| PL10.1 | [PL10.1] HBV and HCV co-infection: natural history and management Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL10.1 Yves Benhamou Abstract not available. SESSION 10: HEPATITIS CO-INFECTIONS AND ADVERSE EVENTS II |
| PL10.2 | [PL10.2] Hepatic adverse events (with and without coinfection) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL10.2 Jürgen Rockstroh Meanwhile the benefits of highly active antiretroviral therapy (HAART) with regard to both survival and quality of life have been demonstrated beyond any doubts. Yet, HAART-associated toxicity has evolved as the main reason to discontinue or modify antiretroviral therapy. Hepatotoxicity appears to be of particular impo |
| PL10.3 | [PL10.3] HAART-associated hepatotoxicity in HIV/HCV co-infected patients: the role of liver histologic damage and drug levels Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL10.3 Lidia Aranzabal, Jose L. Casado, Javier Moya, Ana Marin, Carmen Quereda, Ana Moreno, Santiago Moreno HCV infection is a known risk factor for hepatotoxicity in HIV-infected patients. The aim of this study was to asses the influence of liver histologic stage in the rate of HAART-related liver toxicity. Prospective cohort study of 107 HIV/HCV co-infected patients who underwent liver biopsy between October 00 and Septemb |
| PL10.4 | [PL10.4] Is osteoporosis real? Pathogenesis and management Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL10.4 William G. Powderly Bone disorders have emerged in the last five years as potentially an additional long-term complication of HIV infection and/or its treatment. Osteonecrosis, especially involving large joints, has been linked to the duration of antiretroviral therapy. Multiple studies suggest that HIV-infected patients receiving potent |
| SESSION 11: PAEDIATRIC INFECTION |
|
| PL11.1 | [PL11.1] Paediatric issues relevant to the clinical management of HIV-infected adults Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL11.1 Carlo Giaquinto Children differ from adults in the natural history of HIV-1 infection, immunology, virology patterns of drug tocixity and adherence related issues. The response of the immune system is very specific and different in adults and children: children have an active thymus and a greater capacity than adults to regenerate the |
| PL11.2 | [PL11.2] Higher nevirapine doses correlate with improved outcomes in a paediatric population Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL11.2 A. Alexanian1, S. Gibbons2, E.G.H. Lyall1, S. Walters1, S. Khoo2, G. Tudor-Williams1 PURPOSE OF THE STUDY: To determine the dose-trough and trough-outcome relationship for nevirapine (NVP) given as part of combination antiretroviral therapy (CART) to a paediatric population. METHODS: From the database held at the Liverpool TDM service, results of all NVP assays obtained from children from 1999 to Septe |
| PL11.3 | [PL11.3] Antiretroviral therapy and pregnancy outcome: UK/Ireland surveillance data 1990-2004 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL11.3 Pat A. Tookey, Claire L. Townsend, Mario Cortina-Borja, Janet E. Masters, Catherine S. Peckham;;; Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, London, UK To describe trends in the use of antiretroviral therapy (ART) in pregnancy in the UK and Ireland, and associations between ART use and pregnancy outcome. Pregnancies in women with diagnosed HIV are notified to the National Study of HIV in Pregnancy and Childhood (NSHPC) through a confidential voluntary active reportin |
| SESSION 13: NEW TREATMENTS AND TARGETS, LATE BREAKERS AND HOT TOPICS |
|
| PL13.1 | [PL13.1] NEW ANTIRETROVIRALS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL13.1 Robert Murphy Abstract not available |
| PL13.2 | [PL13.2] REPRODUCTION IN HIV-INFECTED COUPLES Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL13.2 Simone Fiore Abstract not available |
| PL13.3 | [PL13.3] Benefit of antiretroviral therapy for serodiscordant couples willing to be parents Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL13.3 Pablo Barreiro, Vincent Soriano, Marina Nuñez, Juan Gonzalez-Lahoz;;; Infectious Diseases, Hospital Carlos III, Madrid, Spain HIV+ persons who wish to be parents with a HIV-neg partner may pose at risk of infection the couple and eventually the newborn. To minimize this risk, in vitro fertilization is often advised in such cases. However, this is an expensive procedure. Furthermore, social and personal believes often discourage some couples f |
| SESSION 14: LATE BREAKERS AND HOT TOPICS |
|
| PL14.1 | [PL14.1] WHY DO PATIENTS STOP ANTIRETROVIRALS USED AS PART OF AN INITIAL HAART REGIMEN? RESULTS FROM THE EUROSIDA STUDY GROUP Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL14.1 A. Mocroft1, A. Phillips1, V. Soriano2, J. Rockstroh2, A. Blaxhult2, C. Katlama2, A. Boron-Kaczmarska2, L. Viksna2, O. Kirk2, J. Lundgren2 Patients with HCV were more likely to discontinue their first HAART regimen due to toxicity or patient/physician choice. Managing adverse events must remain a key intervention in maintaining HAART. There is a need for further studies to describe the relationship between HCV, specific antiretrovirals and different treatment strategies. |
| PL14.2 | [PL14.2] THE COMBINATION OF TENOFOVIR DF (TDF), EMTRICITABINE (FTC) AND EFAVIRENZ (EFV) HAS SIGNIFICANTLY GREATER RESPONSE VS FIXED DOSE ZIDOVUDINE/LAMIVUDINE (CBV) AND EFV IN ANTIRETROVIRAL NAÏVE PATIENTS: A 24-WEEK PRELIMINARY ANALYSIS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL14.2 J.R. Arribas1, E. DeJesus2, R. Campo3, J. Jemsek4, J.E. Gallant5, B. Gazzard6, A.L. Pozniak6, B. Lu7, M.D. Miller7, A. Cheng7, For the Study 934 Team Through week 24, the combination of TDF, FTC and EFV resulted in a significantly greater number of patients achieving and maintaining HIV RNA < 400 and < 50 c/mL vs CBV+EFV with fewer discontinuations due to adverse events. |
| PL14.3 | [PL14.3] 24-WEEK DATA FROM RESIST 2: PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF EITHER TIPRANAVIR/RITONAVIR (TPV/R) OR AN OPTIMIZED RITONAVIR (RTV)-BOOSTED STANDARD-OF-CARE (SOC) COMPARATOR PI (CPI) IN A LARGE RANDOMIZED MULTICENTER TRIAL IN TREATMENT-EXPERIENCED HIV+ PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL14.3 Pedro Cahn Results indicate that TPV/r provides superior antiretroviral activity to currently available CPI/r in a cohort of treatment-experienced HIV+ patients. |
| PL14.4 | [PL14.4] COMPARISON OF ATAZANAVIR (ATV) WITH RITONAVIR OR SAQUINAVIR VS LOPINAVIR/RITONAVIR IN PATIENTS WITH MULTIPLE VIROLOGIC FAILURES: BMS AI424-045 96 WEEK RESULTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL14.4 M. Johnson1, E. DeJesus2, B. Grinsztejn3, C. Rodriguez4, L. Nieto-Cisneros5, J. Coco6, A. Lazzarin7, K. Lichtenstein8, A. Rightmire9, L. Odeshoo9, C. McLaren9, G. Leleu10 All regimens comparably safe and tolerated. At 96 weeks ATV/r demonstrated similar efficacy and significantly improved lipid profile and less diarrhoea vs LPV/r. |
| POSTERS TREATMENT STRATEGIES |
|
| P1 | [P1] NEVIRAPINE, EFAVIRENZ, OR ABACAVIR FOR SIMPLIFICATION OF EFFECTIVE PROTEASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY (THE NEFA STUDY): 3-YEAR RESULTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P1 Esteban Martinez1, Daniel Podzamczer2, Esteban Ribera3, Pere Domingo4, Jose M. Gatell1 The NEFA study at 3 years showed similar efficacy but less discontinuations due to adverse events and a more favourable lipid profile in the ABC arm. Use of prior suboptimal NRTI therapy was associated with higher virological failure in the ABC arm. |
| P2 | [P2] LONG-TERM EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF): A 144-WEEK COMPARISON VERSUS STAVUDINE (D4T) IN ANTIRETROVIRAL-NAÏVE PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P2 A. Pozniak1, J. Gallant2, S. Staszewski3, B. Lu4, K. Yale4, M. Miller4, J. Enejosa4, A. Cheng4 Through 144 weeks, the efficacy of combination therapy with TDF was comparable to d4T in antiretroviral-naïve patients. The renal safety profile was similar between the arms. Patients in the TDF arm had a significantly better lipid profile and less lipodystrophy. |
| P3 | [P3] CONCURRENT ADMINISTRATION OF TENOFOVIR (TDF) AND DIDANOSINE (ddI) COMPROMISES IMMUNOLOGIC RECOVERY IN TREATMENT-EXPERIENCED PATIENTS. RESULTS FROM THE TORO STUDIES Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P3 B. Clotet, E. Negredo, A. Bonjoch, R. Paredes Combined use of TDF and ddI resulted in poorer immune recovery over 48 weeks in TORO studies even among those with similar viral suppression (<400 c/ml). |
| P4 | [P4] A SYSTEMATIC REVIEW OF THE EFFICACY OF HAART IN HIV-INFECTED, ANTIRETROVIRAL-NAÏVE PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P4 Brian A. Boyle1, Christos J. Paul2, Linda M. Gerber2 The results of the systematic review of these studies, which involved over 5000 patients with a wide range of viral loads and CD4 counts, will be presented and will demonstrate that when the method of analysis and patient variables at entry are accounted for most NNRTI- and PI- based regimens have similar virologic and immunologic performance at the end of 48 weeks of therapy. |
| P5 | [P5] INTERRUPTION/STOPPING HAART AND RISK OF CLINICAL DISEASE PROGRESSION TO AIDS/DEATH IN EuroSIDA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P5 C. Holkmann-Olsen, A. Mocroft, S. Vella, A. Blaxhult, N. Clumeck, O. Kirk, M. Fisher, C. Katlama, A. Phillips, J. Lundgren Results indicate that risk of AIDS/Death in general increases several-fold upon treatment interruption/stopping. The absolute risk remains closely linked to the latest CD4/HIV-RNA level and was similarly low in patients with CD4 >200/mm3 both in TI- and non-TI-group, supporting further investigation in role of TI for this subgroup by a RCT. |
| P6 | [P6] AN OPEN LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF ENFUVIRTIDE IN PATIENTS CHANGING THERAPY TO AN NRTI SPARING REGIMEN Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P6 David Cooper1, Dominic Dwyer2, Cassy Workman3, Janaki Amin1, John Miller4, Gillian Hales1, Sean Emery1 The strategy of an NRTI sparing regimen plus enfuvirtide provided significant viral suppression and immunologic recovery at week 48 with concomitant improvements in both lean and fat mass. |
| P7 | [P7] TO DETERMINE THE MOST POTENT COMBINATION OF DRUGS TO CONTROL PLASMA VIRUS LOAD AND CD4 CELLS AT PRIMARY HIV INFECTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P7 Sarah Fidler, Julie Fox, Christophe Fraser, Norbert Tamm, Simon Dustan, John Clarke, Myra McClure, Jonathan Weber Abstract not reproduced at author's request. |
| P8 | [P8] RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NANDROLONE DECANOATE IN HIV-INFECTED MEN WITH MILD TO MODERATE WEIGHT LOSS WITH rHGH AS REFERENCE TREATMENT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P8 Theodorus B.P. Geurts1, Thomas W. Storer2, Linda J. Woodhouse2, Fred Sattler3, Shalender Bhasin2 ND is superior to placebo, and not significantly different from rhGH in its ability to increase LBM in men with HIV-wasting. |
| P9 | [P9] THREE YEARS FOLLOW-UP IN PATIENTS TREATED ACCORDING TO CD4-GUIDED STIs Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P9 F. Maggiolo, G. Gregis, G. Quinzan, D. Ripamonti, L. Ravasio, C. Arici, M. Airoldi, F. Suter HAART can be safely and steadily interrupted in patients who started it with >350 CD4 cells. Patients with a lower CD4 nadir, despite a sustained immune-recovery, have higher risk of rapid decrement of CD4 cells. Optimal timing to start therapy may be re-thought. |
| P10 | [P10] VIROLOGIC EFFICACY OF THREE ONCE-A-DAY HAART REGIMENS. PLANNED INTERIM ANALYSIS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P10 Franco Maggiolo1, Diego Ripamonti1, Guglielmo Migliorino2, Laura Sighinolfi3, Giampietro Gregis1, Giampaolo Quinzan1, Clara Abeli2, Laura Ravasio1, Monica Airoldi1, Fredy Suter1 The studied once-a-day regimens show a high virologic efficacy even in advanced, compromized patients. In the case of virologic failure the resistance mutation pattern is highly influenced by the choice of NRTIs and about half of the patients do not present NNRTI related mutations. OD therapy favor adherence. |
| P11 | [P11] COMPARISON OF ANTIRETROVIRAL AGENTS IN TREATMENT-EXPERIENCED PATIENTS: ENFUVIRTIDE DEMONSTRATES SUPERIOR EFFICACY COMPARED TO OTHER AVAILABLE AGENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P11 G. Diego Miralles, Ralph A. DeMasi In triple class experienced pts, the presence of ENF in a regimen resulted in better virological and immunological outcomes than those observed with alternative available agents. |
| P12 | [P12] STUDY DESIGN ISSUES FOR REGISTRATION STUDIES OF ENFUVIRTIDE - A NEW ANTIRETROVIRAL (ARV) CLASS IN ADVANCED HIV INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P12 J. Chung1, U. Dhingra1, C. Wat2, L. Donatacci1, L. Smiley3, M. Salgo1 The TORO (T20 vs. Optimized Regimen Only) studies successfully incorporated resistance testing for selecting an individualized OB at screening, and a switch study design allowing patients on OB alone to revise their regimen and add ENF, setting a new standard for registration studies in advanced patients. |
| P13 | [P13] HAS POTENCY OF CURRENT HAART REACHED A PLATEAU? RESULTS OF THE MASTER COLLABORATION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P13 C. Torti1, G. Paraninfo1, F. Maggiolo2, E. Quiros1, A. Patroni1, N. Ladisa3, A. Antinori4, F. Castelnuovo1, G. Rizzardini5, A. Orani6, L. Sighinolfi7, S. Casari1, G. Carosi1 EFV and LPV/r effectiveness was comparable in the mid term in naïve patients. These results suggest that potency is not prejudicial, when HAART is tailored to patient conditions within the frame of current recommendations. On the basis of these results, a prospective randomized study (Sisther) has been initiated. |
| P14 | [P14] VIRO-IMMUNOLOGICAL OUTCOME OF FAILING HEAVILY PRE-TREATED HIV PATIENTS WHO MAINTAINED OR CHANGED THE HIGHLY ACTIVE ANTIRETROVIRAL REGIMEN (HAART). (MASTER-IMPROVE TRIAL) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P14 P. Nasta1, G. Cocca2, G. Zoboli3, C. Nigro4, M.C. Colombo5, E. Barchiesi6, C. Calzetti7, B. Celesia8, G. Carosi1 A 24 wks MASTER-IMPROVE trial documented a 70% of VL suppression and a CD4+ slight increase in early switch arm. A relatively slow rate of VL increase and a substantially stable CD4 count were shown in Pts remaining on failing HAART. Further analysis on change in resistance mutations pattern are ongoing. |
| P15 | [P15] ANTIRETROVIRAL (ARV) THERAPY IN SPECIAL POPULATIONS: RESPONSE TO LOPINAVIR/RITONAVIR (LPV/R), TENOFOVIR (TDF), AND EMTRICITABINE (FTC) IN ARV-NAÏVE PATIENTS BY GENDER, ETHNICITY, AND HEPATITIS CO-INFECTION STATUS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P15 P. Easterbrook1, S. Green 2, A. Wilken 3, C. Barros 4, P. Domingo 5, C. Naylor 6, J. Hairrell 6, K. Luff 6, M. King 6, S. Brun 6 A regimen of LPV/r dosed QD or BID + TDF + FTC demonstrated similar virologic and immunologic responses regardless of gender, ethnicity, or hepatitis co-infection status. |
| P16 | [P16] EFFICACY OF TENOFOVIR-DF AS INTENSIFICATION OF ZIDOVUDINE/LAMIVUDINE/ABACAVIR FIXED DOSE COMBINATION IN THE TREATMENT OF HIV-POSITIVE PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P16 Charles Farthing1, Homayoun Khanlou1, Bill Guyer2 Using TDF as intensification of ZDV/3TC/ABC-FDC represents a viable treatment option. |
| P17 | [P17] EFFECT OF TREATMENT INTERRUPTIONS ON ESTIMATION OF BASELINE ANTIRETROVIRAL SUSCEPTIBILITY AND SUBSEQUENT VIROLOGICAL RESPONSE IN TREATMENT-EXPERIENCED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P17 G.D. Miralles1, S. Deeks2, M. Dolker3, J.A. Thommes3, R.A. DeMasi1 Continuation of ARV in pts failing therapy results in continued virological and immunological effects as compared to interrupting therapy. GT susceptibility is over-estimated for patients OFF ARV at the time RT sampling. These data are inconsistent with the hypothesis that a treatment interruption improves subsequent response to salvage therapy and should be considered when using GT/PT for guiding ARV therapy. |
| P18 | [P18] PRIMARY HIV INFECTION: IS OUTCOME AFTER TREATMENT INTERRUPTION INFLUENCED BY TREATMENT INITIATION? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P18 Deborah Konopnicki, Stephane De Wit, Coca Necsoi, Kabamba Kabeya, Nathan Clumeck 64% of the p treated early in PHI could subsequently interrupt their T for more than 1 y. Patients in which T had to be reinitiated within 1 y were characterised by a earlier initiation of T and a trend to a lower CD4 cell count at T initiation. Whether this reflects a more severe disease or a blunted immune response needs to be further investigated. |
| P19 | [P19] REDUCTION IN BODY WEIGHT AND CD4 LYMPHOCYTE COUNT WITH SIMPLIFICATION REGIMENS INCLUDING TENOFOVIR AND DIDANOSINE (TD). A SCHEME TO AVOID? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P19 Rosario Palacios, Jesús Santos, Mercedes González, Josefa Ruiz, Manuel Márquez Simplification with TD and a NNRTI may lead to a drop in body weight and CD4 lymphocyte count. Weight loss is greater in patients with a lower CD4 nadir. The appropriateness of this regimen for simplification merits further evaluation. |
| P20 | [P20] DISCONTINUATION OF HAART: PREDICTIVE VALUE OF AND IMPACT ON IMMUNOLOGICAL CHANGES Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P20 Giota Touloumi1, Nikos Pantazis1, Heide A. Stirnadel2, Kholoud Porter3 In this large study, a substantial number of subjects discontinued HAART at 2 years. Further research is needed to investigate the reasons for which women are more likely to have a TD. Given that CD4 cell loss is greater in individuals with low pre-HAART nadir CD4 cell counts, caution is suggested when TD is considered in such subjects. |
| P21 | [P21] ATAZANAVIR/RITONAVIR/SAQUINAVIR WITHOUT ANY OTHER ANTIRETROVIRAL DRUGS IN PROTEASE INHIBITOR EXPERIENCED PATIENTS WITH NO REVERSE TRANSCRIPTASE INHIBITOR OPTIONS: A 24 WEEK COHORT ANALYSIS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P21 C. Rottmann1, B. Dauer1, N. v. Hentig1, M. Kurowski2, M. Stuermer1, S. Staszewski1 ATV/r + SQV therapy may be an option as salvage therapy for patients with RTI resistance or toxicity but may not be suitable for patients with heavy PI resistance and very low CD4 nadir. |
| P22 | [P22] CLINICAL EXPERIENCE WITH ATAZANAVIR Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P22 Paul Holmes, Paul Randell, Mark Bower, Brian Gazzard, Mark Nelson ATZ may be successfully utilized in individuals requiring switch of antiretroviral agents, in individuals who are PI naïve, and in those who are PI experienced. |
| P23 | [P23] EFFICACY AND TOLERANCE OF LOPINAVIR/RITONAVIR IN CLINICAL PRACTICE: AN OBSERVATIONAL PROSPECTIVE COHORT OF 1278 PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P23 Alain Lafeuillade1, Isabelle Cohen-Codar2, Michel Dupon3, Jean-Michel Livrozet4, Laurence Morand-Joubert5, François André Allaert6 This study shows a good efficacy of LPV/r-containing regimens and modest effects on lipid levels: early increase and no additional drug intervention generally required. |
| P24 | [P24] DOUBLE BOOSTED PROTEASE INHIBITORS IN SALVAGE THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P24 Bower, B, Gazzard, M. Nelson LPV/SQV is the preferred double boosted PI combination. The pharmacokinetic interaction between LPV and APV with both drug levels reduced may be a reason for these individuals to perform less well. LPV/SQV regimens are not recommended in patients with UPAMs or >4 PI mutations. LPV/APV regimens are not recommended unless careful TDM is performed. |
| P25 | [P25] EARLY RESPONSE TO A ONCE-DAILY REGIMEN CONSISTING OF BOOSTED ATAZANAVIR PLUS TWO NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS IN PROTEASE INHIBITOR-EXPERIENCED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P25 B. Dauer1, M. Stuermer1, G. Nisius1, A. Mueller1, M. Kurowski2, T. Lutz3, S. Klauke4, S. Staszewski1 In pts with >400 copies (n=6), ATV Cmin was a median 538 ng/ml (range 319-1340); RTV Cmin was a median 108 (range 19-197). Despite low plasma concentrations, early virologic response may be achieved with once daily ATV/r plus 2 NRTIs. |
| P26 | [P26] LOPINAVIR/R OR EFAVIRENZ PLUS TWO NRTI AS FIRST-LINE ANTIRETROVIRAL THERAPY: A NON RANDOMISED COMPARISON Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P26 A. De Luca1, A. Cozzi Lepri2, A. Antinori3, M. Zaccarelli 3, A. D'Arminio 4, M. Bongiovanni 4, S. Di Giambenedetto 1, D. Zinzi 3, P. Cicconi 4, F. Resta 5, B. Grisorio 6, S. D'Elia 7, R. Cauda 1 No differences in terms of tolerability and response to LPV or EFV could be detected. Although our study was not randomised, the results may reflect conditions under which drugs were used as well as real differences in potency/induced toxicity. |
| P27 | [P27] COST EFFECTIVENESS OF LOPINAVIR/R (LPV/R) VS. ATAZANAVIR IN TREATING ANTIRETROVIRAL-NAÏVE PATIENTS: MODELING THE COMBINED EFFECTS OF HIV AND HEART DISEASE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P27 K.N. Simpson1, M.P. Luo2, E. Chumney1, J. Macyck2, M. King1, S. Brun1, T. Ashraf1 The effect of LPV/r on long-term CHD risk was minimal compared to the increased risk of AIDS/death projected for ATV. The cost of lipid-lowering drugs and treatment for CHD was insignificant compared to the overall cost savings from LPV/r therapy. The choice of initial HAART regimen should be based on a regimen's expected efficacy and durability. |
| P28 | [P28] LOPINAVIR/RITONAVIR (LPV/R)-BASED THERAPY IN ANTIRETROVIRAL (ARV)-NAÏVE, HIV-INFECTED PATIENTS: 6-YEAR FOLLOW-UP OF STUDY 720 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P28 R.M. Gulick1, B. da Silva2, F. McMillan2, C. Benson3, A.C. White4, M. Glesby1, M. Thompson5, M. Albrecht6, P. Wolfe7, R. Murphy8, H. Kessler9, J. Eron10, C. Hicks11, K.R. King2, D. Calhoun2, N. Braun2, M. King2, S. Brun2 LPV/r-based therapy demonstrated sustained ARV activity and was generally well tolerated in ARV-naïve pts through 6 years of therapy. |
| P29 | [P29] EFAVIRENZ VERSUS LOPINAVIR/RITONAVIR IN AN ANTIRETROVIRAL COMBINATION WITH A BACKBONE REGIMEN OF TWO NRTIs Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P29 Periklis N. Panagopoulos, Sotirios Tsiodras, Garifalia Poulakou, Ioannis Katsarolis, Antonios Papadopoulos, Anastasia Antoniadou EFV as well as LOP/rit based HAART regimens accomplished an equally substantial effect on immunological and virological parameters in naïve patients. We cannot definitively exclude superiority of one arm in experienced patients since LOP/rit group had worse immunological status. |
| P30 | [P30] DATA FROM THE CLARE (CORE CENTER LOPINAVIR/R (LPV/R) ANTI-RETROVIRAL EFFECTIVENESS) COHORT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P30 R. Sherer4, O.M. Adeyemi1, E. Simeone1, S. Shott1, J. Despotes1, M. Lee1, J. Tschampa3 Describe the efficacy of LPV/r regimens in an urban clinic. A prospective observational study. 10/02 -10/03, HIV+ pts on LPV/r enrolled. At entry (E) and week 4-12 and week 13-36 visits, labs and anthropometrics were done. 120 HIV+ pts on LPV/r for a med. of 7 (0-41) mths enrolled. |
| P31 | [P31] RESPONSE TO LOPINAVIR/RITONAVIR-BASED HAART AND ITS DEPENDENCE ON PRIOR ARV EXPERIENCE: 24-WEEK INTERIM ANALYSIS (VIHVIR+ STUDY) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P31 Angel Burgos1, Esther Cabrero1 Since lopinavir / ritonavir (LPV/r) was approved for treatment of HIV in Spain (Aug 01) many supported its use as rescue for heavily pretreated patients (PT) while others supported its use in less experienced PT. |
| P32 | [P32] USE OF LPV/R IN HIV-INFECTED PATIENTS FAILING A FIRST PROTEASE-INHIBITORS-CONTAINING HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P32 Marco Bongiovanni1, Teresa Bini1, Antonio Di Biagio2, Paola Meraviglia3, Federica Tordato1, Paola Cicconi1, Antonella d'Arminio Monforte1 Among 15 patients not reaching HIV-RNA<50 cp/ml, 5 had ?5 mutations in the protease region which reduce susceptibility to LPV/r (1 discontinued LPV/r for gastrointestinal intolerance), 5 had no mutations (2 discontinued LPV/r for gastrointestinal intolerance) and 5 had ≥6 mutations (all discontinued LPV/r); all pts discontinuing LPV/r do not achieve HIV-RNA <50 cp/ml throughout the study. LPV/r showed to be highly effective and well tolerated in HIV pts failing a first PI-HAART. |
| P33 | [P33] VIROLOGICAL AND IMMUNOLOGICAL OUTCOME OF STAVUDINE (D4T) AND TENOFOVIR (TDF) COMBINATION AS NRTI BACKBONE IN PATIENTS WITH HIGH RATE OF TIMIDYNIC ANALOGUE MUTATIONS(TAM) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P33 Paola Nasta, Giuseppe Paraninfo, Andrea Patroni, Silvia Costarelli, Giampiero Carosi Although an high number of TAM, d4T+TDF combination containing HAART regimens seems to be effective in heavily pre-treated Pts. |
| P34 | [P34] USE OF ANTIRETROVIRAL DRUGS IN CORRECTIONAL FACILITIES Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P34 E. Pontali, L. Papa, F. Toscanini, A. Levati, C. Lugani, R. Papatola, M. Zaccardi, F. Ferrari HIV+ prisoners can receive adequate ART in CFs. However, differences exist in drug use between in and out of CFs (NVP > EFV; frequent triple NRTIs) and in the use of double NRTIs combinations. Such differences can be justified by the specific characteristics of the HIV+ prison population. Furthermore, in consideration of the wide variety of employed regimens and of the turn-over of prisoners (to and from freedom), the need of a good prison pharmaceutical service must be underscored to guarantee the proper and regular procurement, and the availability (for new entries from freedom, transfers) of antiretroviral drugs. |
| P35 | [P35] USE OF A TRIPLE NUCLEOSIDE ANTIRETROVIRAL REGIMEN (TRIZIVIR™) IN CLINICAL PRACTICE: A RETROSPECTIVE ANALYSIS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P35 Ines V. Pinto, Anabela S. Marques, Vanda Castro, Jose Vera Simplification with TZV in pts with undetectable viremia provides continued virological suppression. When TZV is used in naïve pts, our results show that the majority of pts with baseline VL >30.000 c/ml fail virologically. |
| P36 | [P36] ABACAVIR, LAMIVUDINE AND ZIDOVUDINE (ALZ) IN ANTIRETROVIRAL-NAÏVE HIV-INFECTED PATIENTS WITH PROFOUND IMMUNOSUPPRESSION (CD4+ CELLS < 100/mm³: A MULTICENTER OBSERVATIONAL STUDY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P36 Juan Berenguer1, Pérez-Elas María Jesus2, Resino Salvador1, Knobel Hernando3, Rivas-González Pedro4, José María Gatell5 In this large cohort of naïve HIV+ Pt with CD4+ < 100/mm³ and frequent prior ADC, the triple-NRTI regimen of ALZ was relatively well tolerated and effective. Poor adherence and baseline VL were factors independently associated with VF. |
| P37 | [P37] SOME TRIPLE NUCLEOSIDE REGIMENS MAY BE A GOOD TREATMENT ALTERNATIVE IN A SUBSET OF HIV+ PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P37 Ivana Maida1, Marina Nunez2, Paloma Gil2, Juan Gonzalez-Lahoz2, Vicente Soriano2 The limited potency of TZV must be balanced with the benefit derived from its convenience. Our data suggest that TZV might be a valid alternative for some HIV populations, such as those at higher risk for liver toxicity and/or poor drug compliance and/or with a need for simple and free-from-interactions regimens. |
| P38 | [P38] RETROSPECTIVE EVALUATION OF NRTI-ONLY HAART REGIMENS CONTAINING TDF Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P38 James D. Scott, Peter R. Wolfe2, Robert K. Bolan3, Ryan Quist1, Bill Guyer4 Virologic response of patients given NOR was comparable to those given NNPIR. However, there was a selection bias in favor of the NOR group towards undetectable baseline VLs. Development of K65R was rare. |
| P39 | [P39] HEAD-TO-HEAD COMPARISON OF THE ONLY TWO FIRST-LINE ANTI-HIV REGIMENS RECOMMENDED FOR ANTIRETROVIRAL NAÏVE PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P39 Roberto Manfredi, Leonardo Calza, Francesco Chiodo International guidelines propose either L or E as equivalent first-line therapy of HIV disease, but in absence of randomized data the regimen selection should consider the initial immunologic-disease status. Given the different cost of these 2 therapeutic approaches, appropriate pharmacoeconomic studies are also needed. |
| P40 | [P40] EVALUATION OF IMMUNOVIROLOGICAL OUTCOME AND SAFETY OF ATAZANAVIR CONTAINING HAART (EAP) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P40 Federica Tordato1, Elisabetta Chiesa1, Amedeo Capetti2, Antonio Di Biagio5, Clara Abeli4, Stefania Merli3, Marco Bongiovanni1, Roberto Rossotti1, Antonella d'Arminio Monforte1, Teresa Bini1 In our study ATV containing HAART was well tolerated in advanced HIV pts. Use of ATV seems associated with a moderate reduction of VL. |
| P41 | [P41] CLINICAL EXPERIENCE WITH RITONAVIR BOOSTED ATAZANAVIR Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P41 Mark Pakianathan1, Waleed Hamad1, Joanna Taylor1, Macky Natha2, Helen Pritchitt1, Brett Marrett1, Tariq Sadiq1, Mark Wansborough Jones1 ATZ/r appears safe and effective in the management of treatment experienced patients including those switching from an effective PI contianing regimen. Longer term follow up is required to ascertain durability. |
| P42 | [P42] ATAZANAVIR USE IN THE GERMAN EARLY ACCESS PROGRAM Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P42 A. Stoehr, K. Graefe, A. Plettenberg Switch to an ATV containing regimen in this highly heterogeneous group of patients showed good immunologic and favourable virologic results. Chlesterol and glucose remained stable, initially elevated triglycerides decreased to normal. Most patients showed the typical drug related side effect hyperbilirubinema without liver toxicity, with one patient switched to unboosted ATV. Other side effects were rare, the acceptance was good. For some "hard to treat" patients qd ATV containing ART was the first effective treatment. |
| P43 | [P43] LONG-TERM FOLLOW-UP OF A COHORT OF ANTIRETROVIRAL EXPERIENCED HIV-1 INFECTED PATIENTS SIMPLIFIED TO TRIZIVIR Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P43 Andrea Holmes, Laura McCullagh, Colm Bergin, Fiona Mulcahy Following discussion of ACTG 5095 at IAS in 2003, use of AZT/3TC/ABC has been discouraged. Our experience is of a low rate of virological failure. |
| P44 | [P44] PATIENT SATISFACTION WITH ABACAVIR (ABC)-LAMIVUDINE (3TC) FIXED DOSE COMBINATION (FDC) TABLET ONCE DAILY (QD) COMPARED WITH ABC AND 3TC TWICE DAILY (BID) IN HIV-1 INFECTED PATIENTS (ESS30008) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P44 Maria Watson1, Christina Hill-Zabala1, Nestor Sosa2, Edwin DeJesus3, Allison Florance1 Compared with ABC+3TC BID, satisfaction with tx convenience was significantly improved in pts on ABC/3TC FDC QD. Symmetrical dosing regimens seem to enhance satisfaction. |
| P45 | [P45] ABACAVIR + LAMIVUDINE (ABC/3TC) FIXED DOSE COMBINATION (FDC) ONCE DAILY (QD) COMPARED TO ABC+3TC TWICE DAILY (BID) IN HIV-1 INFECTED SUBJECTS (ESS30008) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P45 Christina Hill-Zabala2,Nestor Sosa1, Edwin DeJesus3, Gisela Herrera4, Allison Florance2, Judy Johnson2, Maria Watson2, Mark Shaefer2 24-wk interim analysis established ABC/3TC FDC QD as noninferior to ABC+3TC BID in a NNRTI or PI-containing regimen. A nucleoside backbone of ABC+3TC administered QD or BID is effective, durable, and well-tolerated. |
| P46 | [P46] PILOT STUDY OF ONCE-DAILY (QD) QUAD THERAPY WITH TRIZIVIR (ABC/3TC/ZDV) AND EFAVIRENZ (EFV) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P46 Peter Ruane1, Joseph Lang2, Edwin DeJesus3, Daniel Berger4, Robin Dretler5, Allan Rodriguez6, Doug Ward7, Michael Lim8, Qiming Liao8, Sunila Reddy8, Marty StClair8, Mark Shaefer8 In this pilot study of subjects suppressed on TZV BID + EFV, switching to TZV QD + EFV (3 tablets QD) was associated with similar rates of virologic suppression and tolerability, compared to continued TZV BID + EFV. |
| P47 | [P47] EFFICACY, SAFETY, ADHERENCE AND PHARMACOKINETICS OF THE SIMPLIFICATION TO A ONCE DAILY REGIMEN WITH NNRTIS IN PATIENTS PREVIOUSLY RECEIVING ANTIRETROVIRAL THERAPY TWICE DAILY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P47 Javier Moya, Jose L. Casado, Lidia Aranzabal, Ana Marin, Ana Moreno, Santiago Moreno The use of a QD regimen with ddI+3tC+NNRTIs is useful, well-tolerated, and increase adherence, even in patients receiving a BID regimen. Plasma trough levels of nevirapine support its use in a QD regimen. |
| P48 | [P48] ONCE DAILY TENOFOVIR, LAMIVUDINE AND EFAVIRENZ IN PREVIOUSLY SUPPRESSED HIV-1 INFECTED PATIENTS. 12 WEEKS PRELIMINARY DATA FROM THE SEINORTE COHORT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P48 J. Arrizabalaga1, K. Aguirrebengoa2, A. Chocarro3, M.J. Munoz4, J.A. Oteo5, S. Echevarria6, P. Labarga7, C. Farinas6, G. Peralta8, J. Camino1, P. Ferrer9 ARV treatment simplification to a once daily regimen containing TDF, 3TC and EFV seems to be safe, well-tolerated and virologically and immunologically effective. |
| P49 | [P49] EFFICACY OF A ONCE DAILY (QD) REGIMEN OF NEVIRAPINE (NVP), LAMIVUDINE (3TC) AND TENOFOVIR (TDF) IN TREATMENT-NAÏVE HIV INFECTED PATIENTS: A PILOT STUDY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P49 William Towner, Hai Linh Kerrigan, Marc LaRiviere, Townson Tsai, Jim Nomura, Joseph Chang, Erika Marmolejo At 24 weeks of therapy, only 43% of antiretroviral naïve pts given NVP/3TC/TDF as QD therapy achieved a VL < 75 c/ml. Despite good adherence, those with BL VL > 100,000 c/ml were most prone to failure, largely due to NVP resistance (Y181C). |
| P50 | [P50] EXPERIENCE OF COMBINATION HAART WITH 3TC+DDI+EFV IN A SIMPLIFIED QD REGIMEN AND IN PATIENTS WITH IMMUNOVIROLOGIC FAILURE DUE TO LACK OF ADHERENCE TO MORE COMPLEX HAART REGIMENS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P50 Francisco J. Vera, Josefina Garcia, Onofre J. Martinez, Rafael Vilaplana, Trinitario Sanchez, Jose A. Garcia During follow-up, the combination 3TC-DDI-EFV proved to be a highly efficacious and well tolerated in patients with QD simplification regimen. In patients with poor adherence, other strategies must be considered to provide best results in terms of adherence and efficacy. |
| P51 | [P51] ONCE-DAILY COMBINATION THERAPY WITH LAMIVUDINE, TENOFOVIR AND NEVIRAPINE IN NAÏVE AND PRETREATED HIV1-INFECTED PATIENTS: 48-WEEK RESULTS OF THE READMUNE STUDY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P51 Laurent Roudiere The once-daily combination of 3TC, TDF and NVP could be a new option for naive HIV-infected patients and for treatment simplification in pretreated patients. In case of virologic non response or failure, the low genetic barrier of the 3 drugs led to the rapid appearance of mutations associated with high level of resistance. |
| P52 | [P52] SAFETY AND PHARMACOKINETICS OF THE USE OF NEVIRAPINE ONCE DAILY IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P52 Jose L. Casado, Javier Moya, Lidia Aranzabal, Ana Marin, Ana Moreno, Santiago Moreno Nevirapine 400 mg once daily shows a similar pharmacokinetic profile to the use of 200 mg twice daily, and it could improve the adherence. The rate of rash or hepatotoxicity was not higher than expected, and was related to alcohol abuse and previous liver disease. |
| P53 | [P53] ONCE-DAILY BOOSTED DUAL PROTEASE INHIBITOR AS SALVAGE THERAPY IN HEAVILY PRETREATED HIV-INFECTED PATIENTS. A PILOT STUDY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P53 Luigia Elzi, Hans H. Hirsch, Julian Mettler, Monika Blasko, Manuel Battegay Our preliminary results suggest that boosted dual PI regimen given OD (LPV/r plus IDV), possibly as DOT, may be an important salvage therapy for selected pts with poor adherence and no NRTI/NNRTI options. |
| P54 | [P54] CLINICAL AND PSYCHOLOGICAL IMPACT OF PROLONGED NELFINAVIR-CONTAINING REGIMENS. PSIRENE STUDY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P54 Carmina R. Fumaz, Jose Lopez Aldeguer, Fernando Lozano, Hernando Knobel, Pompeyo Viciana, Bonaventura Clotet A correlation (p<0.05) between higher time on tt and low levels of D and F was found. After 72 w a NFV-containing regimen maintains viral suppression, stable QOL and high ADH. ES improved, especially D and F. A relative complex tt with virological success and well-tolerated could be mantained for prolonged time. |
| P55 | [P55] LOWERING STAVUDINE DOSAGES DOES NOT COMPROMISE ANTI-VIRAL EFFICACY IN HIV-1 INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P55 Myriam Kirstetter2, Cyrille Delpierre1, Lise Cuzin1, Muriel Alvarez1, Sarah Khatibi1, Eric Bonnet1, Martine Obadia1, Bruno Marchou1, Patrice Massip1 Reduced-dose stavudine containing regimens maintained virologic suppression and CD4 increase on a 12-months period. Further studies are needed to assess the improvement of the long term toxicities. |
| P56 | [P56] DEVELOPING A COMPREHENSIVE COMMUNITY PREPAREDNESS FOR ARVS TREATMENT IN UGANDA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P56 Matovu Umar Community preparedness for ARV'S will mean having the necessary information, knowledge, skills and materials including regular, uninterrupted supplies of Medicine and diagnostics. |
| P57 | [P57] A COMPARISON OF SIX ANTIVIRAL REGIMENS IN DRUG-NAÏVE PATIENTS (THE CRIPPLED STUDY) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P57 Giuliano Rizzardini1, Daria Trabattoni2, Amedeo Capetti 3, Marco Migliorino1, Gianmarco Vigevani3, Mario Clerici2 These preliminary results suggest that ABC-containing regimens are associated with the highest CD4 counts and the strongest suppression of HIV plasma viremia, whereas boosterized PI-containing regimens have a more robust effect on functional immune parameters after 6 months from starting thepaphy in drug-naïve patients. |
| P58 | [P58] TOLERABILITY, VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF EFAVIRENZ IN PRE-TREATED LONG TERM HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P58 Axel Adam1, Carl K. Schewe1, Thomas Meier2, Hauri Goey1, Lutwin Weitner1 In clinical practice Efavirenz exhibits strong antiviral and immunologic activity comparable to controlled clinical trials even in pre-treated long term HIV-infected patients with good tolerability and a low rate of virologic failure. |
| P59 | [P59] ARAMIS: AN OBSERVATIONAL PROSPECTIVE STUDY OF PATIENTS RECEIVING A ONCE DAILY ANTIRETROVIRAL REGIMEN. FIRST DATA ANALYSIS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P59 R. Landman1, Y. Mouton2, I. Ravaux3, P. de Truchis4, A. Smith1 These first data confirm the high satisfaction index and adherence of pts during the first months of a QD antiretroviral regimen. |
| P60 | [P60] IMPROVED AND DURABLE CONTROL OF HIV-VIRAEMIA AMONG PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY FROM 1998 TO 2003 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P60 Laura Lehtola-Vanhanen, Pia Kivelä Veli-Jukka Anttila, Jussi Sutinen, Matti Ristola HAART has changed the lives of HIV-infected patients dramatically, but it can not be achieved without good adherence. We have shown here that long lasting treatment goals wtih HAART can be achieved in more than 85% of patients. This improved and durable virological succes can be obtained by a well-structured clinical system taking care of our patients and by emphasising adherence as the most important tool of achieving our goals of therapy. |
| P61 | [P61] THE EFFICIENCY OF SHORT COURSE OF HAART IN PATIENTS WITH PRIMARY HIV-INFECTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P61 Andrey V. Miroshnichenko, Alexey V. Kravchenko For patients with primary HIV-infection who initially have VL more than 100,000 copies/ml and CD4 cell numbers less than 350 cells/ml, the course of HAART should be prolonged up to 6 or even 12 months. |
| P62 | [P62] EFAVIRENZ AND NEVIRAPINE IN CLINICAL PRACTICE. A RETROSPECTIVE STUDY IN A COHORT OF NAÏVE AND EXPERIENCED SUBJECTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P62 Benedetto M. Celesia, Luciano Nigro, Alda Ragusa, Maria T. Mughini, Filippo Palermo, Fabio Bisicchia, Rosario Russo For patients with primary HIV-infection who initially have VL more than 100,000 copies/ml and CD4 cell numbers < 350 cells/ml, the course of HAART should be prolonged up to 6 or even 12 months. |
| P63 | [P63] EFFICACY OF EFAVIRENZ VS. NEVIRAPINE WITH A BACKBONE OF TWO NRTIS. RESULTS AT 48 WEEKS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P63 Jorge M. Contarelli, Lucila I. Massera, Gabriela E. Alberich, Martha G. Michaan Restoration of CD4 cell was 64% and 215% for EFV, and 72% and 169% for NVP respectively. (p = 0.07). At 12 month 85,7% in the arm on EFV and 71,0% on NVP remain undetectable (p = 0.6). Adverse events were seen in 16,0% with EFV and 8,3% with NVP. The rate of discontinuation were 3,8% with NVP and 4,67% with EFV. Both NNRTI have similar efficacy and durability at 48 weeks. Adverse events were higher with EFV but the rate of discontinuation or withdraw treatment were similar in both arms. |
| P64 | [P64] SUPERVISED TREATMENT INTERRUPTION (STI) IN CHRONICALLY HIV INFECTED PATIENTS WITH LONG TERM WELL CONTROLLED VIRAL LOAD UNDER ANTIVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P64 Philippe A.L. Henrivaux1, Benoit Kabamba2, Yvette Fairon3, Patrick Goubau2 STI in HIV patients with very low viral load on ART, under carefull clinical and biological control, remained safe in our experience. Different profiles of evolution of CD4 cells and viral loads are observed during STI. Some patients benefit from a long treatment interruption avoiding side effects of continuous drug exposure. Therefore, it would be interesting to predict the evolution during STI. |
| P65 | [P65] MULTICENTER STUDY OF AN INDINAVIR/LOPINAVIR BASED REGIMEN IN SALVAGE THERAPY OF NUCLEOSIDE-ANALOGUES EXPERIENCED PATIENTS (MILESTONE) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P65 E. Lauenroth-Mai1, H. Gellermann2, S. Fenske2, W. Mondorf3 The combination of IDV and LPV/r provided a robust virological and immunological response in multiple treatment-experienced subjects that was maintained throughout the observation period of approximately one year. |
| P66 | [P66] DIFFERENT IMPACT OF EFFICACY, TOXICITY AND CONVENIENCE ON THE PRESCRIPTION OF ANTIRETROVIRAL DRUGS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P66 Vicente Soriano,Inmaculada Jimenez-Nacher, Carmen de Mendoza, Benito Garcia-Diaz Trends in ARV prescription reflect the priorities perceived by physicians at any given time point. While potency of PIs seem to drove prescriptions before 1999, the awareness of their potential toxicities pushed NNRTIs since then. More recently, convenience seems to have emerged as a new priority, which has favoured the prescription of TZV or TDF. |
| HIV MANAGEMENT IN RESOURCE-POOR SETTINGS |
|
| P67 | [P67] HIV-PATIENTS ACROSS EUROPE: REGIONAL DIFFERENCES IN PATIENT CHARACTERISTICS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P67 D. Podlekareva, W. Bannister, L. Viksna, A. Mocroft, B. Knysz, P. Reiss, N. Chentsova, D. Duiculescu, J.D. Lundgren, O. Kirk These results reflect substantial regional differences in demographic and clinical characteristics of HIV-pts across Europe and demonstrate the more recent epidemic in CE and EE. The implications of the limited usage of HAART in EE require continuous follow-up. The high percentage of AIDS pts in CE and EE who have TB is a special concern, as high prevalence of multi-resistent mycobacteria have been reported in these regions. |
| P68 | [P68] TWO-YEAR OUTCOMES OF THE FIRST PUBLIC-PRIVATE COMMUNITY ANTIRETROVIRAL PROGRAMME IN CAPE TOWN , SOUTH AFRICA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P68 Catherine Orrell, Linda-Gail Bekker, Motasim Badri, Robin Wood In patients with advanced HIV the initial regimen of d4T, 3TC and NVP or EFV is well tolerated. This community cohort displays high levels of adherence and viral suppression. |
| P69 | [P69] EVALUATION OF HIV MANAGEMENT IN PREGNANT WOMEN IN FOUR CENTRES IN NIGERIA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P69 Chinazo O. Nwashili1, Uzoma O. Azubike2, Grant-Isibor I. Irene3 Poverty, ignorance and fear of stigmatization are huge obstacles in HIV management in resource-poor settings. Although drugs were without cost for participants 75% of HIV positive women refused to participate for fear of stigmatization. Use of Nevirapine was more acceptable because of the dosing. Bi and tritherapy was not readily available because of cost. Monotherapy will increase the chances of resistance developing in resource-poor setting which will eventually become a problem if not addressed. |
| P70 | [P70] COMMUNITY TREATMENT SUPPORT IN A RESOURCE LIMITED SETTING: THE USE OF DOT-HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P70 John A. Idoko1, Oche O. Agbaji1, Patricia O. Agaba1, Jean Louis A. Sankale2, Phyllis M. Kanki2 The virological and immunological responses to treatment at 6 months demonstrate that in resource limited settings, the use of sustained adherence education and family and community members to implement DOT-HAART can greatly enhance adherence to antiretroviral therapy and therefore ensure a durable virologic response. |
| P71 | [P71] TB A KEY DETERMINANT OF ART SUCCESS IN INDIAN SETTING: A MULTICENTRIC STUDY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P71 Dattatray G. Saple1, Satish B. Vaidya1, Shailendra N. Sawleshwarkar 1, Ravi Vadrevu2, Ved P. Pandey3 Choice of HAART regimen in absence of TB does not significantly affect success. Atypical TB is more likely to experience ART failure. ART success rates with Rifampicin based ATT are likely to be similar in typical and atypical TB presentations. |
| P72 | [P72] HEMATOLOGIC COMPLICATIONS IN THE ERA OF HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P72 S.N. Pujari, A. Patel2, S. Bhagat1, J. Patel2, K. Patel2, S. Katke1 Hematologic complications are common in patients with clinical AIDS. Macrocytosis with AZT/d4T can serve as one of the markers for assessing adherence. HAART is associated with lower prevalence of hematologic complications in spite AZT use. However CD4<200 is a major risk factor for development of hematologic complications. |
| P73 | [P73] TRAINING 23,000 HEALTH CARE WORKERS IN HUBEI PROVINCE, PEOPLES REPUBLIC OF CHINA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P73 Renslow Sherer, Caroline Teter1, Gui Xien2, Bonnie Shen1, Diana Liu Ping1 Large scale HIV training in China is feasible. Local health leadership, a strong university partner, a revered local HIV expert, and regional ownership are invaluable. |
| P74 | [P74] HIV INFECTION AMONG PREGNANT WOMEN AND NEWBORN AND ANTIRETROVIRAL CHEMOPREVENTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P74 Elena N. Vinogradova1, Alexey A. Iakovlev2, Eugene F. Senchik1, Aza G. Rakhmanova2 Infants from HIV positive mothers without prenatal care need special medical and social support. We are discussing the possibility to have a special unit for abondened infants from HIV positive mothers. |
| P75 | [P75] THE 'REAL' ANTI RETROVIRAL THERAPY EXPERIENCE OF RESOURCE POOR SETTINGS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P75 Milind Bhrushundi1, Ramesh Mundle1, Radha Munje2, Dinesh Agrawal3 ART coverage was 18.90%. Most of the patients opted for the cheaper regimens. Adherence was more with the regimen less than Rs2000 per month. This is again not a real resource poor settings as those who could afford the consultation charges have attended the OPD. The really real resource poor setting may be still different. |
| P76 | [P76] PROVISION OF ANTI-RETROVIRAL THERAPY IN A CLINICAL COHORT IN RURAL SW UGANDA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P76 Lieve Van der Paal, Billy N. Mayanja, Joseph O. Mugisha, Leigh Anne Shafer, Heiner Grosskurth In spite of starting ART with relatively advanced HIV disease (WHO stage 3 or 4), most patients improved clinically as well as immunologically. In this rural African setting, mortality is highest in patients with CD4 counts below 50 cells/μl. Almost 20% of patients had to switch drugs after starting treatment. This indicates the need for frequent monitoring during the first months on ART. |
| P77 | [P77] FREE ART INITIATIVE - CHALLENGES IN A DEVELOPING COUNTRY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P77 Alaka K. Deshpande, Anshuman Malviya The experience from planning, procurement, implementation and evaluation will be presented. |
| P78 | [P78] PRELIMINARY CLINICAL EXPERIENCE OF 3 DRUG ANTIRETROVIRAL THERAPY IN 68 PERSONS WITH HIV/AIDS FROM MUMBAI , INDIA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P78 Mahendra M. Kura HAART therapy under careful supervision is beneficial in reducing morbidity improving quality of life free of OI's however mortality continues.Cost and compliance are major hurdles in the Indian set up. Long term studies still needed. |
| P79 | [P79] EXPERIENCE OF ANTIRETRIVIRAL DRUG USE IN A ROUTINE CLINICAL SETTING IN KAMPALA , UGANDA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P79 Doris Mwesigire A good immunological and clinical response to ART in a routine clinical setting was found. Development of side effects and longer duration on ART are associated with non-compliance which reduces immunological response strategies to maintain a high level of compliance with ART, including intensive patient education are important. |
| P80 | [P80] EPIDEMIOLOGIC AND CLINICAL ASPECTS OF HIV INFECTION AMONG FOREIGN WORKERS LIVING IN TEL AVIV (ISRAEL) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P80 Ben Werner, Israel Yust, Nurit Vardinon, Elizabetta Mardkhah, Zivia Werner, Michael Burke Various endeavours, including our free testing, reduced medical and lab. fees and providing available drugs, have improved overall prognosis in this high-risk group somewhat and reduced vertical transmission remarkably. Nevertheless, much more remains to be done to combat the HIV epidemic and achieve Western standards in this subpopulation. |
| P81 | [P81] EARLY PI TO NNRTI SWITCH IN LATE HIV DISEASE: A COST EFFECTIVE LONG TERM TREATMENT PLAN IN RESOURCE LIMITED SETTINGS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P81 Kiran N. Katkar Early PI to NNRTI switch appears effective feasible option in settings where costs and treatment simplifications over-ride in determining ART success rates. Benefits need to be confirmed in larger RTCs with longer longitudinal follow-up with monitoring pVL and resistance testing. |
| P82 | [P82] GEDE FOUNDATION PARTNERSHIP PROGRAMME TO IMPROVE HEALTH INSTITUTIONS AND STATE GOVERNMENTS' CARE AND PREVENTION EFFORTS FOR SLOWING HIV/AIDS SPREAD Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P82 A. Olusola, M. Njoku, H. Khamofu, S. Agwale This observation demonstrates the dire need of ARVs drugs across Nigeria. It also confirms the urgent need of improved access to ART by People Living with HIV/AIDS (PLWHAs). It concludes with a call for many more people to team up with the government to make ARVs more accessible and available. |
| P83 | [P83] INFORMATION TECHNOLOGY USE IN HIV/AIDS TREATMENT AND CARE: MAJOR ISSUES AND CONCERN IN NIGERIA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P83 A.O. Adeyemi, M.H. Ayegboyin There is a need to lay a proper infrastructure for Electronic Medical Records in all our hospitals involved in HIV/AIDS treatment and care. There is a need to set up rural and urban telehealth facilities that will re-train or update our providers in HIV management. Besides, the potentials of Telehealth should be maximally explored in Nigeria through the creation of Telehealth training centers in areas with highest HIV prevalence. There is also a need to introduce handheld computer or personal digital assistants (PDA) to assist providers. |
| P84 | [P84] DISCLOSURE OF SERO-STATUS AS A KEY DETERMINANT OF SUCCESSFUL DRUG THERAPY (TASO MBARARA EXPERIENCE) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P84 Nathan Tumwebaze For the success of drug interventions and treatment among people living with HIV/AIDS, the issue of disclosure of sero-status should be encouraged for better quality of life. |
| P85 | [P85] TREATMENT OF HIV INFECTED PATIENTS WITH COMBRETUM MICRANTHUM IN WEST AFRICA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P85 G. Ferrea, P. Vigano, G.B. Priuli, J. Abogdaze, S. Cavallari, T. Vincenzi, G. Cenderello CM is a low cost and safe treatment. So we need further study in order to define different schedules of treatment and a more appropriate clinical and immunological evaluations. |
| P86 | [P86] MEDICAL DONATIONS TO DEVELOPING NATIONS AND SHORTFALLS IN THE GLOBAL FUND Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P86 Jeremy Landau, Belinda Cantebury-Counts It becomes clear that many Developing Nations lack the infrastructure and financial resources to assess and meet the treatment needs of their HIV/AIDS population. In addition, limitations within the Global Fund necessitate other means of addressing the HIV/AIDS pandemic. Donor programs heighten awareness, provide much needed medical resources, and extend lives. |
| P87 | [P87] PROVIDING ANTIRETROVIRAL THERAPY FOR AN IRANIAN HEALTH INSURER: ASSESSING THE COSTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P87 Vahid Nowbahar, Farzad Jalali We demonstrated that for a moderate increase in health insurance premium, health insures in Iran could afford to provide ART to its members. |
| P88 | [P88] CLINICAL OUTCOME OF HIV INFECTED PATIENTS ACCORDING TO IMMUNOLOGIC RESPONSE AFTER HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P88 Seyed Amir Mohajerani, Minoo Mohraz, Nader Zarinfar, Mehrnaz Rasoolinejad, Mahboobe Hajabdolbaghi Initial CD4 as a prognostic factor was valuable only in patients with history of monotherapy, also low initial CD4 was correlated to death. Initial CD4 may help clinician to predict patient's outcome to HAART. Drug resistance is the major factor to treatment failure. it is correlated to lack of drug diversity, and virologic lab Tools. |
| P89 | [P89] ASSESSING MEN'S KNOWLEDGE AND ATTITUDE TOWARDS MICROBICIDES Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P89 James M.J. Mayanja This study shows that while men understand the need of women to protect themsleves, they would like to be involved in decision making process. Introduction of microbicides will certainly influence use of condoms. Success of microbicides will be aided by support from men. |
| P90 | [P90] INCREASED SKIN INFECTION BY EXFOLIATIVE STAPHYLOCOCCUS AUREUS AND HIGH USAGE OF STEROIDS - HEALTH PROBLEMS FOR HIV/AIDS AND NON HIV/AIDS PEOPLE IN KENYA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P90 Ngugi M. William, Muthotho N. James The use of this very low concentration of chlorhedine/cetrimide ointment by NGOs, has drastically reduced the suffering of patients. We recommend topical steroids should not be used on HIV/AIDS and Non HIV/AIDS people with this infections. |
| ADHERENCE, RESISTANCE AND MONITORING |
|
| P91 | [P91] ADHERENCE IN COMBINATION WITH LOPINAVIR INHIBITORY QUOTIENT AND NUMBER OF ACTIVE ARVS PREDICTS VIROLOGIC RESPONSE IN HIGHLY ARV-EXPERIENCED PATIENTS RECEIVING HIGH-DOSE LOPINAVIR/RITONAVIR Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P91 Richard J. Bertz1, Jian Ling Li1, Richard A. Rode1, Bernard Vrijens2, Cheryl R. Foit1, Karmin Y. Robinson1, Scott C. Brun1 In combination with LPV IQ and number of active NRTIs, adherence to LPV/r predicts VR in multiple PI- and NNRTI-experienced PT at WK 24 and 48. |
| P92 | [P92] SALVAGE HAART GUIDED BY RULES-BASED (RB) OR PHENOTYPE-BASED (PB) HIV-1 GENOTYPE INTERPRETATION WITH OR WITHOUT TDM: THE RADAR TRIAL Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P92 C. Torti1, E. Quiros1, M. Regazzi2, A. De Luca3, F. Mazzotta4, G. Carosi5, RADAR-Master Group Ctrough correlates with VR independently from adherence and type of regimen. Moreover, VR was higher in pts randomized to TDM, although only in the short-term and in those assigned to the PB system. |
| P93 | [P93] ESTIMATION OF CLINICALLY RELEVANT CUTOFFS FOR PHENOTYPIC RESISTANCE DATA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P93 L. Bacheler1, B. Winters2, P.R. Harrigan3, M. Perez-Elias4, M. Miller5, S. Emery6, F. van Leth7, P. Robinson8, J.D.D. Baxter9, A. Pozniak10 CCO defined in this study apply a consistent approach to multiple drugs and a heterogeneous population of HAART treated subjects and are applicable to diverse patient populations. |
| P94 | [P94] ESTIMATED EXTENT OF CROSS-RESISTANCE TO PROTEASE INHIBITORS (PI) BOOSTED WITH RITONAVIR AMONG PI-EXPERIENCED SUBJECTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P94 Vincent Soriano, Carmen de Mendoza, Luisa Valer, Angelica Corral, Juan Gonzalez-Lahoz The main difference between TPV/r and other PI/r could be associated with the number of PR resistance mutations needed to affect its activity. The molecular flexibility of TPV could explain why a larger number of PR resistance mutations could be needed to abolish its inhibitory effect. Therefore, the drug might still be active when other ritonavir boosted PIs are not. |
| P95 | [P95] TREATMENT INTERRUPTIONS MAY INCREASE THE RISK OF TRANSMISSION OF DRUG-RESISTANT VIRUSES AMONG RECENT SEROCONVERTERS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P95 Vincent Sorianoon behalf of the Spanish HIV Seroconverters Study Group, Carmen de Mendoza, Carmen Rodriguez, Jose M Eiros, Javier Colomina, Federico Garcia, Pilar Leiva, Concepcion Tuset The rate of primary resistance in recent HIV seroconverters in Spain has steadily declined since 1997. Our data do not suggest that an increased proportion of non-B subtypes account for this finding. In contrast, we found that discontinuation of therapy might be associated with an increased risk of transmission of resistant viruses. |
| P96 | [P96] ANTIVIRAL EFFICACY OF STAVUDINE/TENOFOVIR COMBINATION IN HIV-INFECTED PATIENTS EXPERIENCED TO HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P96 A. Antinori1, M.P. Trotta1, P. Nasta2, T. Bini3, S. Bonora4, A. Castagna5, T. Quirino6, S. Landonio3, S. Merli 3, V. Tozzi1, M. Zaccarelli1, P. Marconi1, G. Di Perri4, M. Andreoni7, C.F. Perno1, G. Carosi2 Combining a thymidine-analogue with TDF could represent an effective strategy in pts with previous exposure to NRTIs. Genotype at baseline may predict virological success with type-1 TAMs negatively affecting VR. |
| P97 | [P97] INCORPORATING PATIENTS' SUGGESTIONS IN INDIVIDUALIZED INTERVENTION PROGRAM FOR IMPROVING ADHERENCE TO ANTIRETOVIRALS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P97 A. Antinori2, A. Ammassari1, M.P. Trotta2, P. Marconi2, R. Murri1, A. Cozzi-Lepri3, S. Melzi4, M. Zaccarelli2, P. De Longis2, G. Bontempo2, N. Ladisa5, L. Sighinolfi6, P. Nasta7, G. Madeddu8, A. d'Arminio Monforte4 Better patient-physician communication with the delivery of more detailed information related to treatment could be an useful and easy intervention to improve HAART adh. |
| P98 | [P98] BASELINE RESISTANCE IN AN ART-NAÏVE POPULATION: A POSSIBLE CONFOUNDING FACTOR? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P98 C. Craig1, C. Stone1, T. Bonny2 Thus ART-naïve subjects with significant resistance BL muts can by chance be randomised unequally in a large clinical study affecting on-therapy virology findings in the small VF subpopulations. |
| P99 | [P99] GENOTYPIC RESISTANCE TO BOOSTED AMPRENAVIR (APV) AND LOPINAVIR (LPV) OF CLINICAL ISOLATES FROM PATIENTS FAILING PROTEASE INHIBITORS (PI)-CONTAINING HAART REGIMENS: PREVALENCE AND PREDICTORS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P99 Andrea De Luca1, Simona Di Giambenedetto1, Antonella Cingolani1, Alessandra Bacarelli1, Giorgio Gatti2, Roberto Cauda1 After failing PI-based regimens, a vast majority of isolates retains genotypic susceptibility to APV/r and LPV/r. When planning a PI therapy, interpretation of genotypic PI resistance must consider the effect of PK boosting. |
| P100 | [P100] PREVALENCE OF MULTIPLE PROTEASE MUTATIONS AT POSITIONS 33, 82, 84 AND 90 AMONG PI-EXPERIENCED PATIENTS AND THE EFFECT ON VIROLOGIC RESPONSE TO LOPINAVIR/RITONAVIR-BASED REGIMENS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P100 M. King1, M. Norton1, S. Brun1, A.G. Marcelin2, I. Cohen-Codar3, E. Guillevic3, V. Calvez2, D. Kempf1 The presence of multiple PI mutations from positions 33, 82, 84, and 90 was uncommon in these pts despite extensive PI exp. Moreover, virologic response to LPV/r was not significantly reduced among pts with 3-4 such mutations. These results suggest that the presence of 3-4 mutations at the above positions may not be a reliable predictor of long-term LPV/r virologic potency. |
| P101 | [P101] EFFICACY OF FIRST-LINE ANTIRETROVIRAL THERAPY GUIDED BY RESISTANCE TESTING: THE RESINA STUDY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P101 Mark Oette1, Rolf Kaiser2, Ruth Leidel1, Martin Daeumer2, Torsten Feldt1, Arne Kroidl1, Gerd Faetkenheuer2, Stefan Mauss3, Juergen K. Rockstroh4, Dieter Haeussinger1 Prevalence of primary resistant HI-virus was 11 % in chronically infected HAART-naive patients in Germany. Unlike previous data, first-line HAART was equally effective in patients with and without resistant virus. Thus, genotypic resistance testing should become routine practice before first-line HAART. |
| P102 | [P102] RELATIONSHIP OF UNDETECTABLE VIRAL LOAD, CHANGE IN CD4 COUNT AND ENFUVIRTIDE TREATMENT ON HEALTH-RELATED QUALITY OF LIFE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P102 N. Clumeck1, C. Cohen2, M. Thompson3, J-M Molina4, N. Wintfeld5, J. Green5 The improvements in HRQoL that have been previously presented are primarily explained by the greater efficacy of ENF+OB. After controlling for improvement in VL and CD4 count, there does not appear to be a negative effect of ENF administration on HRQoL. |
| P103 | [P103] NUCLEOTIDE AND AMINO ACID POLYMORPHISMS AT DRUG RESISTANCE SITES IN NON-B SUBTYPE VARIANTS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P103 Mark A. Wainberg1, Dan Turner1, Shlomo Maayan2, Bluma Brenner1 Conclusion The existence of different subtypes may only rarely affect patterns of drug resistance-associated mutations. |
| P104 | [P104] RESISTANCE CONFERRING MUTATIONS IN B VERSUS NON-B HIV CLADES AFTER TREATMENT FAILURE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P104 Franco Maggiolo1, Annapaola Callegaro2, Ravasio Laura1, Diego Ripamonti1, Giampietro Gregis1, Giampaolo Quinzan1, Luigi Fiorina2, Antonio Goglio2, Fredy Suter1 B and non-B HIV clades develop different resistance patterns during HAART both in the RT and Protease genes. In the near future HAART will be more widely available in sub-saharian Africa, where non-B strains are prevalent. The knowledge of resistance patterns in these subtypes will help care-givers to make decisions about drug sequencing and the risk of developing specific or inter-class drug resistance. |
| P105 | [P105] DRUG-RESISTANT GENOTYPES AMONG PATIENTS WITH HIV-1 B SUBTYPE AND NON-B VARIANTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P105 G. Di Nicuolo1, M. Gargiulo2, S. Battisti1, M. Starace1, T. Pizzella 2, M. D'abbraccio2, R. Punzi3, F. Simeone4, A. Maddaloni2 Our results showed a low diversity in the prevalence of drug resistance mutations between B and non-B HIV-1 strains. The genetic diversity of non-B variants probably does not play a major role in the development of resistance to antiretroviral drugs. |
| P106 | [P106] EVALUATING THE RISK OF DEVELOPING MULTI-DRUG RESISTANCE, USING A DATA-BASE OF PATIENTS UNDERGOING A GENOTYPE RESISTANCE TEST AFTER TREATMENT FAILURE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P106 M. Zaccarelli, V. Tozzi, F. Forbici, R. D'Arrigo, M.P. Trotta, G. Liuzzi, F. Soldani, P. De Longis, P. Narciso, C.F. Perno, A. Antinori Our data suggest that the probability of developing MDR in NRTI and PI classes increases by time of exposure. In contrast, high levels of MDR were observed in NNRTI-exposed patients with steady proportions overtime. Such types of data may help to control the occurrence of MDR in clinical practice. |
| P107 | [P107] PERSISTENCE OF NNRTI-RELATED MUTATIONS NOTWITHSTANDING THE ABSENCE OF PHARMACOLOGICAL PRESSURE WITH NNRTI IN VIVO Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P107 F. Soster1, E. Bulgheroni1, O. Vigano1, M. Bongiovanni1, M. Corbellino1, C. Magni2, T. Quirino3, M. Galli1, S. Rusconi1 Our study evidenced no reversion of NNRTI-related mutations in a group of NNRTI-naive patients during the entire observation period. This finding has important consequences on future treatment options, since we evidenced that these mutations remained stable overtime. We are conducting studies that will evaluate the impact of these particular mutations on HIV-1 replication capacity. |
| P108 | [P108] IMPACT OF CLINICAL CUT-OFF AND M41L AND L210W MUTATIONS OVER THE SUSCEPTIBILITY TO TDF AS INTERPRETED BY THE VIRTUAL PHENOTYPE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P108 F. Garcia1, M.C. Nogales2, J. Alcami3, I. Viciana4, S. Garcia-Bujalance5, C. Llopis6, J. Niubo7, M. Omeñaca8, J.C. Palomares9, F. Fernandez9, A. Farga 10 Cut-off 4.0 does not detect the reduction in susceptibility to TDF in presence of M41L and L210W. TDF cut-off 3.0 is sensitive to M41L and L210W effect, but there are a very high number of tests susceptible. The effect of M41L and L210W over TDF can only be observed with cut-off of >1.4. |
| P109 | [P109] APPROACHES FOR DEFINING CLINICAL CUTOFFS FOR PHENOTYPIC RESISTANCE DATA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P109 B. Winters1, L. Bacheler2, P.R. Harrigan3, M. Perez-Eliaz4, M. Miller5, S. Emery6, F. van Leth7, P. Robinson8, J.D. Baxter9, A. Pozniak 10 CCO based on % decrease of reference response are broadly applicable across a wide range of drugs, patient characteristics and treatment regimens and will enhance the clinical utility of phenotypic HIV resistance tests. |
| P110 | [P110] ATAZANAVIR DETERMINES A LOW DEGREE OF RESISTANCE EVOLUTION IN PI-EXPERIENCED HIV-1-INFECTED SUBJECTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P110 Francesca Soster, Elisabetta Bulgheroni, Mirko Lo Cicero, Ottavia Vigano Federica Tordato, Massimo Galli, Stefano Rusconi Genotype evolution within the protease region did not emerge during salvage therapy of multidrug-experienced patients. This feature warranted treatment response in HAART-failed patients and thus does not preclude the success of other PI-containing regimens. |
| P111 | [P111] SELECTION OF K65R MUTATION AND IMPACT ON VIRTUAL PHENOTYPE IN A LARGE SPANISH RESISTANCE COHORT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P111 M. Garcia Deltoro1, J.A. Garcia1, T. Puig2, R. Delgado3, M.C. Martinez-Toldos4, N.M. Martinez5, C. Gutierrez6, S. Melon7, J. Aguero8, M.J. Pena9, R. Carmona10, L. Perez-Alvarez10 Over half of the patients developing K65R were receiving treatment with TDF - the occurrence of this mutation was infrequent in patients treated with of TDF and Thymidine Analogs. A high frequency of K65R with M184V and Q151M was recorded. The drugs phenotypically most affected by the isolated appearance of K65R were 3TC and TDF. |
| P112 | [P112] GENOTYPIC AND PHENOTYPIC PATTERNS AND REPLICATION CAPACITY (RC) OF HIV-1 CONTAINING THE K65R OR L74V MUTATIONS IN REVERSE TRANSCRIPTASE (RT) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P112 Damian J. McColl1, Neil T. Parkin2, Michael D. Miller1 The K65R mutation continues to occur at a low and stable frequency (4.3%) in patient-derived HIV. L74V/I, M184V and TAMs occur at higher frequencies. TAMs do not associate frequently with K65R but frequently associate with L74V/I, leading to broad cross resistance. K65R and M184V cause significant reductions in RC; TAMs or L74V/I do not significantly reduce RC. |
| P113 | [P113] PRIOR ABACAVIR (ABC) OR DIDANOSINE (DDI) THERAPY WITH DEVELOPMENT OF L74V IS A RISK FACTOR FOR VIROLOGIC NON-RESPONSE AND DEVELOPMENT OF K65R IN PATIENTS TAKING TENOFOVIR DF (TDF) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P113 D.J. McColl2, A.S. Bae1, J.M. Waters1, N.A. Margot2, K. Borrota-Esoda1, M.D. Miller2 Prior ABC or ddI therapy can select for either L74V or K65R and can result in a bulk population genotype that shows L74V but does not detect low-level K65R. Subsequent therapy with TDF (that selects only K65R), may cause expansion of a pre-existing K65R mutant and poor virologic response. These data have implications for sequencing of NRTIs. |
| P114 | [P114] SUCCESSFUL ANTIRETROVIRAL SEQUENCING OF PATIENT-DERIVED HIV-1 ISOLATES CONTAINING A K65R MUTATION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P114 Bill Guyer2, Wenoah A. Veikley1, Anne Hey1, Trevor N. Hawkins1 In our practice we infrequently saw a K65R mutation develop and were able to successfully construct subsequent HAART regimens, with TDF being a part of the majority of these regimens. |
| P115 | [P115] K65R: A MULTIRESISTANCE MUTATION WITH INCREASING PREVALENCE IN CLINICAL PRACTICE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P115 C. Claudius, T. Berg, S. Dupke, W. Schmidt Since K65R causes multinucleosid resistance, HIV treatment regimens which exert high selective pressure on selection of K65R should be avoided. In accordance with other publications our results indicates that usage of certain TDF-based regimes seems to be a major cause for the observed increase in detection of K65R mutation since the end of 2002 (1). Combination of TDF with ZDV might prevent selection of K65R (2). |
| P116 | [P116] ATAZANAVIR (ATV) CCtrough, GENOTYPE AND GIQ AS PREDICTORS OF A 24-WEEK VIROLOGICAL RESPONSE IN HIGHLY EXPERIENCED PATIENTS TREATED WITH UNBOOSTED ATV Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P116 Elena Seminari1, Nicola Gianotti1, Simon Tiberi1, Enzo Boeri2, Paola Villani3, Mario Regazzi3, Monica Guffanti1, Giuliana Fusetti1, Adriano Lazzarin1, Antonella Castagna1 In this small group of failing, heavily pretreated pts, the n of PRMs at baseline is the only predictor of 24-week VR to unboosted ATV. |
| P117 | [P117] CHANGES IN ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY MEDICATIONS AND DETERMINANTS OF WORSENING ADHERENCE: RESULTS FROM THE ADICONA STUDY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P117 M.P. Trotta1, A. Ammassari2, A. Cozzi-Lepri3, P. Marconi1, R. Murri2, P. De Longis1, N. Ladisa4, M. Zaccarelli1, G. Bontempo1, P. Nasta5, G. Madeddu6, A. d'Arminio Monforte7, A. Antinori1 In our cohort, 45% of pts reported at least one non-adherence behaviour during follow-up. Worsening adh across the time was associated with more longer HAART exposure, and with treatment modification, emphasizing the importance of appropriate and frequent monitoring of adherence. |
| P118 | [P118] RESPONSE TO HAART IN EASTERN EUROPE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P118 W. Bannister1, D. Podlekareva2, A. Horban2, A. Mocroft1, A. Rakhmanova2, B. Ledergerber2, S. Chaplinskas2, J. Gatell2, J. Lundgren2, O. Kirk2, A. Phillips on behalf of the EuroSIDA Study Response to HAART appears to be similar across regions including EC. As numbers of patients studied in EE increase, it will be possible to make more robust comparisons between EE and other regions. |
| P119 | [P119] TEMPORAL PATTERNS OF HIV-1 GENOTYPIC RESISTANCE AMONG ANTIRETROVIRAL EXPERIENCED PATIENTS IN GREECE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P119 D. Paraskevis1, E. Magiorkinis1, G. Magiorkinis1, A. Katsoulidou1, H. Sabatakou2, G. Perdios2, P. Gargalianos2, M. Lazanas3, M. Chini3, V. Paparizos4, C. Botsi4, G. Panos5, G. Chryssos6, A. Karafoulidou7, O. Katsarou7, A. Antoniadou8, G. Poulakou8, I. Kontos9, T. Kordossis9, G. Petrikkos9, C. Haida1, A. Hatzakis1 The prevalence of NRTI and PI resistance was found to decrease, in contrast to the increasing prevalence of NNRTI resistance during the period 1999-2004. The decreasing overall prevalence of resistance could be due to the use of more effective drugs and the better practices for treating HIV-1 infection, in the last years. |
| P120 | [P120] PREVALENCE OF DRUG RESISTANCE IN NEWLY DIAGNOSED HIV-1 PATIENTS IN GREECE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P120 Dimitrios Paraskevis1, Emmanouil Magiorkinis1, Ada Katsoulidou1, Eleni Hatzitheodorou1, Anastasia Antoniadou2, Antonios Papadopoulos2, Garifallia Poulakou2, Vassilios Paparizos3, Chryssoula Botsi3, Nikolaos Stavrianeas3, Moyssis Lelekis4, Maria Chini4, Panagiotis Gargalianos4, Nikolaos Magafas5, Marios Lazanas 5, Georgios Chryssos6, Georgios Petrikkos7, Georgios Panos8, Theodoros Kordossis9, Maria Theodoridou10, Vassiliki Sypsa1, Angelos Hatzakis1 Transmission of HIV-1 drug resistance in Greece, during the time period 2002-2003, was found to occur at a frequency of 8% and it was associated only with NRTIs or NNRTIs. |
| P121 | [P121] RESISTANCE MUTATIONS TO ENFUVIRTIDE (T-20) IN HIV-1 GP-41 SEQUENCES IN PLASMA AND SEMINAL FLUID Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P121 Giuseppina Liuzzi, Roberta D'Arrigo, Mauro Zaccarelli, Daniela Zinzi, Fabio Continenza, Andrea Antinori, Carlo Federico Perno Failure to T-20-containing regimen is usually associated to the detection of mutations at different amino-acids scattered in the 36-46 region. We have successfully demonstrate that is possible to detect also in semen drug resistance mutations to T-20. |
| P122 | [P122] STUDY OF HIV PATIENTS WHO PRESENT VIROLOGICAL FAILURE (VF) WITH THE K65R MUTATION IN THE REVERSE TRANSCRIPTASE GENE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P122 Jesús Santos, Isabel Viciana, Rosario Palacios, Mercedes Gonzalez, Josefa Ruiz, Manuel Márquez The presence of the K65R has increased over recent years. The ddI-TDF combination was the most common regimen, though there were no differences with the controls. A history of sub-optimal therapy and the presence of TAMs appear to protect against the K65R. This mutation doesn't appear to compromise rescuability. |
| P123 | [P123] IMPACT OF PEGILATED INTERFERON ON QUALITY OF LIFE, PSYCHOLOGICAL WELL-BEING AND ADHERENCE OF HIV-HCV COINFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P123 Carmina R. Fumaz1, Jose A. Munoz-Moreno1, Maria Jose Ferrer2, Angel Ballesteros 1, Elisabeth Masmitja1, Daniel Fuster1, Cristina Tural2, Bonaventura Clotet2 QOL impaired with Peg IFN although recovered after tt. Peg IFN a-2a had lower negative impact on QOL and DE. ADH remained stable. Psychological support is advisable in HIV-HCV coinfected p on Peg IFN due to QOL impairment and the presence of DE. |
| P124 | [P124] PEGILATED INTERFERON IN HIV-HCV COINFECTED PATIENTS: FACTORS ASSOCIATED WITH THE PRESENCE OF MODERATE AND SEVERE DEPRESSION DURING TREATMENT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P124 Carmina R. Fumaz1, Jose A. Muñoz-Moreno1, Maria Jose Ferrer2, Angel Ballesteros1, Elisabeth Masmitja1, Nuria Perez-Alvarez1, Daniel Fuster1, Cristina Tural2, Bonaventura Clotet3 Worse QOL and inadequate ADH were associated with MO/SE D. In HIV-HCV coinfected p on Peg IFN, D should be monitored to maintain QOL and a correct ADH to antiretrovirals. |
| P125 | [P125] AZT RESISTANCE OBSERVED AMONG HIV POSITIVE PREGNANT WOMEN IN INDIA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P125 R.B. Rayapu1, S.B. Rani2, R.K. Sandhya3, K. Ayodhya Ramaiah4, R. Sharath5 The mutations (genotyping) associated AZT resistance were seen in nearly 24% HIV positive pregnant women with increasing prevalence during the observation period and an association with the length of drug exposure. The virus of HIV-1 infected pregnant women on AZT frequently develops antiviral drug resistance. There is a need for sensitive and easy to perform assays to detect developing drug resistance. |
| P126 | [P126] DO AFRICAN PATIENTS ACCEPT AND ADHERE TO HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY (HAART)? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P126 N. Lomax1, H. Wheeler1, S. Barta1, A. Fakoya2 The number of patients who achieved an undetectable viral load was comparable in the two groups. Despite lower inital CD4 counts Africans achieved similar rises in CD4 counts from baseline over time. This retrospective study suggests that in a multidisciplinary setting the uptake of and adherence to HAART is similar in African and non-African patients. |
| P127 | [P127] PARTICIPATION IN CLINICAL TRIALS AND VIROLOGICAL RESPONSE TO HAART AT THE ROYAL FREE HOSPITAL Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P127 Colette Smith, Margaret Johnson, Zoe Cuthbertson, Anne Carroll, Caroline Sabin, Fiona Lampe, Mike Youle, Andrew Phillips Patients included in 1st-line HAART RCTs are reflective of the cohort, except for risk group. Those in an RCT were less likely to discontinue an antiretroviral and may have an improved short-term viral response but a similar immunological response compared to those starting HAART in routine clinical care. |
| P128 | [P128] LACK OF APPROPRIATE HIV CARE IN AN INNER-CITY INTRAVENOUS DRUG USERS POPULATION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P128 Silvia A. Guillemi, Evan Wood, Simon Bonner, Thomas Kerr, Robert Hogg, Julio G. Montaner Almost 30% of this group of HIV positive IDU's had not up to date CD4 monitoring, and at least half of those requiring HAART were not on it. Lack of medical care access seems to be significant predictors of low HIV/AIDS care. Prior discontinuation of HAART was mostly due to intolerance. |
| P129 | [P129] METHOD OF EVALUATING ADHERENCE AND EFFICACY OF HAART IN HIV-INFECTED INTRAVENOUS DRUG-USERS (IVDUS) RECEIVING DIRECTLY OBSERVED THERAPY (DOT) IN A METHADONE (MET) MAINTENANCE PROGRAM Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P129 Jesse Raffa1 , Jason Grebely1 , Harout Tossonian1, Brendon Trotter1, Mark McLean2, Stanley De Vlaming2, Brian Conway1 We've observed rates of adherence within our DOT program that are comparable to the minimum thresholds suggested in the non-IVDU populations (>90%). Despite this, rates of viral suppression in our population do not substantially increase beyond 60% adherence, suggesting viral suppression in IVDUs within a DOT program may behave differently from non-IVDUs receiving HAART. |
| P130 | [P130] OPTIMAL ADHERENCE TO ENFUVIRTIDE ACHIEVED IN THE US EARLY ACCESS PROGRAM Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P130 J. Goodly1, M. Dolker1, R. DeMasi2, A. Mazikewich1, K. Khoo1, J. Thommes1 The requirement of a subcutaneous injection of ENF was not a deterrent to adequate adherence in the US EAP. Self-reported adherence was similar across all subsets of patients defined by demographic and baseline characteristics, with the majority of all patients reporting greater than 85% adherence. |
| P131 | [P131] ADHERENCE TO TREATMENT IN SWEDISH HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P131 Bjorn Sodergard1, Margit Halvarsson2, Sofia Mindouri1, Stefan Lindback2, Anders Sonnerborg2, Mary Tully1, Asa Kettis Lindblad1 "Adherent" patients were more likely to have a very good relationship with their health care professionals than "non-adherent" patients (90% versus 81%, p<0.01). "Adherent" patients more frequently had viral loads below detection limit than did "non-adherent" patients (85% versus 75%, p<0.01). High motivation and good relationship with health care professionals are factors that may be related to good adherence and hence low viral loads. |
| P132 | [P132] NO AIDE-MEMOIRE FOR AIDS THERAPY - A LOST OPPORTUNITY FOR ADHERENCE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P132 Anthony J. France, Kirsteen J. Hill Anti-retroviral drugs are not packaged in user-friendly formats. Adherence could be improved if we changed the packaging to match that used for contraceptive pills and anti-hypertensive drugs. |
| P133 | [P133] UNDERSTANDING PATIENT PREFERENCES FOR HIV DRUGS USING ADAPTIVE CONJOINT ANALYSIS: FEASIBILITY ASSESSMENT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P133 Jamie Jordan2, Kathleen Beusterien1, Kristina Quattek2, Emuella Flood1 Changes in drug resistance, regimen complexity, risk of sleep disturbance and medication failure would likely make the most difference in the perceived value of an HIV medication. |
| P134 | [P134] THE PREVALENCE AND PROFILES OF PATIENTS WHO PRACTICE RELIGION AND PRAYER AT AN AIDS REFERENCE CENTRE IN BRUSSELS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P134 Elizabeth O'Doherty, Stephane De Wit, Nathan Clumeck Health professionals should be aware that r/p may have a significant place in p lives and may influence their attitudes to adherence practices. |
| P135 | [P135] IMPACT OF PHYSICIAN COUNSELLING AND SUPPORT TO PATIENTS IN THE ROUTINE CLINIC SETTING AT AN AIDS REFERENCE CENTRE IN BRUSSELS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P135 Elizabeth O'Doherty, Stephane De Wit, Nathan Clumeck Even in a pluridisclipinary setting, the impact of information received from their physician is strongest in p perception. Therefore, the influence of physicians' commitment to adherence and patient support should never be underestimated. This is especially so with seemingly disadvantaged and difficult populations. Such commitment may be applied also to poorly resourced situations. |
| P136 | [P136] ONCE-A-DAY ANTIRETROVIRAL THERAPY IS PREFERRED BY HIV+ PEOPLE IN A WEB SURVEY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P136 Simone Di Marcotullio1, Rita Murri2, Filippo von Schloesser1, Raffaella Crisafulli3, Piergiorgio Lupoli3 A web survey on adherence to drugs seems feasible; it allows to easily and rapidly collect data. Suboptimal adherence is still very common. A ONCE regimen is the preferred choice especially when total number of daily pills is not bigger than 4. |
| P137 | [P137] DURATION AND REASONS FOR DISCONTINUATION OF THE 1ST HAART REGIMEN IN GREEK HIV PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P137 M. Lelekis1, N. Tsogas2, G. Xilomenos1, N. Mangafas2, M. Chini1, M. Boboli2, J. Perdios1, P. Gargalianos1, M.C. Lazanas2 n conclusion, 6/10 pts discontinued HAART in less than 2 years mainly because of SE, irrespectively of the antiretroviral regimen. Pts on NNRTIs discontinued treatment much earlier than those on PIs. Pts who discontinued HAART due to VF have started treatment with lower CD4 counts. The PI group had higher discontinuation rate due to pts request (adherence issues-more complicated regimens) |
| P138 | [P138] MULTIPLE VALIDATED MEASURES OF MEDICATION ADHERENCE AMONG PATIENTS RECEIVING ANTIRETROVIRAL THERAPY IN THAILAND Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P138 Wantana Maneesriwongul1, Ann B. Williams2 Both pill counts and the EMD tend to give lower adherence and are not feasible in practice. Pill counts need great deal of patients' cooperation while EMD is very expensive. Patient self report by VAS and a 7-recall questionnaire are more feasible although tend to give higher adherence. Concerning ease of administration, the VAS and a 7-recall questionnaire are the preferred measures to assess medication adherence in Thailand. |
| P139 | [P139] THE INTESA (INTERVENTION TO SUSTAIN ADHERENCE) STUDY: PRELIMINARY RESULTS AT 24 WEEKS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P139 Giancarlo Orofino1, Maria Bolgiani2, Marta Guastavigna2, Paolo Leombruni2, Silvia Quaglia1, Pietro Caramello1, Sinibaldo Carosella1 The limited number of patients does not allow to reach statistically significant results. The VS is high in both groups. The very high level of self reported AD underlines the difficulty in obtaining a reliable measure of AD.The regular AD assessment may constitute itself an intervention that increases AD. |
| P140 | [P140] PATIENTS' ATTITUDES TOWARDS ANTIRETROVIRAL REGIMENS AND ADHERENCE TO THEM Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P140 E. Pontali, M. Setti, G. Murdaca, R. Villa, F. Indiveri Most of pts reported excellent ADH to ART (64%). Interestingly, correlation with D-M was found only in cases were insufficient (pts' judgement) info. on ART was provided and when ART significantly interfered with daily life. ADH improvement in this cohort can be achieved through counselling on ART and personalization of ART. |
| P141 | [P141] GENOTYPIC INHIBITORY QUOTIENT PREDICTS RESPONSE TO FOSAMPRENAVIR/RITONAVIR Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P141 Fan Xu1, S. Tomkins2, P. Yates1, N. Richards2, S. Sharp2, M.B. Wire3, M. Tisdale1, R. Elston1 The GIQ for FPV/r BID was significantly associated with response at Wk12, Wk24 and Wk48. GIQ offers a method of identifying subjects with the greatest potential to respond to FPV/r BID in combination with N(t)RTIs. |
| P142 | [P142] EFFICACY OF TENOFOVIR COMBINATION THERAPY AND ITS GENOTYPIC RESISTANCE IN MULTIFAILURE HIV-1-INFECTED SUBJECTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P142 Mirko Lo Cicero, Elisabetta Bulgheroni, Alberto Zampiero, Francesca Soster, Ottavia Vigano Paola Cicconi, Massimo Galli, Stefano Rusconi The majority of our heavily treated pts responded to TDF-containing regimens. In non-responders featured a distinct type-1 TAMs pattern (41+210+215) that was not compatible with the K65R mutation. M184V induced a decrease in VL probably due to its influence on replication capacity. |
| P143 | [P143] THE EPIDEMIOLOGICAL CHARACTERISTICS OF POLISH PATIENTS PARTICIPATING IN THE SPREAD PROGRAMME Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P143 Grzegorz P. Stanczak1, Michal J. Majchrzak1, Janusz J. Stanczak1, Ewa A Firlag-Burkacka1, Alicja Wiercinska-Drapalo2 Magdalena Leszczyszyn-Pynka3, Elzbieta Jablonowska4, Ewa A. Tobolewska1, Katarzyna J. Przybylska-Stengiel1, Andrzej Horban1 The main route of infection changes from IVDU to heterosexual contacts. Subtype B still dominates, although non-B subtypes appear also. |
| P144 | [P144] COMPARISON OF THE ROCHE AMPLIPREP AUTOMATED RNA EXTRACTION SYSTEM VERSUS MANUAL RNA EXTRACTION FOR HIV VIRAL LOAD MEASUREMENT BY THE ROCHE COBAS AMPLICOR HIV 1.5 ULTRASENSITIVE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P144 Christopher H. Sherlock1, Linda I. Merrick1, Tanya D. Bush1, Kevin J.P. Craib2 Viral load measurements derived from Ampliprep versus manual RNA extracted samples using the Roche Cobas Amplicor v.1.5 Ultrasensitive assay are statistically equivalent and reproducible. |
| P145 | [P145] ANTIRETROVIRAL RESISTANCE IN HIV INFECTED CHILDREN FAILING TREATMENT REGIMENS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P145 Sarah Ogwang This study shows that most children miss their doses, which greatly impacts on outcome of antiretroviral therapy. The visible genetics assay functioned better with HIV 2 subtype. Genotypic resistance is common among HIV infected children failing antiretroviral therapy. Given the importance of high level of adherence in paedriatric HIV therapy further studies on impact of non adherence on success of antiretroviral is needed. |
| P146 | [P146] ADHERENCE TO ANTIRETROVIRAL THERAPY IN HIV IDUS COMPARE TO NON HIV IDUS AND NON INFECTED Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P146 Kamiar Alaei, Arash Alaei, Davood Mansoori, Masomeh Golkapabari The HAART is well tolerance by HIV/IDUs and has prominent effects on increasing count and curing resistant OIs.The HIV/DUs have more adherence to the HAART compare to others. HIV/DUs shows the similar adherence to HAART as well as Harm Reduction programs, so we cannot have discrimination in HAART. |
| P147 | [P147] SURVIVAL IS NOT IMPROVED IN HIV ELDERLY PATIENTS SINCE THE INTRODUCTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P147 Gwenael Le Moal, Cedric Landron, Genevieve Giraudeau, Cendrine Godet, Gerard Agius Overall survival has not significantly improved in elderly HIV patients since the introduction of HAART due principally to a delayed diagnosis but not to an inefficacity of HAART in this population. |
| P148 | [P148] EXPERIENCE OF ONE YEAR'S RESISTANCE TESTING IN THE EAST OF SCOTLAND Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P148 Mark J. Hopkins1, Clifford L.S. Leen2, Sheila M. Burns1 Retrospective and multiple testing were requested by clinicians when trying to identify suitable salvage therapy. A high proportion of the reports generated for such patients showed no resistance or resistance to only one class of drug as clinicians try to identify archived mutations in these patients. Introducing a lower cut-off limit of 1000 copies/ml for analysis may also have contributed to this by allowing clinicians to request resistance assays on sera that were previously not tested due to low viral load. |
| P149 | [P149] MOLECULAR CHARACTERIZATION OF A NFV-RESISTANT HIV-1 THAT EXHIBITS NFV-DEPENDENT ENHANCEMENT OF REPLICATION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P149 S. Matsuoka, H. Gatanaga, S. Kimura, S. Oka These data suggested that each gag domain carrying CL-4 substitutions play a various role on replication capacity, but the interaction among the substitutions could be described a noble adaptation mechanism of HIV-1 under the selective presser of NFV. |
| ADVERSE EFFECTS OF DRUGS |
|
| P150 | [P150] RITONAVIR CAUSES MORE DELAY IN THE CLEARANCE OF APOLIPOPROTEIN-B Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P150 S. Das1, M. Stolinsky2, W. Jefferson2, N. Jackson2, G. Gilleran1, R. Cramb1, M. Umpleby2, M. Shahmanesh1 Ritonavir causes more delay in apo-B clearance, expanding the apo-B pool size. This provides a possible mechanism for the increase in plasma lipids in RTV containing regimens. |
| P151 | [P151] EXOGENOUS TESTOSTERONE FOR WASTING OR OTHER INDICATIONS IN HUMAN IMMUNODEFICIENCY VIRUS MAY EXACERBATE VISCERAL ADIPOSITY AND CARDIOVASCULAR RISK Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P151 Wendy L. Wobeser, John M. Fotheringham, Peter M. Ford, Teresa Liu, Aisha Ekzhaimy This study suggests that use of ET for wasting or QOL should be undertaken with caution in persons with significant cardiovascular risk factors. It also suggests that, in the absence of resistance training, it may have cosmetically undesirable effects. |
| ADVERSE EFFECTS OF DRUGS - BONE |
|
| P152 | [P152] PREDICTIVE FACTORS OF OSTEOPENIA/OSTEOPOROSIS IN HIV-INFECTED SUBJECTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P152 Marco Bongiovanni1, Alfonso Fausto2, Paola Cicconi1, Laura Menicagli2, Sara Melzi1, Teresa Bini1, Stefano Rusconi1, Francesco Sardanelli2, Antonella d'Arminio Monforte1 Careful surveillance of BMD should be given to HIV pts in particular women, low weighted, long time HIV-positive and older. HAART does not seem to play any role in the development of osteopenia/osteoporosis. |
| P153 | [P153] BONE MASS IN HIV-INFECTED PATIENTS: FOCUS ON THE ROLE OF THERAPY AND SEX Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P153 Marco Borderi1, Fabio Vescini2, Livia Tampellini1, Angela Buffa2, Giuseppe Sinicropi2, Renata Caudarella2, Francesco Chiodo1 We did not find any differences between treatment groups. Surprisingly, we found a higher rate of osteoporosis in males than females, although the males had a significantly higher BMI. We may hypothesize that HIV or HAART are somehow involved in the regulation of aromatase activity and, therefore, on estrogen concentration inside the bone microenvironment, but this hypothesis needs confirmation. |
| P154 | [P154] THE SCOLTA PROJECT: AN ITALIAN APPROACH TO MONITORING THE ADVERSE EVENTS OF NEW ANTIRETROVIRAL DRUGS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P154 Tiziana Quirino, Giancarlo Orofino, Silvia Carradori, Teresa Bini, Simona Landonio, Riccardo Giuntini, Giustino Parruti, Carlo Magnani, Laura Valsecchi, Luigi Pusterla, Paolo Bonfanti The SCOLTA Project (Surveillance COhort Long-term Toxicity Antiretrovirals) is a on line system to assess the incidence of serious and rare adverse events with new antiretroviral drugs; for this aim a website was created (www.cisai.info). It is a prospective, observational, multicenter study; 25 italian Departments of Infectious Diseases participated at the project. All patients who were consecutively started on lopinavir (LPN), tenofovir (TFV), peginterferon (IFN) and atazanavir (ATZ) were enrolled. All grade III or IV adverse events and all unexpected events are reported on the website. |
| P155 | [P155] CLINICAL PICTURES OF PHOSPHOCALCIC METABOLISM DISTURBANCES IN PATIENTS ON ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P155 Dorota C. Bander, Magdalena Pynka, Anita M. Wnuk, Anna Boron-Kaczmarska Normal or elevated total serum calcium concentrations with increase PTH observed in all presented patients suggest primary hyperparathyreoidism on ARV therapy. Mitochondrial toxicity of NRTIs or ARVs interactions with hormone receptors are possible. Elevated PTH serum concentration activates osteoclasts and causes bone destruction and hypercalcemia with potentially severe chronic syndromes. |
| ADVERSE EFFECTS OF DRUGS - CARDIOVASCULAR |
|
| P156 | [P156] RISK FACTORS (RF) ASSOCIATED WITH CARDIOVASCULAR DISEASE (CVD) IN HIV PATIENTS: THE RACE TRIAL Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P156 E. Voigt1, M. Borchert1, M. Vogel1, C. Wyen2, J. Stechel3, J.K. Rockstroh1 CVD is variable by nature in HIV-infected individuals. Patients show various CVD RF other than HAART associated dyslipidemia. However, lipid elevations are common in HIV patients with CVD and patients often have a long exposure to ART. |
| ADVERSE EFFECTS OF DRUGS - HEPATIC |
|
| P157 | [P157] LIVER TOXICITY WITH NEVIRAPINE: INCIDENCE AND RISK FACTORS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P157 Pablo Barreiro, Sonia R-Novoa, Luz Martín Carbonero, Juan González-Lahoz, Vicente Soriano n contrast to early liver enzyme elevations with NVP, always as part of the hypersensitivity reaction, late NALT is more frequent in patients on d4T or PI, and with HCV coinfection. A single determination of NVP levels was not predictive for NALT, although a higher drug exposure in subjects with a polymorphic CYP-2B6 may increase the risk for NALT. |
| P158 | [P158] SEVERE HEPATOTOXICITY ASSOCIATED WITH HAART IN A GREEK HIV POPULATION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P158 N. Mangafas, N. Tsogas, M. Boboli, P. Tserpe, D. Chalkiadaki, J. Salpigtis, M.C. Lazanas SH due to HAART is relatively uncommon in our clinic. Possible explanations are the small percentage of IVDUs and coinfection. However, SH is more common in coinfected patients. Severe hyperbilirubinemia was mainly due to ATV use. Both SH and severe hyperbilirubinemia occurred on an average in less than 2 month-period on HAART. |
| ADVERSE EFFECTS OF DRUGS - LIPODYSTROPHY |
|
| P159 | [P159] FAT REDISTRIBUTION IN HIV PATIENTS ON NON-PROTEASE INHIBITOR REGIMENS: STUDY IN A RESOURCE LIMITED SETTING Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P159 Sherry Koko-Ekong1, Uzoma Azubike2, Ernest Ekong3, Asukwo Uwah4 Fat redistribution is common in HIV infected patients on PI sparing regimens, even though wasting may be a feature of the disease state. This finding should be considered when counseling on the choice and acceptability of ARV drugs especially in resource limited settings. |
| P160 | [P160] DECREASE OF SUBCUTANEOUS ADIPOSE TISSUE IN HIV PATIENTS AFTER REPLACING ESTABLISHED PROTEASE INHIBITORS WITH ATAZANAVIR Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P160 Georg Härter1, Burkhard J. Manfras1, Trein Andreas2, Mueller Markus3, Pauls Sandra4, Kern Peter1 Switching to ATV 400 mg once daily from other PI containing antiretroviral regimen resulted in decreases in total cholesterol and fasting triglycerides levels. Furthermore and most notably, regression of body fat accumulations were observed, confirmed by MRI. Switching from established protease inhibitors to ATV in patients with lipodystrophy syndrome could lead to a rapid regression of pre-existing body fat accumulations and offers a new option in patients with lipodystrophy syndrome. A prospective study for validation of these findings is needed and intended. |
| P161 | [P161] SOCIAL REPERCUSSION SECONDARY TO THE LIPODYSTROPHY SYNDROME IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P161 Ana Marin, Jose L. Casado, Javier Moya, Lidia Aranzabal, Ana Moreno, Antonio Antela, Santiago Moreno Severe lipoatrophy produce social distress and anxiety, with psychological repercussion such as depressive symptoms or anxiety. With the exception of sex, this fact was not modified by social or HIV-related factors. |
| P162 | [P162] CHANGES IN ATTITUDE TOWARD ANTIRETROVIRAL DRUGS AND ADHERENCE IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P162 Ana Marin, Jose L. Casado, Lidia Aranzabal, Javier Moya, Antonio Antela, Ana Moreno, Santiago Moreno Severe lipoatrophy could produce a decreased confidence in antiretroviral drugs and, subsequently, a lower adherence level in HIV-infected patients, especially when quality of life or social distress appears. |
| P163 | [P163] PERSISTENCE OF SEVERE DIFFUSE LIPOATROPHY FOUR YEARS AFTER STOPPING THE CAUSATIVE HAART REGIMEN: REPORT OF ONE CASE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P163 Giustino Parruti, Giuseppe Marani Toro Lipodistrophy is a syndromic complication of antiretroviral treatment, multifactorial in nature. Our observation leads further evidence to the knowledge that lipoatrophy, at variance with fat accumulation phenomena, may be caused by irreversible damage of a subset of adipose tissue sites. Prevention of lipoatrophy is therefore a key issue. |
| P164 | [P164] IN CONTRAST TO GLUTEAL AND FACIAL LIPOHYPOTROPHIA, IPOHYPOTROPHIA OF THE SOLE OF THE FOOT IS NOT ASSOCIATED WITH ECREASED TOTAL BODY FAT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P164 Ricardo Walther, Kristina Koppel, Goran Bratt, Bernt Lund, Lars E. Eriksson, Lena Nilsson-Schonnesson, Eric Sandstrom Data suggest similarities, but also differences between the three lipohypotrophias. All types seem linked to older age and DDI, while lipohypotrophia of the glutea and face, but not the sole seem linked to general body fat loss. Sole and facial lipohypotrophia seem linked to severe baseline immunodeficiency while gluteal lipohypotrophia seem related to longer HIV-infection and higher HOMA. |
| ADVERSE EFFECTS OF DRUGS - METABOLIC |
|
| P165 | [P165] METABOLIC IMPROVEMENT AFTER SWITCH TO TENOFOVIR: ONE YEAR FOLLOW UP Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P165 Georg J. Claas, Johannes R. Bogner, Frank D. Goebel A switch to TDF is associated with a significant decrease of cholesterol and lactate levels. After 12 months there was no trend to lower serum phosphate levels. |
| P166 | [P166] HCV INFECTION INCREASES THE RISK OF GLUCOSE ABNORMALITIES IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P166 E. Tamburrini1, A. Cingolani1, E. Visconti1, C. Pinnetti1, S. Di Giambenedetto1, A.F. Cavaliere2, R. Cauda1 GMD represent a relevant issue in the management of HIV-1 + pregnant women. Coinfection HIV/HCV increase the risk of GMD. HIV+ pregnant women treated with d4T-including regimens must be closely monitored for GMD. |
| P167 | [P167] ROSIGLITAZONE FOR HIV LIPOATROPHY: 84 WEEKS FOLLOW-UP Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P167 Dianne Carey1, Andrew Carr2, Cassy Workman3, Gary Rogers4, Allison Martin1, Handan Wand1, Sean Emery1, David Cooper1 A 48-week, randomised, placebo-controlled, double-blinded study found rosiglitazone (RSG) 4 mg bd did not improve lipoatrophy in HIV-infected adults on ART, despite significantly improving insulin sensitivity and adiponectin levels. We assessed whether lipoatrophy might improve over longer follow-up. |
| P168 | [P168] THE IMMUNOLOGICAL AND VIROLOGICAL IMPACT OF STATIN THERAPY IN INDIVIDUALS ON HIGHLY ACTIVE ANITRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P168 Milena Stevanovic, Laura Waters, Rachael Jones, Sundhiya Mandalia, Mark Bower, Mark Nelson, Brian Gazzard Statins have been shown to be effective at reducing total cholesterol and triglyceride levels in HIV-infected patients. No significant impact of statin therapy on immunological or virological responses was observed in our cohort of HAART treated patients. |
| P169 | [P169] REDUCTION IN CHOLESTEROL AND TRIGLYCERIDES AFTER TENOFOVIR DF (TDF) ADDITION/SWITCH IN HIV-INFECTED TREATMENT-EXPERIENCED PATIENTS PARTICIPATING IN THREE CONTROLLED TRIALS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P169 A. Pozniak1, J. Suleiman2, B. Lu3, L. Zhong3, V. Ho3, J. Enejosa3, A. Cheng3 The use of HAART has been associated with side effects including dyslipidemia. Appropriate management of lipid disorders in HIV-infected patients is needed. Lipid data from patients who enrolled in GS902, 907 and 903E were analysed. |
| P170 | [P170] LOPINAVIR/RITONAVIR DOES NOT ALTER VERY-LOW-DENSITY LIPOPROTEIN (VLDL) COMPOSITION IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P170 Werner Richter1, Florian Berger2, Stefan Mauss2 Hypertriglyceridemia is frequently observed in HIV-infected patients treated with antiretroviral drugs. It is characterized either by a normal number of large triglyceride-rich VLDL or an increased number of small triglyceride-poor VLDL. The latter carry an increased risk of coronary heart disease as shown in patients with familial combined hyperlipidemia. We investigated whether lopinavir/ritonavir at standard doses changes VLDL composition from large buoyant to small dense. |
| P171 | [P171] OUTCOME OF LIPID PARAMETERS IN DYSLIPIDEMIC HIV INFECTED PATIENTS STARTING ATAZANAVIR CONTAINING HAART (EAP) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P171 Federica Tordato1, Marco Bongiovanni1, Amedeo Capetti2, Antonio Di Biagio5, Clara Abeli4, Paola Meraviglia3, Roberto Rossotti1, Elisabetta Chiesa1, Antonella d'Arminio Monforte1, Teresa Bini1 In our cohort of HAART-experienced pts with high lipid levels at baseline, the introduction of ATV, even boostered, seems associated with a significant decrease of serum lipid levels. |
| P172 | [P172] VARIATION IN PLASMA HOMOCYSTEINE (HCY) LEVELS AFTER SWITCHING TO ATAZANAVIR/RITONAVIR (ATZ/R) CONTAINING REGIMENS IN AN EXPANDED ACCESS PROGRAM AT A SINGLE CLINICAL CENTRE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P172 C. Torti1, M.C. Uccelli1, P. Nasta1, A. Panzali2, G. Cologni1, F. Moretti1, E. Quiros1, R. Volpi2, R. Del Bono2, S. Casari2, G. Carosi1 These data suggest a potential benefit of switching to ATZ/r with regard to Hcy reduction or normalization. Further studies on this factor are therefore advisable. |
| P173 | [P173] FREQUENCY OF INSULIN RESISTANCE IN HIGHLY EXPERIENCED HIV-1 INFECTED PATIENTS ASSESSED IN THE ATAZANAVIR EARLY ACCESS PROGRAM Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P173 Monica Guffanti1, Andrea Caumo2, Simon Tiberi1, Alba Bigoloni1, Stefania Salpietro1, Elena Seminari1, Anna Danise1, Livio Luzi2, Adriano Lazzarin1, Antonella Castagna1 The assessment of the metabolic status of HIV+ pts by means of the HOMA could be considered as useful and cost-effective tool for identifying pts at risk of DM. |
| P174 | [P174] ANTIRETROVIRAL-RELATED HYPERTRIGLYCERIDEMIA: ROLE OF POLYUNSATURATED N-3 FATTY ACIDS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P174 Roberto Manfredi, Leonardo Calza, Francesco Chiodo Drug therapy of HT is needed in HAART-treated p, since limited benefit is expected from a diet-exercise program. Our preliminary data, which for the first time compare PUFA and fibrates, confirm the higher efficacy of fibrates, but also show a favorable, safe, and sustained activity of PUFA. Since hypolipidemic drugs are borne by a non-negligible toxicity, PUFA may represent an effective alternative to fibrates. |
| P175 | [P175] EXTREMELY DIFFERENT DYSMETABOLIC PROFILE OF THE TWO AVAILABLE NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE INHIBITORS: NEVIRAPINE AND EFAVIRENZ Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P175 Roberto Manfredi, Leonardo Calza, Francesco Chiodo A prolonged follow-up shows that E may not resolve (or might prompt) dysmetabolism. The 2 NNRTI have a different toxicity profile. The potential pathways of the dysmetabolic patterns of these 2 NNRTI warrant investigation. |
| P176 | [P176] LIPID PROFILE IN HIV INFECTED ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P176 L. Manolescu1, S. Ruta 1, R. Matusa 2, P. Marinescu 3, C. Sultana 1, C. Cernescu 1 Even in adolescents the ritonavir containing regimens were associated with important lipid metabolism abnormalities. Dyslipidaemia could be accounted at least in part to PI-mediated mitochondrial dysfunction and not to metabolic disturbances induced by long lasting HIV infection. |
| P177 | [P177] HIV-ASSOCIATED METABOLIC SYNDROME AND LIPODYSTROPHY IN ALL SLOVENIAN PATIENTS TREATED WITH ANTIRETROVIRAL DRUGS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P177 Janez Tomazic1, Andrej Janez2, Ludvik idmar1, Primoz arner1 A total of 60 patients (74%) developed metabolic and/or lipodystrophy alterations. Lipodystrophy includes a variety of clinical manifestations, which can be included in a case definition. Early testing for metabolic parameters should be implemented at the initiation of treatment (danger of accelerated atherosclerosis). Appropriate management for lipodystrophy and glucose or lipid metabolism is needed. |
| P178 | [P178] EFFICACY AND TOLERABILITY OF RTV-BOOSTED ATAZANAVIR COMBINED WITH TENOFOVIR IN PATIENTS WITH DYSLIPIDEMIA ON ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P178 E. Lauenroth-Mai1, A. Stoehr2, B. Kuhlmann3, B. Hintsche4, S.T. Dupke5 This results indicate the virologic and immunologic effectiveness of ATV/r in pretreated pts with a marked improvement of serum lipid profiles. |
| P179 | [P179] CONTINUOUS IMPROVEMENT OF DYSLIPIDEMIA IN PATIENTS SWITCHING FROM D4T TO TENOFOVIR: 24 WEEK DATA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P179 Josep M. Llibre1, Pere Domingo2, Maria J. Perez3, Pablo Labarga4, Rosario Palacios5, Maria I. Ruiz6, Jesus Santos5, Rainel Sanchez de la Rosa7, Santiago Moreno3 This extended analysis at 24 wk suggests that switching to TDF maintains the improvement of dyslipidemia associated with D4T-based regimens, while maintaining good immunological status. |
| P180 | [P180] THE ROLE OF TUMOR NECROSIS FACTOR A AND CORTISOL IN PATHOGENSIS OF METABOLIC SYNDROME Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P180 Janez Tomazic2,Nina Gorisek1, Mario Poljak3, Ludvik idmar2, Primoz arner2 No significant dynamics of tumor necrosis factor a and cortisol was detected in treated patients neither with nor without metabolic syndrome. |
| P181 | [P181] METABOLIC SYNDROME AND LIPODYSTROPHY IN ANTIRETROVIRAL NAÏVE PATIENTS AFTER 48 WEEKS OF TREATMENT WITH LOPINAVIR/RITONAVIR CONTAINING REGIMEN Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P181 Janez Tomazic1, Miša Pfeifer2, Ludvik idmar1, Primoz arner1, Marko Pokorn1 Over the first 48 weeks of the study, lopinavir/ritonavir based therapy was associated with significant changes in glucose and lipid metabolism. None of the patients suffered from lipodystrophy (self assessment, physical examination, DEXA). |
| P182 | [P182] EFFECT OF PROTEASE INHIBITORS ON HYPERLIPIDEMIA IN HIV-INFECTED PATIENTS: BELGRADE STUDY POPULATION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P182 Gordana J. Dragovic1, Djordje L.J. Jevtovic2 The frequency of hyperlipidaemic risk factors was very high in our patient population. PI-treated subjects should also be evaluated for their lipoprotein pattern, which may require antihyperlipidaemic interventions. |
| ADVERSE EFFECTS OF DRUGS - MITOCHONDRIAL |
|
| P183 | [P183] COMPENSATORY MECHANISMS PRESERVE MITOCHONDRIAL FUNCTION IN HIV PATIENTS ON DIDANOSINE PLUS STAVUDINE EXHIBITING MITOCHONDRIAL DNA DEPLETION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P183 Sonia S. Lopez1, G. Garrabou1, M. Rodriguez de la Concepcion2, E. Martinez3, E. Pedrol4, M. Giralt2, F. Cardellach1, J.M. Gatell3, F. Vilarroya2, J. Casademont1, O. Miro1 Decreased mitochondrial mass and mtDNA content are associated with ddI+d4T treatment, but COX-II expression and COX activity remains unaltered. These data suggest that, at least during the initial phases of treatment, up-regulatory transcriptional or post-transcriptional mechanisms compensate mtDNA depletion caused by ddI+d4T. |
| P184 | [P184] ADDITION OF TENOFOVIR TO A DIDANOSINE-BASED HAART DOES NOT INCREASE MITOCHONDRIAL DNA DEPLETION BUT DECREASES CITOCHROME C OXIDASE FUNCTION AND MITOCHONDRIAL MASS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P184 Gloria Garrabou1, S. Lopez1, A.B. Infante1, E. Negredo2, J. Puig2, L. Ruiz2, E. Sanjurjo1, J. Casademont1, F. Cardellach1, B. Clotet2, O. Miro1 A decrease in mitochondrial mass, mtDNA content and COX activity is detected after 12 months of the addition of TDF to HAART schedules containing ddI. This diffuse deterioration of mitochondrial parameters could be due to TDF itself, the increase of ddI concentrations caused by TDF or both. The relevance of these biochemical findings in clinical practice remains to be determined. |
| P185 | [P185] MITOCHONDRIAL TOXICITY OF NUCLEOSIDE ANALOGUES AND THE APPLICATION OF REAL-TIME PCR Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P185 Claire J. Weekes, Gino Brunori, Tracy M. Walker, Rhiannon M. Lowe, Angela T. White, Joel D. Parry This suggests that the location of the selected mitochondrial gene on the genome does not appear to influence the sensitivity of the real-time PCR assay for NRTI-related depletion of mtDNA in vitro. |
| P186 | [P186] NON-INVASIVE ASSESSMENT OF HEPATIC MITOCHONDRIAL TOXICITY IN HIV-INFECTED PATIENTS WITH NORMAL SERUM LACTATE BY 13C-METHIONINE BREATH TEST Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P186 Matthias Banasch, Oliver Goetze, Norbert Brockmeyer, Wolfgang E. Schmidt Our results provide evidence, that the MBT prove an invaluable diagnostic tool for monitoring of hepatic mitochondrial function in HIV-disease. We are the first to show, that not only ART-treated patients but also therapy-naïve exhibit significantly mitochondrial impairment. |
| ADVERSE EFFECTS OF DRUGS - NEUROLOGICAL |
|
| P187 | [P187] SUBCLINICAL HIV-1 ASSOCIATED DISTAL SENSORY POLYNEUROPATHY (DSP) IN THE HAART ERA IN A GREEK COHORT OF HIV(+) PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P187 Elias Skopelitis, Panayiotis I. Kokotis, Athanasios N. Kontos, Nikolaos Karandreas, Theodore Kordossis Double cases of DSP diagnosed by EMG than by clinical testing. Low CD4 count and prolonged disease duration are risk factors for DSP in advanced HIV infection. |
| ADVERSE EFFECTS OF DRUGS - OTHER |
|
| P188 | [P188] HIV INFECTION IS ASSOCIATED WITH INCREASED SKELETAL APOPTOSIS ASSESSED BY TUNEL Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P188 S.S. Lopez1, G. Garrabou1, J. Fernandez-Sola1, E. Pedrol2, E. Badia1, A.B. Infante1, E. Martinez3, F. Cardellach1, J.M. Gatell3, J. Casademont1, O. Miro1 Skeletal muscle of HIV-infected patients exhibits increased apoptosis compared with healthy uninfected individuals. Further studies are necessary to elucidate the mechanisms by which HIV infection leads to increased apoptosis. |
| P189 | [P189] TOXICITIES AND ADVERSE EVENTS FOLLOWING GENERIC HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT IN SOUTH INDIAN HIV-INFECTED INDIVIDUALS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P189 N. Kumarasamy1, S. Saghyam1, S Solomon1, A.J. Cecelia1, T.P. Flanigan2, H TokughaYepthomi1, P. Balakrishnan1, K.H. Mayer2 This report shows that anemia and hepatitis can occur within 12 weeks of generic ART. Hence frequent early monitoring for these toxicities are needed where generic HAART is used. |
| P190 | [P190] THE SIDE EFFECT PROFILE ASSOCIATED WITH USE OF NEVIRAPINE IN A COHORT OF PREGNANT WOMEN IN LONDON Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P190 Usharani Natarajan1, Alexander Pym2, Jane Anderson2, Annemiek de Ruiter1, Philip Hay3, Candice McDonald4, Graham P. Taylor5 Although lower overall rates of adverse reaction were seen than in other studies, a majority occurred at CD4 counts above 200 cells/mm³ where Nevirapine should be used with careful monitoring. |
| P191 | [P191] SIDE EFFECTS OF HAART LEADING TO DRUG INTERRUPTION IN A GREEK HIV POPULATION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P191 N. Mangafas, N. Tsogas, P. Tserpe, A. Tjoumani, L. Treatment interruptions due to side effects are very common. Long-term complications of HAART are the primary reason of treatment discontinuation as there is a significant shift from short-term (GI disorders, myelosuppression) to long-term (lipodystrophy and hyperlipidemia) toxicities in the last 3 years. |
| P192 | [P192] FACTORS ASSOCIATED WITH THE PRESENCE OF ADVERSE EVENT MARKERS IN THOSE STARTING HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P192 Colette Smith, Fiona Lampe, Andrew Phillips, Mike Youle, Margaret Johnson, Caroline Sabin Although a high proportion of those starting HAART are checked for adverse event markers some groups may be more likely to be monitored. Analyses involving these markers may not be entirely representative of complete clinic populations. |
| P193 | [P193] REGIONAL DIFFERENCES IN TREATMENT FAILURE IN THE 2NN STUDY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P193 F. van Leth, D.B. Hall, J.M.A. Lange The present data indicate that differences in treatment change were the primary reason behind the treatment by region interaction in treatment failure. These differences can be partially explained by differences in adverse events, and trough concentrations of the NNRTI. However, additional factors including regional differences in physician treatment or patient behaviours may be important. |
| P194 | [P194] HIGH DOSE EFAVIRENZ WITH RIFAMPICIN FOR HIV INFECTED PATIENTS WITH CONCOMITANT TUBERCULOSIS: ONE SIZE DOES NOT FIT ALL Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P194 Paul Brennan-Benson1, Richard Lyas2, Mark Pakianathan1, Thomas Harrison2, Derek Macallan2 The use efavirenz at high dose in patients taking rifampicin cannot be universally endorsed. Data have previously suggested that a CYP2B6 variant more common in patients of black ethnicity may be assocaited with delayed efavirenz clearance. This may explain the high levels of efavirenz observed in our patients. TDM may have a useful role in minimising serious side effects. |
| P195 | [P195] ANTIRETROVIRAL THERAPY AND EMERGING GYNECOMASTIA. WHICH CORRELATIONS? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P195 Roberto Manfredi, Leonardo Calza, Francesco Chiodo The frequent association of G with other HAART-related metabolic anomalies suggests some common pathway with HIV- and antiretroviral-associated disturbances, so that further investigation should be deserved to the role of single compounds, and their combinations. |
| P196 | [P196] THREE-YEAR ANALYSIS OF THE RENAL SAFETY OF TENOFOVIR DF (TDF) VERSUS STAVUDINE (D4T) WHEN USED IN COMBINATION WITH LAMIVUDINE (3TC) AND EFAVIRENZ (EFV) IN ANTIRETROVIRAL-NAÏVE PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P196 S. Staszewski1, J.E. Gallant2, A. Pozniak3, B. Lu4, K. Yale4, J. Enejosa4, A. Cheng4 This three-year analysis demonstrates comparable renal safety between tenofovir DF and to d4T. Neither proximal renal tubular dysfunction nor Fanconi's syndrome were seen through 144 weeks. |
| P197 | [P197] EFFICACY AND TOLERABILITY OF DIDANOSINE COMBINED WITH TENOFOVIR IN AMBULATORY HIV-1 INFECTED INDIVIDUALS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P197 Rose K. Baker2, Ben Young1, Kathy C. Wood2 LD ddI/TDF regimens are significantly less toxic compared to HD ddI/TDF regimens, and have comparable efficacy as measured by 6 month and 12 month CD4 and viral load values. |
| P198 | [P198] SAFETY AND EFFICACY OF TENOFOVIR (TDF) + DIDANOSINE (DDI EC)-BASED REGIMENS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P198 Vicente Estrada1,Juan González-Castillo1, Pilar Cubo1, Sonia Muñoz1, Rainel Sanchez de la Rosa2 Adjusting ddI dosage to patients' weight, TDF+ddI EC is a virologically efficacious, safe and well tolerated backbone. |
| P199 | [P199] EFFICACY AND SAFETY OF DIDANOSINE (DDI) AND TENOFOVIR (TDF) COMBINATION AS NRTI BACKBONE OF HAART.(48 WK PRELIMINARY RESULTS FROM RECOVER STUDY) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P199 M.J. Galindo1, J. Lopez Aldeguer2, M. Salavert2, V. Estrada3, J.C. Lopez4, F. Dronda5, R. Rubio6, V. Falco7, A. Chocarro8, P. Ferrer9, S. Moreno and Recover Study Group5 Combination of ddI+TDF as the NRTI backbone of HAART is virologically and immunologically efficacious and also safe in patients who switch a single NRTI to TDF due to adverse events. |
| P200 | [P200] LONG-TERM SAFETY AND TOLERABILITY OF STAVUDINE(D4T) COMBINED WITH TENOFOVIR (TDF) IN ANTIRETROVIRAL SALVAGE REGIMENS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P200 Paola Nasta, Giuseppe Paraninfo, Andrea Patroni, Silvia Costarelli, Giampiero Carosi d4T+TDF combination represent a safety NRTIs backbone for heavily pre-treated Pts. Treatment interruption was significantly related to the association of d4T+TDF with boosted PI.Worsened lipoatrophic damage represent the most frequent cause of interruption. |
| P201 | [P201] MYOPATHY IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P201 D. Ladage, R. Spoo, A. Woehrmann, N. Schmeisser, A. Rubbert, G. Faetkenheuer Myopathy among HIV positive patients had a frequency of 2,7% in our cohort, other studies postulating a frequency of up to 25%. There was no evidence for autoimmune or infectious diseases explaining the symptoms. The subject remains to be investigated in larger trials. |
| P202 | [P202] PREDICTORS OF LPV/R DISCONTINUATION FOR TOXICITY IN HAART-EXPERIENCED HIV PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P202 Marco Bongiovanni1, Paola Cicconi1, Teresa Bini1, Simona Landonio2, Letizia Testa3, Elisabetta Chiesa1, Antonella d'Arminio Monforte1 LPV/r was substantially well tolerated. Diarrhoea was the more frequent AE leading to discontinuation. Highly compromised patients have a higher risk of discontinuing LPV/r and should be strictly monitored. |
| P203 | [P203] HYPERSENSITIVITY TO NEVIRAPINE (NVP) IN ANTI-RETROVIRAL NAÏVE HIV SERO+VE SUBJECTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P203 Subir Kumar Dey1, Nishit Kumar Pal2 High rate of hypersensitivity to NVP in Asian population is a stumbling block towards increasing access for all HAART as groups of Anti-retroviral drugs are very costly and newer approaches like Structured Interrupted Therapy requiring less drugs needs to be devised in resource constrained settings like India, home to 5.1 million HIV+ves. |
| P204 | [P204] A COMPLETE DRUG HISTORY SHOULD BE SOUGHT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P204 M. Moriarty1, L. McCullagh1, K. Sabra1, C. Bergin2, F. Mulcahy2 Our HIV patients use herbal medicines. They are known to interact with conventional medicines, disease states and are associated with adverse reactions. A full drug history should include herbal medications, and the potential effect of these preparations on co-prescribed drugs should be considered. |
| P205 | [P205] COMPARATIVE ANALYSIS OF ADVERSE EFFECTS IN PATIENTS STARTING PI OR NNRTI BASED HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P205 Pawel Swiecki, Ewa Firlag-Burkacka, Andrzej Horban Both groups achieved similar treatment efficacy. All patients should be monitored for possible hepatotoxicity, more pronounced in PI group. Both groups experienced similar increases in cholesterol levels. TG was more increased in PI group. |
| P206 | [P206] A RETROSPECTIVE STUDY COMPARING THE SAFETY AND EFFICACY OF TENOFOVIR (TDF) WITH DIDANOSINE EC (DDI EC) 250 MG AS PART OF A HAART REGIMEN Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P206 Debra Johnson, Daniel Pearce1 In conclusion, based on the data collected for more than 3 years, TDF plus ddI EC 250 mg with a NNRTI or PI appears to be well tolerated, simple, safe and efficacious. |
| P207 | [P207] VIROLOGIC EFFICACY OF TENOFOVIR (TDF)-BASED REGIMENS WITH OR WITHOUT DIDANOSINE (DDI) IN TREATMENT-EXPERIENCED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P207 Jason Grebely, Jesse Raffa, Alexander Winther, Leslie Gallagher, Brian Conway The combination of TDF/DDI can be used as a successful NRTI backbone in second-line and salvage therapy independent of prior DDI exposure. However, inclusion of a PI in combination with a DDI/TDF as opposed to an NNRTI may be preferable in these non-naïve patients because of a greater genetic barrier to resistance. |
| P208 | [P208] DIDANOSINE/TENOFOVIR COMBINATION IN SALVAGE THERAPY: ANTIVIRAL ACTIVITY AND SAFETY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P208 A. Antinori, M.P. Trotta, P. Lorenzini, P. Marconi, M. Zaccarelli, F. Forbici, P. Sette, D. Zinzi, S. Bonfigli, C. Gori, G. Liuzzi, F. Soldani, U In heavily pre-treated pts, ddI/TDF combination was safe with low-risk of pancreatitis, even though associated to relatively weak virological and immunological response. Association with low genetic barrier-drug seems to not affect treatment efficacy. |
| COMMUNITY INITIATIVES |
|
| P209 | [P209] SUCCESSFUL RESULTS THROUGH A HOLISTIC APPROACH, A FAITH-BASED, COMMUNITY, LOW COST MODEL Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P209 Eric Robert Kamunvi, Ellen MacLachlan, Punima Kashyap Community support programs must have an integrated holistic development approach. Grass root organisations are best suited for community involvement and commitment. Treating a whole person, and not just the body, is what is needed and it is affordable. |
| P210 | [P210] AN ENFUVIRTIDE EMPOWERMENT PROGRAM: DO NOT ENTER Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P210 D. Varsalone1, K. Swartz2, D. Mohammed3 Through patient education, empowerment and support our patients have been able to overcome injection phobia and anxiety around self-injection. Participants have benefited immunologically and virologically from ENF therapy. Data from a subset of patients showed a mean CD4 increase of 93 cells/mm³ and decrease in viral load of 0.9 log10 copies/ml over 3 months on treatment. Over a period of more than 6 months 93 of 100 (93%) patients that have entered our program and started ENF therapy are still on therapy, compared with 12 of 30 (40%) patients who did not participate. Fear around self-injecting need not be a barrier to success with ENF. We continue to further develop our program, and encourage others to develop similar programs in their own communities. |
| P211 | [P211] ENHANCED PRIMARY CARE: IMPROVED CARE THROUGH COLLABORATION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P211 Alan Brotherton, Lisa McCann, Tony Maynard, Kate Fisher In-surgery support improves access to services for patients with chronic/multiple issues and assists GP integration with other services; enables patients to address long standing problems; improves the GP/CBO interface and provides a framework for effective shared care interventions eg drug and alcohol. Flexibility, adaptability are key to the success of such projects. Community engagement and capacity to work across health service and disciplinary boundaries are an advantage for CBOs. |
| P212 | [P212] A PUBLIC HEALTH APPROACH FOR ANTIRETROVIRAL TREATMENT IN 3 DISTRICTS OF GUJARAT STATE: INVOLVING PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS AND THE COMMUNITY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P212 Rakeshbhai V. Patel The development of AIDS-competent and ARV-competent communities requires training, information and ongoing support. People with HIV have a number of roles to play in community preparedness for ARVs. Community preparedness for ARVs will depend on coordination of support for those involved in treatment and will mean having the necessary information, knowledge, skills and materials including regular, uninterrupted supplies of medicines and diagnostics. |
| P213 | [P213] COMMUNITY INITIATIVE IN RESPONSE TO ART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P213 Patrick Ndawula, Kiguli Annette Rachel Community involvement enhances stigma free environment. Mostly self-stigma boosts PLWH/A openness which in turn lead to disclosure/partner notification for support, care, PLWH/A adherence and response to ART. |
| POST-EXPOSURE PROPHYLAXIS |
|
| P214 | [P214] A COORDINATED APPROACH TO HIV POST EXPOSURE PROPHYLAXIS ENSURES APPROPRIATE MANAGEMENT AND HIGH COMPLETION RATES Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P214 L. Sathia, C. Collister, J.C. Walsh 1/3 of this cohort had exposures involving a known HIV positive source. 92% were offered PEP appropriately (90% target). 96% of these completed 28 days PEP (target 75%), with 85% of all cases receiving PEP within 72 hours (aim 90%). A specialised PEP clinic allowed provision of a comprehensive, multidisciplinary service and ensured active recall of those at risk. Success of the clinic is highlighted by high rates of PEP completion, and Hep B vaccination. Scope for improvement in provision of HIV antibody testing 6 months post-PEP (target 75%, achieved 61%). |
| IMMUNOLOGY AND IMMUNE BASED THERAPIES |
|
| P215 | [P215] EVALUATION OF T-LYMPHOCYTE DYNAMICS AND HOMEOSTASIS IN HIV-POSITIVE PATIENTS WITH DISCORDANT RESPONSES TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P215 Giulia C. Marchetti, Antonella d'Arminio Monforte, Massimo Galli, Mauro Moroni, Chiara Molteni, Andrea Gori, Luca Meroni The lack of CD4+ rescue in INRs seems to reflect the persistence of a highly activated apoptotic immune system, despite successful viremia suppression. The elevated IL-7 levels, with TRECs comparable to FRs, and memory T-cell pool outgrowth, altogether suggest the persistence of a "conserved" thymic output, which is however unable to compensate the activation-induced CD4+ depletion and aberrant memory/naïve T-cell distribution. |
| P216 | [P216] USE OF INTERLEUKIN-2 IN THE CONTEXT OF STRUCTURED ANTIRETROVIRAL TREATMENT INTERRUPTION IN PATIENTS WITH PRIMARY HIV-1 INFECTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P216 Giulia C. Marchetti1, Miriam Cesari1, Alessandra Bandera1, Daria Trabattoni2, Chiara Molteni1, Monica Schenal2, Luca Meroni1, Mauro Moroni1, Massimo Galli1, Fabio Franzetti1, Mario Clerici2, Andrea Gori1 IL-2 during STI in patients treated during PHI is safe, and induced a CD4+ rise for 8 months without HAART, with HIV viremia control. Augmentation of HIV-specific responses suggest that IL-2 is able to maintain CD4+ HIV-specific immunity, with no effect on CD8+ cytotoxicity. |
| P217 | [P217] PRELIMINARY RESULTS FROM A CLINICAL TRIAL OF HIV-1 WHOLE KILLED VACCINE IN HAART-NAÏVE, ASYMPTOMATIC HIV-INFECTED INDIVIDUALS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P217 Mario Clerici1, Daria Trabattoni1, Renato Maserati2, Giuliano Rizzardini3, Francesco Mazzotta4, Georgia Theofan5, DorothyH. Bray6, Andrea Gori1 After one injection of REMUNE in HAART naïve subjects increased maturation of lymphocytes and trend in reduction of activated CD8+CD38+ cells have occurred. Further data are required to assess whether these changes will influence CD4 counts. |
| P218 | [P218] LONG-TERM OUTCOME AFTER THERAPEUTIC RGP160 IMMUNIZATIONS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P218 Lars E. Eriksson, Goran A. Bratt1, Britta Wahren3, Eric Sandstrom1 Thirteen years after initiation of a five years period of intermittent rgp160 immunizations, no negative long-term effects of therapeutic rgp160 immuno-therapy on morbidity or mortality could be identified. |
| P219 | [P219] PHENOTYPICAL CHARACTERIZATION OF PERIPHERAL LYMPHOCYTES DURING CD4-GUIDED THERAPY INTERRUPTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P219 Cristina Mussini1, Elisa Nemes2, Enrico Lugli2, Roberta Ferraresi2, Milena Nasi2, Marcello Pinti2, Vanni Borghi1, Giovanni Guaraldi1, Leonarda Troiano2, Roberto Esposito1, Andrea Cossarizza2 The changes in PBL phenotype were very similar to those observed during primary infection, and further underline the importance of the hyperactivation of the immune system (especially of CD8+ cells) during the first encounter - or the "re-encounter" - with the virus. It remains to be established whether or not such hyperactivation could be modulated by external agents. |
| P220 | [P220] HIV DNA DECAY, T-CELL PROLIFERATION AND APOPTOSIS IN NAÏVE HIV-INFECTED SUBJECTS AFTER VARIOUS HIGHLY ACTIVE ANTIRETROVIRAL THERAPIES Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P220 Saverio G. Parisi1, M. Biasin2, G. Carolo3, E. Concia3, L. Piacentini2, G. Magri2, C. Bergamaschi2, G. Palu1, M. Andreoni1, M. Clerici2 The efficacy of a long term HAART was confirmed; the immunological benefits are evident also in ID pts.The trends of IL-7 and Bax/BCL2 ratios suggest the need to analyse all factors regulating T-cell balance in order to evaluate the real immune reconstitution derived from HAART. |
| P221 | [P221] THE PREVALENCE AND RISKS OF IMMUNE RESTORATION DISEASE AFTER HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P221 Djordje L.J. Jevtovic, Jovan Ranin, Dubravka Salemovic, Ivana Pesic, Sonja Zerjav To avoid IRD in advanced patients, HAART should be initiated before the CD4 cell count drops to below 100. |
| P222 | [P222] ENFUVIRTIDE (ENF, T-20) IN DRUG-EXPERIENCED PATIENTS: PRELIMINARY IMMUNOVIROLOGIC RESULTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P222 Sergio Lo Caputo1, Andrea Gori2, Renato Maserati3, Giuliano Rizzardini4, Daria Trabattoni2, Francesco Mazzotta1, Mario Clerici2 These preliminary data indicate that therapy switch to T-20 in drug experienced multifailed patients is associated with the elicitation of strong and potentially beneficial immune responses. Short-term immunological effects of T-20 seem might be particularly beneficial in improving the function of CD8+ T lymphocytes. |
| P223 | [P223] DETECTION OF HIV-1 SPECIFIC MEMORY CD4+ CELLS IN HIV-1 PATIENTS. CORELLATION WITH VIRAL LOAD Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P223 Vigklis, S. Boti, J. Stephanou, V. Karachaliou, A. Siorenta, J. Saroglou, P. Gargalianos HAART is followed by a partial recovery of the immune system but the role of HIV-1 specific CD4+ T cell response in controlling the infection remains unclear. The aim of this study was to quantify HIV-1 specific CD4+ memory T cells by using a sensitive multiparamertric flow cytometric method based on the concomitant induction of the intracellular cytokines IFN-?, IL-2, IL-4, IL-10 and intracellular CD69 after stimulation of golgi transport-inhibited lymphocytes with HIV-1 antigens (gag, nef, env, gp120, gp41, p24 Ag). |
| P224 | [P224] EFFECTS OF A NOVEL IMMUNOMODULATOR IN HIV INFECTED INDIVIDUALS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P224 K. Galina, Z. Elena, Z. Iryna Our results suggest a beneficial effect of dzerlo as a potential immunoenhancer in HIV infected patients. Improvements in both laboratory markers (TLC, Hgb) and clinical progression were seen. This compound merits further study as an inexpensive agent for HIV infected individuals in resource poor settings. It will be perspective use combination ARV and this imunomodulate therapy for improve immunological effects. |
| P225 | [P225] FACTORS ASSOCIATED WITH LONG-TERM MORTALITY DURING HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P225 Lars E. Eriksson, Göran A. Bratt1, Kristina Koppel1, Eva-Lena Fredriksson1, Eric Sandström1 Our findings confirm the baseline CD4 count as the most important factor, also when evaluating long-term survival after initiation of HAART. |
| P226 | [P226] AN EMERGING ISSUE IN THE HIV DISEASE SCENARIO: INCREASED PATIENTS' AGE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P226 Roberto Manfredi, Leonardo Calza, Francesco Chiodo Increasing problems related to HIV disease management in the elderly deserve epidemiologic, clinical, and therapeutic investigation, since older age and underlying diseases represent main exclusion criteria for controlled trials, and concurrent illnesses and drug interactions are major problems in daily p management. |
| HIV-RELATED INFECTIONS, CO-INFECTIONS AND MALIGNANCIES |
|
| P227 | [P227] CLINICAL USEFULNESS OF SPOLIGOTYPING IN THE DIAGNOSIS AND TYPING OF MYCOBACTERIUM TUBERCULOSIS IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P227 Lidia Gazzola1, Andrea Gori1, Alessandra Bandera1, Franco Salerno1, Fabio Zanini1, Anna Degli Esposti1, Gian Piero Nardi2, Giulio Ferrario1, Mauro Moroni1, Fabio Franzetti1 Our study suggests the potential usefulness of spoligotyping for screening and epidemiological control of tuberculosis dissemination, particularly when a rapid result is required, such as in outbreak situations, or in the management of MDR-tuberculosis transmission in restricted high risk communities. |
| P228 | [P228] EFFECTIVENESS OF HAART IN ADVANCED INDIVIDUALS WITH NEUROLOGICAL DISEASE: DATA FROM THE ITALIAN REGISTRY INVESTIGATIVE NEURO AIDS (IRINA) COHORT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P228 M.P. Trotta1, P. Lorenzini1, C. Mussini2, A. Cingolani3, S. Bossolasco4, D. Larussa1, F. Moretti5, M. Bongiovanni6, M.G. Finazzi7, A. Ammassari3, C.F. Perno1, A. d'Arminio Monforte6, P. Cinque4, A. Antinori1 Among advanced patients with ND, effective response to HAART was observed, even if 1-year survival remains poor and influenced by ND. Initial viro-immunological response was strongly associated with long-term outcomes, allowing early identification of patients who might benefit from treatment modification/intensification. |
| P229 | [P229] CHARACTERISTICS AND PROSPECTS FOR ANTI-HCV TREATMENT OF AN HIV-HCV-CO-INFECTED POPULATION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P229 Marina Nunez1, Ivana Maida2, Vincent Soriano1, Ana Barrios1, Luz Martin Carbonero1, Juan Gonzalez Lahoz1 One third of our cohort has already received HCV therapy. Current HCV therapy candidates show a poor profile for response. More than half of naïve HCV treatment candidates present contraindications, most often low CD4 counts and depression. 5 % of the cohort is in end-stage-liver-disease. |
| P230 | [P230] CLINICAL EXPERIENCE AND VIROLOGICAL RESPONSE IN AN UNSELECTED COHORT OF HIV INFECTED ADULTS TREATED WITH PEGYLATED INTERFERON α-2A AND RIBAVIRIN FOR HCV CO-INFECTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P230 Erica Peters1, Sheila Cameron2, Ysobel Gourlay1, R. Andrew Seaton1, Ray Fox1 Treatment of HCV with PEG/RBV is feasible in HIV coinfection but adverse effects are common. At twelve weeks <2 log drop in HCV viral load is indicative of non response. SVR in genotype 1 is poor (1/9) but 100% in genotype 3 (2/2). Overall SVR was 27% (3/11). |
| HIV-RELATED INFECTIONS, CO-INFECTIONS AND MALIGNANCIES - HBV |
|
| P231 | [P231] TENOFOVIR IN USE FOR HIV IN CHRONIC HEPATITIS B CO-INFECTED INDIVIDUALS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P231 Christoph Stephan1, Annemarie Berger2, Thomas Lutz1, Brenda Dauer1, Martin Stuermer2, Staszewski Schlomo1 TDF is effective to treat HBV in HIV coinfected individuals. A high replicative HBV infection may be turned to undetectable or at least into a low replicative form. Though a few patients show low-level HBV replication, clinical resistance during 48 weeks was not observed. |
| HIV-RELATED INFECTIONS, CO-INFECTIONS AND MALIGNANCIES - HCV |
|
| P232 | [P232] IMPACT OF NNRTI- OR PI-BASED HAART ON LIVER FIBROSIS IN HIV/HCV COINFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P232 Franco Maggiolo1, Giampaolo Quinzan1, Diego Ripamonti1 , Giampietro Gregis1, Laura Ravasio2, Monica Airoldi2, Fredy Suter2 In this retrospective analysis we were unable to show a significant impact of either PI or NNRTI use on the spectrum of liver disease. In HIV/HCV coinfected patients, until additional data are available, the use of PIs or NNRTIs in HAART should be dictated by the need to control HIV disease and patient preference or tolerance, rather than by the risk to influence the severity of HCV-related liver disease. |
| P233 | [P233] TREATMENT COMBINATION WITH PEGYLATED-INTERFERON AND RIBAVIRIN IN CHRONIC HEPATITIS OF HIV-HCV COINFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P233 Juan P. Zabaleta, Ignacio Santos, Diego A Our results show that combination therapy is effective in 71,4% of the cases in clearing serum HCV-RNA in genotype 3, while in 1 and 4 the efficacy in lower with high number of withdrawals. |
| P234 | [P234] LOWER PLASMA HCV RNA LEVELS AMONG HBSAG CARRIERS IN AN HIV/HCV-COINFECTED POPULATION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P234 Marina Nunez1, Ivana Maida2, Sergio Babudieri2, Luisa Fenu2, Nuria Camino1, Juan Gonzalez Lahoz1, Maria Stella Mura2, Vicente Soriano1 Lower HCV RNA levels were seen in those HIV/HCV-coinfected subjects carrying the HBsAg, even in the absence of active HBV replication, what implies a favorable feature in these patients regarding response to anti-HCV therapy. Further research is needed to elucidate if immune phenomena are involved in the inhibition exerted by HBV over the HCV infection. |
| P235 | [P235] ACTIVE CHRONIC HCV INFECTION WITH NORMAL TRANSAMINASES MORE COMMON AMONG HIV-INFECTED FEMALES Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P205 Marina Nunez, Ivana Maida, Juan Gonzalez Lahoz, Vicente Soriano Around one fifth of the HIV-infected pts with HCV replication analyzed had normal transaminases. Females had more often normal transaminases compared to males. Therefore, HIV-infected pts with positive anti-HCV antibody need a complete evaluation including plasma HCV RNA levels even when transaminases are within normal limits, and this especially applies to females. |
| P236 | [P236] THE IMPACT OF HEPATITIS C CO-INFECTION ON HIV PROGRESSION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P236 Laura Waters, Milena Stevanovic, Rachael Jones, Sundhiya Mandalia, Mark Bower, Mark Nelson, Brian Gazzard This study shows a faster rate of HIV disease progression in HCV/HIV co-infected as compared with HIV mono-infected individuals in our large cohort in the HAART era. |
| P237 | [P237] HEPATITIS C AND HIV CO-INFECTION; WHO IS A CANDIDATE FOR HEPATITIS C TREATMENT? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P237 Joanna M. Turner, Clifford L. Leen, Sheila Morris, Alan Wilson Only 30 (23%) patients were suitable for HCV therapy. This is lower than expected reflecting significant numbers with CD4<200 cells/mm³ (24%) and those who declined HCV treatment (24%). The reasons for the latter warrant further study. |
| P238 | [P238] EFFICACY OF THE FIRST HAART REGIMEN AMONG HCV POSITIVE PATIENTS, DATA FROM WARSAW COHORT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P238 I. Cielniak, M. Niezabitowska, E. Bakowska, A. Ignatowska, E. Burkacka, A. Horban Some study report negative influence of HCV coinfection on CD4 cell count during first HAART therapy, while no such influence on viral load changes were seen. As in other cohort studies no such correlation were seen, we try to look for this association among patients from Warsaw cohort. |
| P239 | [P239] FIRST HAART THERAPY AMONG PATIENTS FROM WARSAW KOHORT: COMPARISON OF HCV + AND HCV - GROUP Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P239 Malgorzata Niezabitowska, Iwona Cielniak, Elzbieta Bakowska, Anna Ignatowska, Ewa Burkacka, Andrzej Horban There were no difference in HCV pos and neg groups in terms of age, number of naïve patients starting therapy, or first HAART regimen. Mean CD4 cell count and viral load at the baseline were similar. Difference were seen in the way of transmition. It reflects HCV way of transmitting trough blood. 86% of HCV pos group were IVDU. This could result in worse compliance and shorter time of duration of the first therapy. |
| P240 | [P240] TRICO: A PILOT STUDY ON THE SAFETY OF TRIPLE THERAPY WITH PEGYLATED INTERFERON + RIBAVIRINE + AMANTADINE IN HIV/HCV CO-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P240 K. Kabeya1, S. De Wit1, J.P. Mulkay2, O. Vandermeeren3, N. Clumeck1 These preliminary results suggest that the triple combination of Pegasys + RBV + AMA is safe and not associated with increased toxicity in HIV/HCV co-infection, allowing to evaluate this triple combination for efficacy in HIV/HCV co-infected patients. |
| P241 | [P241] ELIGIBILITY FOR LIVER TRANSPLANTATION IN HIV AND HCV COINFECTED PATIENTS WITH END STAGE LIVER DISEASE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P241 Mubariz M. Husain, Clifford L. Leen ESLD and fatal liver failure is associated with advancing HIV disease. Principal exclusion factors for transplantation were viral load count < 200 cps/ml and persistent alcohol and drug abuse. Quality of life was a surrogate marker for advancing HIV and psychosocial problems. Potential candidates for OLT need to be screened early and targeted with aggressive detoxification and adherence programmes as well as early hepatology involvement. |
| P242 | [P242] SHORT COURSE DIRECTLY OBSERVED THERAPY (DOT) WITH AZITHROMYCIN FOR BACTERIAL INFECTIONS IN HIV OR HCV-INFECTED INTRAVENOUS DRUG USERS (IVDUS) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P242 H. Tossonian1, J. Raffa1, M. Viljoen2, H. Culbert2, M. Khara2, A. Mead2, S. DeVlaming2, B. Conway1 The availability of potent, once daily antibiotics such as azithromycin (within DOT programs) may be an important and convenient tool for the treatment of RTIs and SSTIs in IVDUs. |
| HIV-RELATED INFECTIONS, CO-INFECTIONS AND MALIGNANCIES - OPPORTUNISTIC INFECTIONS |
|
| P243 | [P243] COURSE AND TREATMENT OF ACUTE HEPATITIS C INFECTION IN HIV-INFECTED PATIENTS: A MULTICENTER PROSPECTIVE TRIAL Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P243 Axel Baumgarten1, Martin Vogel2, Thomas Seidel3, Christian Hoffmann4, Christoph Mayr5, Albert Theisen6, Thomas Lutz7, Michael Rausch8, Heiko Jessen9, Dietmar Schranz10, Stefan Fenske11, Stefan Mauss12, Ulrich Spengler2, Juergen Rockstroh2 Early interferon therapy of acute HCV-infection appears to achieve high virological response rates in patients with HIV-coinfection. |
| P244 | [P244] COMPARATIVE STUDY: THERAPEUTIC REGIMENS IN HIV VERSUS HIV-HCV CO-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P244 Priyo Sasongko Our study has shown that co-infected HCV/HIV patients have different therapeutic regimens. Further studies are required to evaluate the impetus for these varied choices and the quality of hospital management of our HCV/HIV co-infected patients. |
| P245 | [P245] TREATMENT OF MRSA INFECTION WITH TRADITIONAL ORAL ANTIBIOTICS IN A LOS ANGELES HIV+ MSM POPULATION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P245 James D. Scott, Julia Ireland2 In late 2002, an epidemic of methicillin-resistant Staphylococcus aureus (MRSA) skin/soft tissue infections (SSTI) spread through the homosexual male (MSM) population in Los Angeles (LA). Many were also infected with HIV. Most pts at the Jeffrey Goodman Clinic (an HIV specialty clinic in LA) are uninsured and the use of certain medications is restricted for cost-containment reasons. The purpose of this study was to evaluate the clinical effectiveness of, and costs associated with, traditional oral abx in treating MRSA in this epidemic. |
| P246 | [P246] RHODOCOCCUS EQUI PNEUMONIA: COMPLETE RESOLUTION OF A PREVIOUSLY INCURABLE HIV-RELATED OPPORTUNISTIC INFECTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P246 Massimo Giola, Cristina Basilico, Francesco Dinatale, Mario Montanari, Paolo Grossi At the best of our knowledge, this is the first, well-documented case of HIV-related Rhodococcus equi pneumonia that appears to have been completely cured, allowing clinicians to stop antibiotic therapy and to simplify HAART. |
| P247 | [P247] CHRYSOSPORIUM SPP. BRAIN ABSCESS IN AN HIV-INFECTED PATIENT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P247 Christoph Steininger1, Jan van Lunzen1, Ingo Sobottka2, Kathrin Tintelnot3, Hans-Jürgen Stellbrink1 Abstract not reproduced at author's request. |
| P248 | [P248] PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) AND KAPOSI'S SARCOMA (KS) IN A HIV+ PATIENT RESPONDING TO HAART: IMMUNOLOGICAL REGULATION INVOLVED IN THE DEVELOPMENT OF PML Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P248 G. Sotgiu1, R. Maserati2, P. Ferrante3, S. Delbue3, M. Saresella3 In our case a successful HAART regimen did not make a regression of KS and did not avoid the emergence of a PML. This was related to a selective deficit in specific CD4+ cells' recovery as demonstrated by immunologic analysis. |
| P249 | [P249] HIGH PREVALENCE OF H. PYLORI IN HIV-POSITIVE PATIENTS WITH HCV CO-INFECTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P249 Justyna D. Kowalska, Regina B. Podlasin Pts co-infected with HCV had higher HpI, yet with no statistical significance. In our opinion, it might be caused by the small count of pts group and is planned to be revised on the bigger one. |
| P250 | [P250] LEGIONNAIRE'S DISEASE IN HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P250 Leire Apraiz, Joseba Portu, Paola Tarabini, Maitane Izagirre, Mikel Aldamiz-Etxeberria, Montserrat Gomez Pneumonia caused by Legionella is an infrequent cause of pneumonia in patients infected by HIV. We have not noticed an increase in the risk in patients with < 200 CD4 |
| P251 | [P251] RECURRENCE OF CRYPTOCOCCAL NEOFORMANS (C. N.) VAR. GATTII MENINGITIS AFTER 4 YEARS INDUCTION/MAINTENENCE THERAPY IN A HAART TREATED HIV POSITIVE MAN Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P251 F. Ross, R.A. Seaton, D. Kennedy Despite marked improvement in immune function, maintenance fluconazole and negative antigen test monitoring late relapse occurred. This might have been avoided by a longer induction of therapy and/ or a higher maintenance dose of fluconazole. Though evidence is scant about optimum treatment, we will discuss a regime based on the available literature. |
| P252 | [P252] CRYPTOCOCCAL MENINGITIS IN THE HAART ERA: RETROSPECTIVE ANALYSIS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P252 Jorge F. Velez, Daniel G. Guzman, Helena S. Alves, Joaquim M. Oliveira, Jose G. Saraiva da Cunha CM is a disease that occurs in advanced immunodeficiency and, despite appropriate treatment, is associated with high morbidity and mortality rates. A prompt diagnosis and adequate therapy, as well as a control of immunossupression, are important determinants that can improve the prognosis. |
| P253 | [P253] HIV-TUBERCULOSIS COINFECTION. CHANGING PREVALENCE AND IMPACT ON ANTIRETROVIRAL USE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P253 N. Chew, E. Brannigan, R. Lynch, F. Mulcahy, C. Bergin Concomitant treatment of TB and HIV is associated with a favourable HIV outcome in our patient cohort. |
| P254 | [P254] INFECTIOUS SYPHILIS PRESENTING AS A RECTAL MASS IN AN HIV POSITIVE PATIENT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P254 Vincent Lee, Karen McSween, Waleed Hamad, Mark Pakianathan Syphilis serology was positive: TPPA with titres > 1280, VDRL reactive 1 in 256. Syphilis IgG and IgM EIA positive suggesting recent/active infection. He had a negative syphilis test in 2001. He was treated with a course of benzathine penicillin injections and his rectal mass has resolved. A diagnosis of infectious syphilis should be considered in homosexual men presenting with a rectal mass. |
| P255 | [P255] RECURRENT DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX IN A PATIENT WITH RESTORED CD4+ COUNT AND UNDETECTABLE VIRAL LOAD ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P255 Monique I. Andersson2,Ann Harrison1, Stuart C. Glover1, Paul Virgo1, Sarah Johnson1, Mark M. Gompels1 This case supports the data suggesting that in certain patients the immune reconstitution afforded by HAART is selective and incomplete. |
| P256 | [P256] OCULAR LEISHMANIA IN AN IMMUNOCOMPROMISED PATIENT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P256 Christina Meenken1, Michiel A. van Agtmael2, Reinier W. Ten Kate3, Gerardus J. van den Horn4 To focus the attention to a rare but severe manifestation of Leishmania Donovani in immunocompromised patients. |
| P257 | [P257] ATYPIC PRESENTATION OF VISCERAL LEISHMANIASIS (VL) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P257 M. Blanc, B. Colombe, A. Bosseray, P. Leclercq Relpases can occur despite adequate treatment suggesting that successful ART is not sufficient to control the disease. Although rare, VL with pulmonary localisation exists. It is important to realise the specific PCR on the LBA when it is suspected. |
| HIV-RELATED INFECTIONS, CO-INFECTIONS AND MALIGNANCIES - OTHER |
|
| P258 | [P258] IMPROVEMENT OF PSORIATIC LESIONS AFTER STARTING CHLOROQUINE IN 3 AFRICAN HIV POSITIVE PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P258 H.M. Shihab, J.J. Feld, C. Liechty, F. Lutwama, T. Piloya, B.R. Colebunders, F. Waidha Despite the general contraindication to using chloroquine in patients with psoriasis, these 3 cases suggest that with HIV co-infection, chloroquine may be a good and safe therapeutic option. Larger studies are needed to investigate this further. |
| P259 | [P259] IMPACT OF THE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON HOSPITAL ADMISSION RATES AND MORTALITY IN PORTUGUESE HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P259 Emília Valadas1, Carla S. Ribeiro2, Nancy Faria2, José Neves2 Francisco Antunes1 Between 1998 and 2001 there was a marked reduction in the mortality of the HIV infected patients as well as in the admission rates. This was most likely due to the introduction and widespread use of HAART. However, the initial drop in mortality and morbidity seen in the late-HAART era at our setting does not seen to be sustained. HAART failure and limited access to health care, especially in the intravenous drug user group, are possible explanations for these new trends. |
| P260 | [P260] AIDS DEFINING ILLNESSES (ADIS) IN POLAND IN 2003 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P260 Regina Podlasin1, Dorota Bander2, Jadwiga Gizinska1, Teresa Rzeszkowicz1, Iwona Cielniak1, Mussabir Mian3, Grazyna Baralkiewicz4, Ewa Malolepsza5, Marta Gesing6, Aleksander Garlicki7, Jakub Kwiatkowski8, Anita Olczak9, Weronika Rymer10, Alicja Wiercinska11 Stable and low incidence of ADIs in group of ART+ pts indicates sustained, good clinical efficacy of ART. Since three years TBC is the most common ADI in Poland. People unaware of possibility of HIV infection, are diagnosed late. |
| P261 | [P261] A SIGNIFICANT PROPORTION OF HIV INFECTED PATIENTS ADMITTED TO HOSPITAL HAVE IMMUNOSUPPRESSION DUE TO FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P261 Kaveh Manavi, Alexander McMillan Patients on HAART and CD4<200 spent longer periods in hospital compared to those with higher CD4 count. This may have significant implications on the cost of management of HIV infected patients and may highlight the need for earlier treatment of older IVDU patients. |
| P262 | [P262] HEMOPHAGOCYTIC SYNDROME IN HIV INFECTED PATIENT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P262 M.P. Guillaume, N. Driessens, D. Debels, R. Karmali Post-mortem tissues examination revealed positive Toxoplasma Gondii PCR in the liver, spleen and lungs. This case prompts one to add Toxoplasma Gondii at the already large list of infectious agents responsive of hemophagocytic syndrome in HIV patients and to seek for it systematically. |
| P263 | [P263] CAUSES OF DEATH AMONG PATIENTS IN THE EDINBURGH HIV COHORT IN THE ERA OF HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P263 Wendy I. Beadles, Clifford L. Leen AIDS defining events and infection remain a significant cause of mortality in the HAART era. The patients who acquired HIV through IVDU account for a large proportion of deaths. In those patients who continue to misuse drugs there is likely to be an increased risk of pneumonia. This highlights the importance of HCV co-infection and shows that HBV co-infection needs to be further addressed. |
| P264 | [P264] INTESTINAL KAPOSI SARCOMA IN A FEMALE CAUCASIAN PATIENT PRESENTING AS INFLAMMATORY BOWEL DISEASE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P264 Madeleine Rothen1, Niklaus Schaub2, Johannes Beltinger2, Gieri Cathomas3 Kaposi sarcoma may occur in low risk populations and without skin lesions. Resolution of visceral Kaposi sarcoma can be achieved by antiretroviral therapy. |
| P265 | [P265] PATIENT HOSPITALIZATION RELATED TO HIV INFECTION DURING THE PRE AND POST HAART ERAS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P265 Eduardo Perez, Toibaro J. Javier, Lourtau Leonardo, Losso Marcelo We observed no significant differences in the causes of admission in both periods. TB is the most frequent disease that motivates hospitalization. The relation between the number of ambulatory consultations and the one of admissions changed significantly. |
| P266 | [P266] FINE-NEEDLE ASPIRATION BIOPSY IN LYMPHADENOPATHY OF HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P266 C. Pineiro1, R. Serrao1, A. Ferreira1, S. Silva1, S. Xerinda1, A. Prisca1, I. Amendoeira2, H. Barroca2, D. Pinheiro3, T. Carvalho3, R. Marques1, A. Mota Miranda1 Most common FNAB diagnosis: reactive lymphoid hyperplasia n= 175 (54%). TB was diagnosed in 71 (22%) samples based on: acid-fast bacilli in the cytologic smears=33, granulomatous/necrotising caseous patterns = 58, Mt positive PCR = 17, culture = 40. Lymphoma = 3. Disseminated MAC = 3. Other = 3. In 22% of the samples the material was scanty or acellular or non-conclusive - in none of these cases was a malignant tumour later found. FNAB was found to be a simple, safe and reliable evaluating procedure for lymphadenopaties in the HIV-infected pts. A major OI (TB) could be correctly identified and promptly treated. |
| HIV-RELATED INFECTIONS, CO-INFECTIONS AND MALIGNANCIES - TB |
|
| P267 | [P267] TB AND ART THERAPY IN PATIENTS WITH HIV/AIDS IN SOUTH INDIA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P267 R.B. Rayapu, K.A. Ramaiah, R. Sharath Poverty plays a major role in the spread of tuberculosis and HIV. With out proper nutrition, tolerance to drugs is minimum. Apart from providing drug therapy there is need to provide nutritional support also for the effective treatment. Once daily ART and TB therapy co-administered with good nutrition support appears to be safe and effective. |
| P268 | [P268] MANAGEMENT OF HIV RELATED TUBERCULOSIS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P268 Janak K. Maniar1, Tejal K. Shah2, Alok J. Maniar2, Keyur B. Shah2 TB continues to be commonest OI. Pulmonary TB is common anatomical site. HIV related TB has shown higher incidence of extrapulmonary TB, adverse events due to ATT, MDR TB and recurrent episodes of TB. Prophylaxis for TB has limited application in endemic region. Hepatitis B or Hepatitis C co-infection may contribute for higher incidence of ATT induced hepatitis. HAART implementation is expected to reduce TB associated morbidity and mortality. Early recognisation of concurrent OIs and their adequate treatment is essential. |
| P269 | [P269] TUBERCULOSIS IN PATIENTS LIVING WITH HIV/AIDS. A CLINICAL PERSPECTIVE FROM ARGENTINA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P269 Jorge M. Contarelli, Lucila I. Massera, Martha G. Michaan, Gabriela E. Alberich, Adriana E. Cucchetti, Santiago J. Ramirez Borga In spite 20 years of AIDS, TB is a devastating condition particularly in developing countries. Lung TB is the main presentation, and should alert clinicians about HIV. Early diagnosis improved the outcome and diminished secuelae and mortality. |
| CLINICAL PHARMACOLOGY |
|
| P270 | [P270] NEVIRAPINE PLASMA EXPOSURE AFFECTS DURABILITY OF VIROLOGICAL EFFICACY AND SELECTION OF PRIMARY RESISTANCE MUTATIONS: DEFINITION OF MUTANT SELECTION WINDOW Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P270 Stefano Bonora1, Daniel Gonzalez de Requena1, Silvia Garazzino1, Francesca Canta1, Rosalia Marrone1, Mauro Sciandra1, Antonio D'Avolio1, Marta Boffito2, Alessandro Sinicco1, Giovanni Di Perri1 NVP plasma exposure is a determinant factor of the durability of VS. Moreover, the degree of NVP plasma exposure has been found to affect the appearance of resistance, prompting toward the definition of a range of concentrations in which the selection of resistant mutants is the highest (Mutant Selection Window). |
| P271 | [P271] PROTEASE INHIBITORS POTENTIATE CHEMOTHERAPY INDUCED NEUTROPENIA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P271 Elizabeth Davies1, Neil McCall-Peat1, Natalie Ryan2, Anne-Marie Young2, Mark Nelson3, Brian Gazzard3, Mark Bower2 PI based HAART potentiates the myelotoxicity of CDE chemotherapy and this is believed to be a consequence of microsomal enzyme inhibition reducing metabolism of cytotoxics in this regimen. |
| P272 | [P272] PHARMACOKINETICS (PK) OF SAQUINAVIR HARD GEL (SQV)/RITONAVIR (R) IN COMBINATION WITH DIFFERENT DOSES OF ATAZANAVIR (ATV) ONCE DAILY (OD) IN HIV+ PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P272 Marta Boffito1, Desmond Maitland1, Laura Dickinson2 , David Back2, Andrew Hill2, Graeme Moyle1, Mark Nelson1, Carl Fletcher1, Brian Gazzard1, Anton Pozniak1 ATV enhances SQV and r by an unclear mechanism. While SQV enhancement is apparently independent of ATV dose, ATV 300 mg is necessary to increase r exposure. Lower doses of ATV limit the development of hyperbilirubinimia. |
| P273 | [P273] EFAVIRENZ (EFV) CONCENTRATIONS AND HIV VIRAL LOAD IN SEMEN AND BLOOD OF HIV-1-INFECTED MEN Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P273 Giuseppina Liuzzi1, Daniela Zinzi1, Lisa Almond2, Alessandra Amendola1, Mauro Zaccarelli1, Mariarosaria Capobianchi1, Carlo Federico Perno1, David Back2, Andrea Antinori1 We have successfully measured EFV in the semen and shown that EFV-containing regimens appear to be effective in reducing HIV seminal viral load confirming that EFV-containing regimens have antiviral activity within the male genital tract. |
| P274 | [P274] THERAPEUTIC DRUG MONITORING OF ATAZANAVIR IN ROUTINE CLINICAL SETTINGS IN THE UK Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P274 Sara Gibbons, Lesley Robinson, Laura Dickinson, John Tjia, Anthea Robertson, Meredith Stainsby-Tron, Stephen Kewn, David Back, Saye Khoo There is marked variability in plasma ATV concentrations in the clinical setting. This is due to both a variety of dosing regimens and interpatient variability within a dosing regimen, and supports the use of TDM for this drug. |
| P275 | [P275] INTERACTION BETWEEN ATAZANAVIR/RITONAVIR (ATV/RTV) AND NEVIRAPINE (NVP) IS OBSERVED IN A CLINICAL SETTING Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P275 Christopher S. Alexander, Julio G. Montaner, Shawna Langridge, Silvia A. Guillemi, Marianne Harris, Richard Harrigan These results, obtained in a clinical setting, suggest that rtv boosting of ATV reduces the interaction with TDF; however, it may not overcome interactions with NVP. This highlights the importance of completing structured pharamcokinetic studies to fully characterise the interaction of NVP with ATV and ATV/rtv. |
| P276 | [P276] PHARMACOKINETIC INTERACTIONS OF ATAZANAVIR (ATV) AND SAQUINAVIR (SQV) IN A RITONAVIR (RTV) BOOSTED PROTEASE INHIBITOR THERAPY REGIMEN Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P276 Nils H. von Hentig1, Annette Haberl2, Thomas Lutz3, Michael Kurowski4, Schlomo Staszewski2 In a boosted double PI-only regimen, ATV and SQV plasma levels are increased significantly compared to a regimen of either SQV/RTV or ATV/RTV+NRTI, but do not require dose adjustment. Exposure to RTV is significantly higher as part of the ATV-containing regimen vs. SQV+RTV. Higher drug levels may be associated with increased toxicity. |
| P277 | [P277] THE PHARMACOKINETICS (PK) OF SAQUINAVIR AND RITONAVIR IN UGANDAN PATIENTS RECEIVING RITONAVIR BOOSTED SAQUINAVIR HARD GEL AND SOFT GEL Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P277 C. Merry, P. Coakely, C. Kityo, M. Ryan, P. Mugyenyi, D. Back, S. Gibbons, J.M.A. Lange In this setting RTV boosted Invirase appears to be the SQV formulation of choice as it demonstrates less interpatient variability and a greater proportion of patients with therapeutic SQV levels. Low plasma RTV levels are unlikely due to compliance issues because of observed dosing but could possibly be explained by sub-optimal storage at any point in the supply cold chain. This is supported by the results of a recent quality control analysis of ARVs sourced in Africa which demonstrated drug content to USP standards in the two SQV formulations but RTV levels 16 to 19% less than the labelled amount possibly due to inadequate refrigeration 1. Intensive PK studies are feasible in low-income countries and yield valuable data that will ensure optimal treatment outcomes for HIV-infected patients. |
| P278 | [P278] INTRACELLULAR AND UNBOUND CONCENTRATIONS OF EFAVIRENZ (EFV) AND NEVIRAPINE (NVP) IN VIVO Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P278 Lisa M. Almond1, Marta Boffito2, Mark Dalton1, Damitha Edirisinghe1, Alec Bonington3, David J. Back1, Saye Khoo1 There was differential accumulation of EFV and NVP within PBMCs (EFV > NVP). These data imply that IC accumulation of EFV may be related to protein binding. Studies identifying the unbound IC concentration of antiretrovirals are now required. |
| P279 | [P279] LACK OF EFFECT OF GASTRIC ACID REDUCING AGENTS ON LOPINAVIR/RITONAVIR PLASMA CONCENTRATIONS IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P279 Richard J. Bertz, Yi-Lin Chiu, Christian Naylor, Kristin Luff, Scott C. Brun Lopinavir/ritonavir treated patients who received acid reducing agents did not appear to have a reduction in lopinavir and ritonavir trough concentrations through 48 weeks of therapy. Further formal investigation of the effect of potent acid reducing agents on lopinavir/ritonavir pharmacokinetics is warranted. |
| P280 | [P280] A NEW SAQUINAVIR 500 MG FILM-COATED TABLET IS BIOEQUIVALENT TO SAQUINAVIR 200 MG HARD CAPSULES WHEN BOOSTED WITH TWICE-DAILY RITONAVIR IN HEALTHY VOLUNTEERS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P280 Susan Grange1,Beate Bittner1, Amran Saifulanwar2, Arash Bakhtyari3, Myriam Riek1, Beverly Holmes1 The new 500 mg Invirase FCT formulation is bioequivalent to the 200 mg Invirase HC formulation, at the dose of 1000 mg, when boosted with RTV 100 mg. The 500 mg Invirase FCT formulation reduces pill count for boosted SQV (SQV/r) from six to three tablets bid. This will increase patient acceptability of SQV/r, particularly in less treatment-experienced patients. |
| P281 | [P281] LACK OF A DRUG INTERACTION BETWEEN TENOFOVIR DF AND NELFINAVIR Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P281 Brian P. Kearney2,Marta Boffito1, Anton Pozniak1, Anita Mathias2, Jaymin Shah2 This study examined the PK of tenofovir (TFV) and NFV duringlinebreak co-administration as these agents may be coadministered in the treatment of HIV infection. |
| P282 | [P282] AN INVESTIGATION OF THE EFFECTS OF TENOFOVIR ON THE PHARMACOKINETICS OF THE NOVEL CCR5 INHIBITOR UK-427,857 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P282 G. Muirhead1, D. Russell1, S. Abel1, K. Turner1, R. Taylor-Worth1, L.H. Tan2, M. Toh2 As the 90% confidence intervals for the ratio between the geometric means for both AUC12 and Cmax were within 80-125%, it was concluded that there was no significant interaction between tenofovir and UK-427,857. |
| P283 | [P283] AN INVESTIGATION OF THE EFFECTS OF ATAZANAVIR AND RITONAVIR BOOSTED ATAZANAVIR ON THE PHARMACOKINETICS OF THE NOVEL CCR5 INHIBITOR UK-427,857 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P283 G. Muirhead1, S. Abel1, D. Russell1, F. Hackman1, R. Taylor-Worth1, M. Toh2, L.H. Tan2 UK-427,857, an antagonist of the CCR5 co-receptor with potent anti-HIV activity is being developed for the treatment of HIV infection. In clinical practice, UK-427,857, a CYP3A4 substrate, will be administered in combination with other HIV treatments. |
| P284 | [P284] A STUDY TO INVESTIGATE THE COMBINED CO-ADMINISTRATION OF P450 CYP3A4 INHIBITORS AND INDUCERS ON THE PHARMACOKINETICS OF THE NOVEL CCR5 INHIBITOR UK-427,857 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P284 G. Muirhead1, C. Ridgway1, D. Leahy1, C. Mills2, R. van der Merwe3, D. Russell1 UK-427,857, a CYP3A4 substrate, is an antagonist of the CCR5 co-receptor with potent anti-HIV activity and is being developed for the treatment of HIV infection. This study investigated the combined effects of CYP3A4 inhibitors and inducers on the PK of UK-427,857. |
| P285 | [P285] EFFECT OF BODYWEIGHT AND BODY MASS INDEX ON SAQUINAVIR EXPOSURE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P285 Reshma Saskia Autar1, Marta Boffito2, Elly Hassink3, Andrew Hill4, Joep M.A. Lange3, Ruxrungtham Kiat1, David Burger2 The most important factors to explain SQV exposure appears to be RTV AUC and site. Where RTV AUC explains the most and site is likely to be a combination of factors like weight (as shown by the relation between site and weight), genetic, ethnic or life-style differences. |
| P286 | [P286] PATIENTS' WEIGHT DOES NOT SUBSTANTIALLY AFFECT EFFICACY OF HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P286 Bernardino Roca Despite the efficacy of HAART, HIV infection is not adequately controlled in many patients. Insufficient therapeutic drug levels can be a reason for that. Except for didanosine and stavudine, antiretrovirals are administered in fixed doses in adults, independently of weigh, which might result in inadequate therapeutic drug levels in overweight people, as well as toxic therapeutic drug levels in thin people. We assess the influence of patient's weight in HIV RNA and CD4 cell response to HAART. |
| P287 | [P287] PHARMACOKINETIC EVALUATION OF THREE DIFFERENT INTRAMUSCULAR DOSES OF NANDROLONE DECANOATE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P287 Theodorus B.P. Geurts1, Jean M.W. Smeets1, Herman A.M. Verheul1, Suzanne M. de Jager-van der Veen2, Andreas Port3, Wilma M. Bagchus1 It was demonstrated for the first time that after a single i.m. dose of ND, serum levels of nandrolone increased in a linear fashion across a dose range of 50 to 150 mg (the dose range that is also used to treat HIV-wasting). |
| P288 | [P288] FAVORABLE INTERACTION BETWEEN ATAZANAVIR AND FOSAMPRENAVIR WITH AND WITHOUT RITONAVIR IN THE TREATMENT OF HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P288 Charles Farthing, Homayoun Khanlou These preliminary results appear to indicate that a combination of atazanavir 150 mg BID and fos-amprenavir 700 mg BID with low dose RTV may offer adequate Cts for both drugs. Further studies evaluating the pharmacokinetics, and the virological efficacy of this combination are warranted. |
| P289 | [P289] CO-ADMINISTRATION OF ATAZANAVIR WITH PROTON- PUMP INHIBITORS AND H2-BLOCKERS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P289 Charles Farthing, Homayoun Khanlou These findings support that, PPIs and H2RBs probably do interact negatively when used with standard ATV dosing, and that boosting with RTV probably does not result in adequate levels. Further information of ATV-Ct when PPIs and H2RBs were stopped will be made available later. Further study of this important issue is warranted. |
| P290 | [P290] TO DETERMINE FOS-AMPRENAVIR PLASMA CONCENTRATIONS IN HIV-INFECTED PATIENTS: ELISA COMPARED TO HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P290 Elena Seminari2, Gianluca Gentilini1, Armando Soldarini1, Elena Donadel3, Erica Bastiani3, Antonella Castagna2, Adriano Lazzarin1, Fernanda Dorigatti1, Serena Rinaldi3 These preliminary data suggest that there are no significant differences between fos-APV plasma levels measured by HPLC and ELISA. |
| P291 | [P291] RELATIONSHIP BETWEEN LOPINAVIR TROUGHS AND LIVER FUNCTION TESTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P291 Elena Seminari1, Anna Danise1, Hamid Hasson1, Elisabetta Carini1, Armando Soldarini2, Fernanda Dorigatti2, Gianluca Gentilini2, Adriano Lazzarin1, Antonella Castagna1 LPV trough did not differ in HIV infected patients with concomitant HCV/HBV co-infection. GGT and ALP correlate to LPV troughs; no correlation was for LPV troughs and ALT and bilirubin. The observed correlation between GGT and AP and LPV trough could be a causal effect event, as observed in case of enzyme-inducing drugs. |
| P292 | [P292] LOPINAVIR TROUGH CONCENTRATION REMAINS CONSISTENT FOR ADULT PATIENTS REGARDLESS OF AGE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P292 Silvia A. Guillemi, Christopher S. Alexander, Simon Bonner, Lilian Ting, Marianne Harris, Paul R. Harrigan, Julio G. Montaner Based on these data, the physiological changes associated with aging have no effect LPV trough concentrations. It is likely that dosing recommendations for LPV/r provide adequate LPV exposures in patients over 60 years of age. |
| P293 | [P293] THERAPEUTIC DRUG MONITORING (TDM) OF ATAZANAVIR (ATV) DURING THE FIRST 4 WEEKS OF THERAPY , AFTER SWITCHING FROM AN EFAVIRENZ (EFV)-CONTAINING REGIMEN Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P293 Desmond Maitland1, Marta Boffito1, David Back2, Sara Gibbons2, Brian Gazzard1, Graeme Moyle1, Alastair Teague1 Despite the continuing presence of EFV in plasma after stopping the drug, ATV concentrations were above the suggested minimum effective concentration (100 ng/ml) required to inhibit HIV wild type in all subjects. The lowest calculated ATV trough concentration was in an African woman who concurrently had the highest persisting EFV concentration. |
| P294 | [P294] SURVEY OF MEDICATIONS USED BY HIV-INFECTED PATIENTS THAT AFFECT GASTROINTESTINAL (GI) ACIDITY AND POTENTIAL FOR NEGATIVE DRUG INTERACTIONS WITH HAART Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P294 Andrew D. Luber1, Varun Garg2, Shahin Gharakhanian2, Vertex HIV Program Team GI AEs and use of agents that affect GI acidity (Rx/OTC) are common among HIV pts. There is potential for negative drug interactions with agents that require an acidic environment for absorption. These types of interactions may be underappreciated when managing pts on HAART. |
| P295 | [P295] AMPRENAVIR PHARMACOKINETICS IN PATIENTS CO-INFECTED WITH HIV-1 AND HCV Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P295 S. Rusconi1, O. Viganò1, A. Di Biagio2, R. Maserati3, M. Bassetti2, M. Borderi4, L. Sighinolfi5, G. Di Perri6, L. Gazzola1, P. Cicconi1, B. Massetto1, M. Bongiovanni1, M. Corbellino1, M. Moroni1 The standard dosage of APV/RTV 600 mg/100 mg bid was appropriate for pts with a low degree of hepatic involvement. On the other side, APV without RTV as booster did not determine a sufficient drug exposure in pre-treated pts. APV/RTV 450 mg/100 mg bid looked fine in pts with a 6 to 8 CP score. Since these results are not readily transferable to fos-amprenavir (GW433908), further studies are warranted in order to verify the pharmacokinetics of GW433908 in pts with liver impairment. |
| P296 | [P296] INTERINDIVIDUAL VARIABILITY OF NELFINAVIR (NFV) PHARMACOKINETIC (PK) IN A ONCE A DAY REGIMEN Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P296 M. Blanc, F. Stancke, A. Schmuck, P. Leclercq Administration of NFV/r QD appears to be inadequate to reach therapeutic value in all patients. Based on these results, we recommend a TDM of NFV during QD even when it's prescribed after a BID regimen with a good NFV PK previously observed. In case of low concentration during QD regimen a switch to BID can be envisaged. These facts need confirmation. |
| P297 | [P297] NO INFLUENCE OF THE P-GLYCOPROTEIN GENOTYPE (MDR1 C3435T) ON THE VIROLOGICAL AND IMMUNOLOGICAL RESPONSE IN TREATMENT NAïVE PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P297 Ralf Winzer, Peter Langmann1, Michael Zilly1, Franz Tollmann2, Joerg Schubert2, Hartwig Klinker1, Benedikt Weissbrich2 We did not find evidence for an influence of the MDR1 3435 genotype on the virological and immunological response in treatment naïve patients. |
| P298 | [P298] A REVIEW OF THE THERAPEUTIC DRUG MONITORING (TDM) SERVICE IN THE IAN CHARLESON DAY CENTRE (ICDC) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P298 Jayne A. Ballinger, Leonie Swaden, Caroline Sabin, David Stainer, Margaret Johnson In conclusion, of the total number of levels taken 43%(79) were outside the desired range. Since low levels of nevirapine have been associated with subsequent virological failure, these results suggest TDM is appropriate even if a patient has an undetectable viral load. |
| P299 | [P299] PHARMACOKINETICS OF INDINAVIR WHEN CO-ADMINISTERED WITH TIPRANAVIR/RITONAVIR Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P299 C.L.S. Leen1, R. Lessells1, S.M. Morris1, S.H. Khoo2, K. Curry3 Plasma IDV concentrations were above target when administered with TPV/r. Further studies are needed to assess this combination in salvage. |
| PAEDIATRIC INFECTION |
P300 | [P300] ONCE DAILY EMTRICITABINE (FTC) WITH OTHER ANTIRETROVIRAL AGENTS IN HIV-INFECTED PEDIATRIC PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P300 N. Adda4,D. Ndiweni1, A. Violari2, X. Saez-Llorens3, G. Chittick4, J. Hinkle4, J. Harris4 These results suggest that once daily emtricitabine (FTC) in children is well tolerated and has a potent antiviral activity similar to that seen in adults, with a low rate of VF and a low incidence of M184V after 48 weeks. |
| P301 | [P301] A 4-DRUG, PROTEASE-INHIBITOR SPARING, COMBINATION ANTIRETROVIRAL THERAPY FOR INFANTS WITH ADVANCED HIV INFECTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P301 A. Cowper1, E.G.H. Lyall1, S. Walker2, S. Walters1, V. Rosenfeldt Nielsen3, C. Feiterna-Sperling4, S. Segal5, S. Head1, G. Tudor-Williams1 The 4 drug protease inhibitor sparing CART was mostly well tolerated and resulted in exceptionally good virological, immunological and clinical responses in a cohort of young infants and children most of whom had advanced HIV infection. |
| P302 | [P302] HEPATITIS B (HBV)/HIV CO-INFECTION: RESPONSE TO ANTIRETROVIRAL THERAPY IN A PAEDIATRIC COHORT Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P302 C.J. Foster1, G. Tudor-Williams2, S.M. Walters1, U.H.P. Wintergerst3, G.A. Notheis3, E.G.H. Lyall1 Current ART regimens appear to effectively suppress plasma HIV and HBV in this small cohort of children. |
| P303 | [P303] GROWTH CENTILES AND Z-SCORES AFTER SWITCHING TO NNRTI REGIMENS IN HIV INFECTED CHILDREN Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P303 Raffaella Rosso, Chiara Dentone, Sara Ferrando, Antonio Di Biagio, Matteo Bassetti, Antonio Ferrazin, Dante Bassetti Switching to EFZ containing regimens in children seems to have similar effect on their growth as PI regimens (1,2). Longer follow-up could assess whether growth can be sustained for longer period after switching to PI sparing regimens. |
| P304 | [P304] RENO-URINARY DISFUNCTIONS IN CHILDREN WITH AIDS RECEIVING ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P304 B. Tilea1, R. Pascu1, I. Tilea2 In this study the presence of leukocytes in urine was associated with a raise of the creatinine serum level. The renal disfunction found suggests that the nephrotoxicity could be present in the absence of any clinical signs. Nephrolithiasis and urinary bladder lithiasis were noted in both groups who received and who didn't receive IP. |
| P305 | [P305] ETIOLOGICAL ASPECTS OF HYPERTRIGLYCERIDEMIA IN CHILDREN WITH HIV INFECTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P305 Anca Georgescu, Rodica Pascu, Carmen Chiriac In children with HIV, H. is correlated with female sex; positively correlated with hypercholesterolemia and increased levels of GGT, has no correlation with the stage of the disease, nor the HAART scheme, except the ones including Lpv-RTV combination; lack of ARV treatment is a risk factor for H. |
| P306 | [P306] CARDIAC INVOLVEMENT IN HORIZONTALLY HIV-INFECTED CHILDREN (18 MONTHS SURVEY) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P306 Dina Maria Cupsa1, Augustin Cupsa2, Florentina Dumitrescu2, Florin Romanescu2, Lucian Giubelan2 Various cardiac involvement in HIV infected patients impose urgent therapy when cardiac decompensation associated with intercurrent infections are threatening life. Increased life hope by HAART in children leads to necessity of monitoring and treatment of dislipidemies that could generate severe coronarian pathology at the adult age. |
| P307 | [P307] AN AUDIT OF PAEDIATRIC USE AND MONITORING OF TENOFOVIR Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P307 E. Lim, E.G.H. Lyall, C. Kearney, S. Walters, G. Tudor-Williams This preliminary evidence suggests that tenofovir is safe in children but we recommend regular biochemical monitoring and renal ultrasound until more data becomes available. |
| P308 | [P308] VIROLOGICAL OUTCOME OF TDF PLUS ABC-BASED REGIMENS IN PREVIOUSLY HIV SUPPRESSED PATIENTS (24WK PRELIMINARY RESULTS FROM RECOVER STUDY) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P308 Maria J. Perez1, Jose A. Terron2, Antonio Antela1, Pere Domingo3, Esteve Ribera4, Antonio Ocampo5, Jose Hernandez6, Piedad Arazo7, Marisa Alvarez8, Santiago Moreno In heavily pretreated patients, TDF + ABC-based regimens showed lower efficacy with a third NRTI than a PI or NNRTI. In this study a significantly higher (94%) virologic success rate at 24 weeks with TDF + ABC-based regimens plus NNRTIs or PIs was observed. |
| P309 | [P309] COMBINATION THERAPY WITH TENOFOVIR AND ABACAVIR IN CLINICAL PRACTICE Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P309 Douglas J. Ward, John M. Curtin, Charles A. Owen This observational analysis provides no evidence of a clinical negative interaction between TFV and ABC when not used as part of a triple-nucleoside regimen. Although controlled trials of this combination are needed, the combination of these two potent antivirals should not be too quickly discarded. |
| P310 | [P310] KALETRA IN CHILDREN INFECTED WITH HIV Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P310 Eugeny E. Voronin1, Aza G. Rakhmanova1, Konstantin N. Dodonov2, Larissa Y. Afonina2, Youry A. Fomin1 Inclusion of Kaletra (Lopinavir/Ritonavir) in HAART schemes obviously leads to clinical, virology (viral load decrease) and immune (CD4 cell count increase) effects in treated children with no influence on lipid and other metabolic process. The best ARV drug combination is considered to be as NRTI + NNRTI + Kaletra. |
| P311 | [P311] EFFICACY OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN COLOMBIAN CHILDREN UNDER 15 YEARS LIVING WITH HIV/AIDS. A 24 WEEKS FOLLOW UP, 2003 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P311 Alvaro D. Pena Gonzalez1, Maria F. Propato Sanchez1, Martha C. Pachecho Mejia1, Victoria Manjarres2, Martha Penuela Epalza3 Colombia is developing country with resource limited, for this reason make study about HIV/AIDS therapy for long time is difficult. The HAART 1 managed better the HIV/AIDS infection than HAART 2, because decreased VL levels and increasing CD4 at the 24 weeks, this difference was statistically significant. There are necessary others studies, to determinate adverse reactions to HAART between both cohorts. Our research recommend begin HAART including PI to achieve great results. |
| NEW TREATMENTS AND TARGETS |
|
| P312 | [P312] THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PA-457, A FIRST-IN-CLASS, HIV MATURATION INHIBITOR, IN HEALTHY VOLUNTEERS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P312 David E. Martin1, Charles H. Ballow2, Robert Blum2, Judy Doto1, Carl T. Wild1, Graham P. Allaway1 Single, oral doses up to 250 mg of PA-457 were safe and well tolerated. PA-457 was rapidly absorbed with very high plasma concentrations and a long half-life. The target therapeutic concentration (i.e., protein binding adjusted IC90 value) for PA-457 is ~2.3 µg/mL. These data suggest that therapeutic concentrations can be achieved with a single, oral daily dose as low as 50 mg. |
| P313 | [P313] EFFICACY AND SAFETY OF EMTRICITABINE (FTC)-ZIDOVUDINE (ZDV) COMPARED TO LAMIVUDINE (3TC)-ZDV CONTAINING HAART IN HIV+ ADULTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P313 F. Rousseau1, C.A. Benson2, C. van der Horst3, C. Wakeford1, G. Shen1, J.B. Quinn1, E. Mondou1, A. Shaw1 HIV-1 infected adults on a stable HAART regimen containing 3TC+ZDV (individually or as Combivir®) who switched 3TC to FTC had similar efficacy and safety. FTC-containing HAART had durable antiviral activity and safety through 200 weeks. |
| P314 | [P314] SIMILAR VIROLOGY FINDINGS IN ABC/3TC FIXED DOSE COMBINATION (FDC) OAD COMPARED WITH STANDARD DOSING AFTER 24 WEEKS IN ART-EXPERIENCED SUBJECTS (CAL30001, ALTO) Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P314 C. Craig1, C. Stone1, T. Bonny2, K. Fu3 Similar rates of VF and resistance selection between the treatment groups support the finding that ABC/3TC FDC is non-inferior to ABC BID + 3TC OAD. |
| P315 | [P315] IN VITRO ACTIVITY AGAINST HIV-1 PRIMARY ISOLATES WITH REDUCED SUSCEPTIBILITY TO MULTIPLE PROTEASE INHIBITORS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P315 Mirko Lo Cicero1, Elisabetta Bulgheroni1, Alberto Zampiero1, Francesca Soster1, Ottavia Viganò1, Massimo Galli1, Marie-Pierre de Bethune2, Sandra De Meyer2, Stefano Rusconi1 TMC114 showed potent antiviral activity, in the nanomolar range, against MDR clinical primary HIV-1 isolates. These results confirm the data from the extensive profiling of TMC114 against recombinant strains with protease genes from clinical HIV-1 isolates. Phase II clinical trials are currently ongoing in multi-PI-experienced pts to assess the efficacy, safety and tolerability of TMC114 boosted with low dose ritonavir. |
| P316 | [P316] SUSTAINED ANTIVIRAL ACTIVITY OF TMC125 PLUS OPTIMISED ANTIRETROVIRAL THERAPY IN HIGHLY TREATMENT-EXPERIENCED PATIENTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P316 J. Montaner1, A. Lazzarin2, J. Arribas3, A. Pozniak4, M. Peeters5, B. Woodfall5, M. Simonts5, B. Hogg1, S. Bonner1 TMC125, a novel NNRTI, taken at 800 mg bid plus an optimized ART in treatment-experienced patients, demonstrates significant antiviral potency at 48 weeks. Despite the small sample size, the sustained virological response of TMC125 is encouraging when compared to the outcome observed in a similar cohort. Long-term phase IIb studies of TMC125 are ongoing. |
| P317 | [P317] IN VITRO DIFFERENT ACTIVITY OF NEW FUSION INHIBITORS DIRECTED AGAINST A WILD TYPE HIV-1 STRAIN Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P317 E. Bulgheroni1, F. Soster1, A. Scozzafava2, M. Galli1, C.T. Supuran2, S. Rusconi1 These 4 macrocyclic polyamines represent a new promising class of fusion inhibitors. We are conducting further drug combination experiments with wt and resistant HIV-1 isolates to better characterize these presumably CXCR4 receptor antagonists. |
| P318 | [P318] COMPARISON OF TENOFOVIR WITH ZIDOVUDINE WHEN USED WITH EFAVIRENZ AND LAMIVUDINE IN ANTIRETROVIRAL NAÏVE PATIENTS: 40 WEEKS INTERIM RESULTS Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P318 Kaveh Manavi, Collette Burns, Gordon Scott, Alexander McMillan Combination of efavirenz, lamivudine and tenofovir was as potent as efavirenz, lamivudine, zidovudine after 40 weeks in treatment naïve patients. |
| MOTHER-TO-CHILD TRANSMISSION |
|
| P319 | [P319] ANTIRETROVIRAL TREATMENT AT CONCEPTION IN A NATIONAL OBSERVATIONAL STUDY OF PREGNANT WOMEN WITH HIV INFECTION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P319 The Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy Exposure to regimens which are a cause of concern because of possible teratogenicity or toxicity is not uncommon among pregnant women with HIV. Given the high rate of unplanned pregnancy, intervention measures should be considered in order to increase counselling among HIV-positive women of childbearing age and to avoid exposure to antiretroviral drugs or regimens generally not recommended in pregnancy. |
| P320 | [P320] HIV INFECTION AND PREGNANCY. STUDY OF VERTICAL TRANSMISSION IN MALAGA (SPAIN) FROM 1996 TO 2003 Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P320 Rosario Palacios1, Manuel Castaño2, Eva Castells1, José M. Antínez2, Mercedes González1, Francisco Jiménez2, Francisco Orhiuela2, Manuel Márquez1 ARV therapy during pregnancy, delivery and for the newborn are efficient at preventing vertical transmission of HIV. The reduced power of the regimens and the lack of adherence result in inadequate viral control (50% cases). Social marginalisation, the mother being an active drug abuser and occult infection lead to the greatest risk of vertical transmission of HIV in our area. |
| P321 | [P321] HIV IN PREGNANCY: OUTCOMES IN THE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) ERA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P321 Mark Pakianathan,Katharine Bond, Sacha Goolamali, Miriam Mackie, Rebecca Hodgson, Mike Sharland, Austin Ugwumadu, Phillip Hay Abstract not reproduced at author's request. |
| P322 | [P322] COMPARISON OF HEPATIC AND CUTANEOUS TOXICITIES IN PREGNANT WOMEN WITH BASELINE CD4 ≤250 CELLS/MM3 VERSUS THOSE WITH CD4 >250 CELLS/MM3 RECEIVING NEVIRAPINE (NVP)-CONTAINING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY (HAART) FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION (PMTCT) IN THAILAND Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P322 Nittaya Phanuphak, Somsong Teeratakulpisarn, Tanakorn Apornpong, Praphan Phanuphak NVP-based HAART was relatively safe to be used in HIV-1 infected pregnant women as NNRTI component in HAART. However, even with our small sample size, baseline CD4 count seemed to play a role in developing hepatic and cutaneous toxicities during the first 2-8 weeks. Close monitoring is mandatory during this period. |
| P323 | [P323] EFFECTIVENESS OF THE PREVENTION OF MOTHER TO CHILD TRANSMISSION PROGRAMME AND THE INFLUENCE FEEDING OPTION IN URBAN HOSPITAL, KAMPALA/UGANDA Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P323 Samuel Tebandeke Results show the effectiveness of the implementation of the PMTC programme. However the obsreved difference between the EBP and the IF groups underline the importance of postnatal transmission and stress the need to find alternative strategies to avoid late transmission. |
| P324 | [P324] HAART IN PREGNANCY: IS GOLD STANDARD SAFE FOR ALL? Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P324 Elisabetta Chiesa1, Teresa Bini1, Patrizia Biasi1, Amedeo Capetti2, Michela Fasolo3, Antonella d'Arminio Monforte1 HAART is safe and effective during pregnancy; increasing viremia after pregnancy raises adherence concerns. Premature delivery occurs especially in women with incomplete virological suppression. |
| P325 | [P325] PREVENTION OF MOTHER-TO-CHILD HIV TRANSMISSION Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P325 Magdalena Marczynska, Malgorzata Szczepanska-Putz, Sabina Dobosz, Jolanta Popielska, Agnieszka Oldakowska Prevention of vertical HIV transmission relies on knowledge of mothers HIV diagnosis before or at least during pregnancy. Early diagnosis is one of the important components of vertical transmission prophylaxis program. Lack of offering testing for HIV infection to all pregnant women in Poland results in high HIV vertical transmission rates. On the other hand the risk of transmission among children who received prophylaxis is low and similar to transmission rates in west European countries. |
| P326 | [P326] EFFECTIVENESS OF SINGLE DOSE NEVIRAPINE OR AZT IN PREVENTING HIV TRANSMISSION FROM MOTHER TO CHILD Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P326 Peragia Kateregga A single dose of NVP given to HIV infected women at the onset of labor and to the infant within 72hrs after birth reduces the risk of HIV transmission during the first 14-16 weeks of life by 50% compared to AZT regimen. Using this simple and inexpensive NVP can significantly reduce mother to child transmission of HIV in poor resource countries. |
| P327 | [P327] HIV in pregnancy in a DGH Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. P327 J. Williams1, D. Chadwick1, B. McCarron1, G. Phillips2 Diagnosis and treatment before 33/40 suppresses viral load at delivery. Perinatal diagnosis is associated with higher delivery viral loads. Delivery Units should be prepared for this scenario. Nevirapine therapy requires careful monitoring. Dispersal of women in late pregnancy should be avoided as it may contribute to poor HIV care. Prompt communication between centres is important. HIV positive women should be encouraged to plan pregnancy in partnership with their HIV physician and Obstetrician. |
This information is designed to support, not replace, the relationship that exists between you and your doctor.